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1.01.02
Antiangiogenic Strategies for the Treatment of Lung Cancer
O’Reilly, Michael S., MD Anderson Cancer Center, Houston, TX,
USA
The outcome for patients with lung cancer has not significantly
changed for more than two decades. Lung cancer commonly spreads
within the lung and chest to the bone, brain and other metastatic
sites. Angiogenesis is critical for a number of physiologic and patho-
physiologic processes and angiogenesis inhibitors are now being
used in the treatment of lung and other cancers. Although antiangio-
genic agents offer great therapeutic potential, preclinical and clinical
trial results suggest that these agents will have a delayed onset of
activity and may only induce disease stabilization for patients with
advanced malignancy. Further, the vascularization and growth of
primary and metastatic lung cancer is influenced by tumor microen-
vironment and organ microenvironment will therefore influence
response to antiangiogenic therapy. We have developed and charac-
terized mouse models of primary and metastatic human lung cancer
for the preclinical evaluation of antiangiogenic therapies alone and
in combination with biological and conventional therapeutic modali-
ties. Using these models, we have evaluated the feasibility for thera-
peutic strategies of combined radiation therapy and chemotherapy
with antiangiogenic agents. We have found that these strategies are
highly effective but that the regulation of angiogenesis for primary
and metastatic lung cancer differs. These data strongly suggest that
it will be prudent to include biologically targeted therapies in the
multimodality management of lung cancer. However, organ
microenvironment should be considered in the design of antiangio-
genic and targeted therapies for primary and metastatic lung cancer.
Additional work is still needed to provide a rational basis for the
combination of angiogenesis inhibitors with other modalities and to
identify potential problems that might arise from these combinations
so that these agents will be successfully incorporated into existing
therapy in a timely and rational manner.
1.03.02
Advances in Thoracic Imaging
MacMahon, Heber, The University of Chicago, Chicago, IL, USA
Digital Radiography and Multidetector CT have revolutionized tho-
racic imaging over the past ten years, and have greatly enhanced our
ability to detect early disease, and to monitor disease response.
While the immediate benefits of completely digital imaging and
softcopy display have been in the area of more timely interpretation,
and efficient communication of images and results, advanced image
processing and computer-aided diagnosis are only now starting to
impact clinical care.
Though MDCT has attracted much attention, significant progress
has also been made in digital chest radiography. For instance, dual
energy chest radiography is now an FDA approved product that is
widely available. This enables effective separation of bone and soft
tissue components of the image for improved detection of nodules
and other disease. Computer aided detection for nodules, designed
to detect lesions that might be overlooked, has also become com-
mercially available for digital radiographs. 
In thoracic CT, 64-slice scanners have enabled very rapid acquisi-
tion of large detailed datasets, which threaten to overwhelm the
capacity of radiologists to review the hundreds of images produced.
As a result, novel approaches to image presentation have been
developed, including multiplanar reconstructions, maximum intensi-
ty projections, and minimum intensity projections in order to allow
efficient visual analysis. Computer-aided detection has also made
significant advances in CT. Products are now available for detection
of lung nodules and pulmonary embolism, and this approach has
clear potential to improve diagnostic accuracy.
1.03.06
Optimizing Systemic Therapy for Resected Non-Small Cell Lung
Cancer: Individualizing Treatment Recommendations Based on
Patient and Tumor Characteristics
West, Howard (Jack), Swedish Cancer Institute, Seattle, WA, USA
Objectives:
1) To review the most recent data on improving survival for early
stage NSCLC from the addition of adjuvant chemotherapy after
primary resection.
2) To clarify the specific regimens that have been studied and are
considered to be recommended in this setting.
3) To characterize the patient groups, based on clinical characteris-
tics such as NSCLC stage, tumor size, and other clinical charac-
teristics, that most consistently benefit from systemic therapy.
4) To explore the emerging molecular features that may help us
refine which tumors are more likely to recur and/or benefit from
additional systemic therapy.
Abstract: Several recent prospective randomized clinical trials have
demonstrated a significant survival benefit for patients with stage I -
IIIA (non-N2) non-small cell lung cancer (NSCLC) who received
post-operative platinum-based doublet chemotherapy. Although tri-
als with broad eligibility have shown an improvement in overall sur-
vival for this population, these studies have not demonstrated clear
benefit in patients with stage I NSCLC, but rather with benefit gen-
erally restricted to the patients with stage II and IIIA NSCLC. The
CALGB 9733 trial, which enrolled 344 patients with stage IB dis-
ease to receive post-operative observation or carboplatin/paclitaxel,
was preliminarily reported as positive but more recently was shown
to have more marginal benefits that did not meet the primary end-
point of significantly improved overall survival. As the only trial
that had employed a carboplatin-based regimen, and the main source
of evidence in support of adjuvant chemotherapy for stage IB
NSCLC, the revised results now reopen questions about whether
carboplatin-based adjuvant chemotherapy should be recommended
and which, if any, patients with stage I NSCLC should receive addi-
tional treatment. Based on currently available data, multiple studies
support administration of 3-4 cycles of cisplatin-based combination
chemotherapy as a preferred approach in patients with stage II-IIIA
NSCLC and good performance status. Adjuvant chemotherapy
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remains an appropriate consideration for patients with stage IB dis-
ease, particularly for those with higher risk pathologic features.
Carboplatin-based doublet chemotherapy is also a feasible alterna-
tive for adjuvant treatment, perhaps ideally suited for those patients
in whom cisplatin-based chemotherapy would be prohibitively toxic.
Retrospective subgroup analyses based on patient age, tumor size,
and molecular variables from pivotal adjuvant chemotherapy trials
can now suggest potential refinements of which patients may benefit
more or less from systemic therapy. Current and future clinical
research in this setting will also be presented
1.05.01
Incremental Advances Achieved with Molecular Targeted
Therapies
Harari, Paul M., University of Wisconsin School of Medicine and
Public Health, Madison, WI, USA
Objective: Examine the impact and challenges in integrating molec-
ular targeted therapies into cancer treatment. 
The introduction of molecular targeted therapies in oncology is rela-
tively recent, reflecting several decades of modern molecular biolo-
gy coming to fruition in the form of smart new anti-cancer drugs.
Thousands of cancer patients are now receiving molecular therapies
and countless clinical trials are incorporating these new agents into
trial design. The scientific rationale and collective enthusiasm for
advancing these modern cancer therapies is overwhelming. Indeed,
in addition to compelling preclinical results, there are now several
clinical trial successes that support the concept that we are making
true progress. Nevertheless, there are numerous challenges worthy
of acknowledgement with regard to molecular targeting in oncology.
First, there are far more negative than positive clinical trials to date.
There is a tendency for oncologists to rigorously illuminate the posi-
tive trials and downplay or rationalize inherent design inadequacies
for the negative trials. Second, we may inadvertently over dramatize
the impact of positive clinical trials with regard to overall benefits
and translatability to global cancer populations. Third, although the
toxicity profiles for most molecular targeted therapies appear milder
than that of conventional cytotoxic agents, the unique toxicities of
molecular therapies are not trivial, particularly for the average per-
formance cancer patient who may be underrepresented in controlled
clinical trials. Fourth, many of the new molecular targeted therapies
are remarkably expensive. This high cost reflects the manner in
which new drugs are discovered, developed and promoted in the
current era, and this feature carries implications for who will receive
these new cancer drugs in the coming years. As we make stepwise
advances in cancer treatment, it will be important for oncologists to
exercise rigor in describing the benefits achieved with each new
therapy, and to remain actively engaged in promoting the rational
and judicious application of new cancer treatments and technologies. 
1.06.01
Angiogenesis Inhibitors in NSCLC – An Overview
Herbst, Roy S., The University of Texas M. D. Anderson Cancer
Center, Houston, TX, USA
The critical role of angiogenesis in tumor growth and metastasis is
now well established in the literature. Growing tumors stimulate
neovascularization through the secretion of pro-angiogenic growth
factors, in particular, basic fibroblast growth factor (bFGF) and vas-
cular endothelial growth factor (VEGF). Several lines of evidence
have implicated VEGF in tumorgenesis and understanding the role
of VEGF in tumor angiogenesis has facilitated the development of
novel targeting agents that specifically interfere with angiogenesis.
The different approaches to disrupt tumor-induced angiogenesis
encompass tyrosine kinase inhibitor, monoclonal antibodies, small
molecule inhibitors and transcription inhibitors. However, mono-
clonal antibody and tyrosine kinase inhibitors are the most advanced
drug classes currently being investigated in clinical trials. To date,
three anti-VEGF inhibitors namely Bevacizumab, Sunitinib and
Sorafenib have been approved for the treatment of solid human
malignancies including colorectal cancer, gastrointestinal stromal
tumors and renal cell cancer. This lecture will review the current
clinical knowledge on the use of these agents to interfere with
VEGF, VEGFR, matrix breakdown or other mechanisms involved in
angiogenesis and tumor metastasis in NSCLC. The use of combina-
tion antiangiogenic approaches will also be discussed.
1.06.02
Concurrent VEGF And EGFR Blockade in Conjunction with
Curative Intent Chemoradiation for Locally Advanced Head
and Neck Cancer
Brizel, David, Duke University Medical Center, Durham, NC, USA
Background and Significance: Radiotherapy (RT) with concurrent
chemotherapy represents the state of the art in curative intent, non-
surgical treatment for locally advanced squamous carcinoma of the
head and neck. Tumor hypoxia and high levels of angiogenesis are
associated with treatment failure. Preclinical models reveal that
radiotherapy itself may induce tumor secretion of VEGF. Over
expression of epidermal growth factor receptor (EGFR) also occurs
commonly and increases the risk of treatment failure. Curability
may consequently be reduced by multiple mechanisms. The addition
of EGFR blockade to RT alone increases the chance of cure.
Concurrent VEGF and EGFR blockade could be synergistic and
improve the effectiveness of concurrent chemoradiation for
advanced head and neck cancer.
Methods and Materials: Open label single institution pilot study
consisting of an inital, lead in phase of treatment and a subsequent
chemoradiation phase.
Lead In Phase:
Cohort 1: Bevacizumab (10 mg/kg) days -14 and 0
Cohort 2; Erlotinib (100 mg) daily days -14-0
Cohort 3: Bevacizumab (10 mg/kg) days -14 and 0; Tarceva
(100 mg) daily from day-14-0
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Chemoradiation Phase
RT: 1.25 Gy BID M-F with a 6 hour interfraction interval
Total dose 70 Gy/7 weeks; treatment break during week 4.
CDDP: 33 mg/m2 M-W on weeks 1 and 5 of RT
Bevacizumab (10mg/kg): Monday of weeks 1,3,5,7 of RT
Erlotinib (100 mg): Daily for weeks 1-7 of RT including weekends
and break week
Efficacy Assessments: 
• Dynamic contrast enhanced MRI and MR proton spectroscopy at
baseline, end of lead-in phase, end of week 1 of chemoRT, and
end of chemoRT
• Pro-angiogenic and EGFR related cytokines: VEGF, b-FGF, IL-
8, D-dimer, EGF, TGF α,osteopontin at same time as DCE-MRI
Results and Conclusions: Ten patients have been enrolled and
accrual is ongoing. Preliminary data will be presented and dis-
cussed.
1.06.04
Studying mTOR and mTOR Inhibitors in Head and Neck
Cancer
Burtness, Barbara, Fox Chase Cancer Center, Philadelphia, PA, USA
Phosphotidylinositol 3-kinase (PI3K) is an evolutionarily conserved
lipid kinase which signals through the serine-threonine Akt cell sur-
vival kinases and their target the mammalian target of rapamycin
(mTOR), providing the cell with adequate biosynthesis for cell
growth, proliferation and survival. mTOR complex 1 (TORC1)
mediates its effects on bioenergetics through activation of S6 kinase
1 and suppression of 4E-BP1, an inhibitor of translation. mTOR sig-
naling is required for expression of HIF-1α, which promotes angio-
genic signaling. Because of mTOR’s central role in meeting the
biosynthetic and angiogenic demands of tumor proliferation and
progression, inhibitors of mTOR - rapamycin and its analogs - are
under investigation as anticancer agents. Treatment with the mTOR-
inhibiting rapamycin analog RAD001 can result in increased activa-
tion of Akt through a positive feedback mechanism mediated by
TORC2, but this perhaps can be abrogated by combining RAD001
with inhibitors of phosphoAkt.
Abnormalities of the PI3K signaling pathway are common in squa-
mous carcinomas of the head and neck. Approximately one third
have amplification of the Akt2 gene. Expression of phosphorylated
Akt is a negative prognostic indicator in oropharynx cancer, and
retains significance independent of cytoplasmic or nuclear epidermal
growth factor receptor. Loss of the tumor suppressor PTEN (protein
phosphotase and tensin homologue deleted from chromosome 10)
has been reported in over half of oral squamous cell cancers. 
Clinical trials have demonstrated activity for rapamycin analogs
CCI-779 and RAD001 in a number of tumors. Combination of
RAD001 with oral tyrosine kinase inhibitors has been reported in
patients with glioma, and phase I studies are currently investigating
the combination of RAD001 with cetuximab, an antibody to the lig-
and-binding domain of EGFR. Studies are underway to combine
RAD001 with chemotherapy in head and neck cancer. mTOR inhibi-
tion is a promising line of clinical investigation for squamous cell
cancers of the head and neck.
1.06.06
Angiogenesis Inhibitors in Early Development for Lung Cancer
Belani, Chandra P., University of Pittsburgh School of Medicine,
Pittsburgh, PA, USA
Formation of new blood vessels is a rate-limiting step for cancer
progression. Therefore, inhibition of neovascularization has been
pursued as a treatment strategy for cancer during the past three
decades. Vascular endothelial growth factor (VEGF), secreted by the
cancer cells, and is an important mediator of angiogenesis. Direct or
indirect targeting of the ligand (VEGF) at the mRNA or protein
level, direct targeting of its receptors, VEGFR1, VEGFR2, and neu-
ropilin 1 (NP1), or by blocking downstream signaling pathway com-
ponents can lead to angiogenesis inhibition representing a promising
new targeted therapeutic treatment strategy for a variety of malig-
nant disorders including lung cancer.
Bevacizumab, a humanized monoclonal antibody that binds with
high affinity to VEGF-A, has recently demonstrated a survival
advantage when added to chemotherapy for patients with nonsqua-
mous advanced NSCLC. Clinical trials are also underway to evalu-
ate the utility of various small-molecule inhibitors that target the
VEGF receptor and agents that cause regression of existing tumor
vasculature (vascular targeting agents). Inhibitors of the VEGF tyro-
sine kinase that may have incremental benefits in lung cancer
include Vatalanib (PTK 787), sorafenib (BAY 43-9006), AZD 2171,
Sutent (SU 11248), etc. Sorafenib (targets VEGFR2 and VEGFR3,
PDGFR-β, Raf, c-Kit and FLT3) is associated with fatigue, anorex-
ia, diarrhea, rash and hand-foot syndrome. Vatalanib (targets
VEGFR1, VEGFR2, VEGFR3, PDGFR-β and c-Kit) has been
known to cause fatigue, light-headedness/dizziness, nausea and
thrombotic events. Fatigue, nausea, diarrhea, mucositis and hand-
foot syndrome have been reported with sunitinib ( targets VEGFR2,
c-Kit, PDGFR-β, and FLT30. AEE 788 targets VEGFR, EGFR and
HER-2, with IC50 levels in the nm range for EGFR (28nm) and
MAPK (22nm) . Pharmacokinetic data suggest once daily dosing
and responses with cavitations have been reported in NSCLC in an
ongoing study. BIBF 1120 (B1) is a unique angiokinase inhibitor
targeting VEGFR, EGFR and PDGFR with a half life of 6.8 hours,
suggesting QD or BID dosing. The IC50 levels for VEGFR (34nm)
VEGFR-2 (21nm), VEGFR-3 (13nm), PDGFR (60nm) and EGFR-1
(69nm) are all in the nm range. In the clinic, stable disease has been
observed with BIBF 1120 in a patient with NSCLC. GW786034 is a
VEGF receptor tyrosine kinase inhibitor with potent activity against
VEGFR-1, -2, -3, PDGFR-α, -β and c-kit and is undergoing evalua-
tion as a single agent in NSCLC. CP-547,632, a selective inhibitor
of VEGFR2 yielded a response of only 20% when combined with
carboplatin-paclitaxel regimen in NSCLC. AG 013736 targets
VEGFR1, VEGFR2, VEGFR3, PDGFR-β and c-Kit and has also
demonstrated evidence of activity in NSCLC with substantial cavita-
tions in the tumor. This agent has a short half-life of 2-5 hrs.
Possible benefits of oral VEGFR TKI’s include oral dosing and fea-
sibility of targeting multiple kinases. Agents that target multiple
pathways or multiple levels of the same pathway have the potential
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for enhanced anti-tumor activity, but it makes it difficult to develop
predictors of response because of multiplicity of targets. Fatigue is a
more-common side effect across the multitargeted TKIs than for mon-
oclonal antibodies and hypertension (class effect) which presents a
unique challenge, is usually manageable with medical treatment.
Other antiangiogenic strategies in development include VEGF Trap,
thalidomide and its analogs, synthetic ribozyme that cleaves
VEGFR-1 specific mRNA, IMC-1121B - fully human antibody to
VEGFR-2 , SDF-1 inhibitor and Spectrum Selective Kinase
Inhibitors (SSKIs) such as XL-647 (targets VEGFR- 2,EGFR, HER2
and EphB4) and XL 999 (VEGFR-1, VEGFR-2 ,VEGFR-3,
PDGFR, FGFR, c-kit, and Flt-3). Thalidomide, with known antian-
giogenic effects, is emerging as a promising treatment as mainte-
nance therapy for SCLC. VEGF Trap belongs to the class of
VEGFR-1/VEGFR-2 fusion protein and targets VEGF-A., prevent-
ing VEGF from binding to its receptors. Involvement of the SDF-
1/CXCR4 pathway in cancer related angiogenesis has prompted the
development of a novel SDF-1 inhibitor to evaluate its mechanistic
and therapeutic potential. Standard chemotherapeutic drugs such as
paclitaxel, when modified by the frequency and dose of administra-
tion, can also target angiogenesis, and have led to the development
of metronomic therapies.
1.07.01
Pharmacogenetics of Anticancer Agents: Focus on Lung Cancer
Ratain, Mark J., University of Chicago, Chicago, IL, USA
Pharmacogenetics, the study of the relationship of inherited variabil-
ity to clinical outcomes, is of increasing importance in oncology. As
an example, the FDA approved in 2005 the first drug-specific phar-
macogenetic test, the use of UGT1A1 genotyping (to detect a pro-
moter polymorphism) in conjunction with the prescribing of irinote-
can. Studies are ongoing to assess the potential utility of UGT1A1
genotyping to permit higher (and potentially more efficacious) doses
of irinotecan in the “low risk” genotype subset. Another potential
example of the use of pharmacogenetic testing is in conjunction
with EGFR-targeted agents. It is well recognized that the presence
of a somatic mutation in the tyrosine kinase domain of EGFR is
associated with both a better prognosis and a higher probability of
response to EGFR-targeted agents. A parallel set of investigations
have demonstrated the high frequency of putatively functional
germline polymorphisms in EGFR, including polymorphisms in the
promoter, intron 1, and exon 13. These variants all demonstrate
marked population differences, and have been suggested to be asso-
ciated with population differences in the pharmacodynamics of
EGFR-targeted agents, and potentially even with the presence of the
somatic mutation itself. Germline variability has also been suggested
to be related to variability in the pharmacodynamics of pemetrexed,
as expression of thymidylate synthase (TYMS) has been associated
with response to this agent. Furthermore, germline variability in the
5’-untranslated region of TYMS has been associated with expression
of this gene. In summary, there is great potential to utilize genotyp-
ing of candidate polymorphisms to guide choice of drugs (and
dosages) in lung cancer. These studies can be completed using either
a single tube of blood or a buccal swab, collected at any time. Such
studies should be incorporated into all large studies in lung cancer.
2.01.01
The Influence of Molecular Risk Markers on Cancer Prevention
Trial Design
Lippman, Scott, University of Texas MD Anderson Cancer Center,
Houston, TX, USA
Early translational studies of high-dose isotretinoin in head and neck
cancer prevention provided the proof of principle of, and presaged
the emergence of molecular-targeted approaches for, cancer chemo-
prevention. Biomarkers are important in all aspects of molecular-tar-
geted chemoprevention-as predictors of response, short-term meas-
ures of drug activity, and cancer risk/prognosis markers. Epidermal
growth factor receptor (EGFR) gene amplification, protein overex-
pression, and tyrosine kinase (TK) domain mutations predict lung
tumor response to EGFR TK inhibitors (TKIs); they also are found
in non-malignant lung and head-and-neck tissues (e.g., IEN), sug-
gesting their potential for predicting response to EGFR TKI chemo-
prevention. Promising new drug activity biomarkers are emerging
from genomic profiling in head and neck and lung cancer prevention
trials. One of the most exciting developments in molecular biomark-
er research is the development of loss of heterozygosity (LOH) as a
practical risk marker for use in head and neck cancer chemopreven-
tion trials. Definitively treated oral cancer patients who develop IEN
with LOH at 3p14 and/or 9p21 have a 69% risk of a new oral cancer
within 3 years. Although lower, the oral cancer risk of patients with
oral IEN alone (no oral cancer history) with LOH at 3p14 and/or
9p21 (and at one or more of 4q, 8p, 11q, 13q or 17p) is still very
high at 35% within 3 years. These LOH criteria will define high risk
in selecting patients for a phase III (cancer endpoint) oral cancer
prevention trial targeting EGFR and scheduled to open later this
year—the first prevention trial using a molecular risk marker as an
eligibility criterion. Molecular targeting and risk modeling are facili-
tating the convergent development of drugs for both therapy and
prevention. Prevention trials in high-risk IEN can have a size, dura-
tion, costs and ethical considerations (high risk justifies potential
serious adverse effects) resembling those of therapy trials. 
2.01.02
Vitamin D Biology and Lung Cancer
Johnson, Candace S.; Trump, Donald L., Departments of Medicine
and Pharmacology, Roswell Park Cancer Institute, Buffalo, NY, USA
Vitamin D (1,25 dihydroxycholecalciferol or calcitriol), a central
factor in bone and mineral metabolism (1,2), has significant antitu-
mor activity in vitro and in vivo in a variety of murine and human
tumor models including lung, squamous cell carcinoma (SCC) and
prostate cancer model systems. Calcitriol induces a significant
G0/G1 arrest with a decrease in S phase and modulates p21Waf1/Cip1
and p27Kip1. Calcitriol induces PARP cleavage, increases bax/bcl-2
ratio, reduces the P-Erk-1/2 and P-Akt, induces caspase-dependent
MEK cleavage and up-regulation of MEKK-1, all potential markers
of the apoptotic pathway. Calcitriol significantly enhances the in
vitro and in vivo antitumor efficacy of the platinum analogues and
taxanes. Based on these pre-clinical data, we performed two phase I
clinical trials of calcitriol with either carboplatin or paclitaxel and
administered higher doses of calcitriol than previously reported,
without toxicity. Pharmacokinetic (pk) data following oral adminis-
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tration indicate that the serum calcitriol AUC is not proportional to
calcitriol dose suggesting a decrease in bioavailability and calcitriol
exposure. In a phase I trial of iv calcitriol the MTD was 96 µg/day
x1, weekly) and AUC increased in a dose-dependent manner. The
histopathological steps of lung carcinogenesis include the conver-
sion of normal epithelium to metaplasia, to dysplasia, to carcinoma
in situ, and eventually to invasive carcinoma. These pathway alter-
ations represent potential chemo-prevention targets. The ability of
calcitriol to induce cell cycle arrest, apoptosis and differentiation at
doses without toxicity, make calcitriol an attractive chemo-preventa-
tive agent and studies are ongoing to utilize our lung cancer screen-
ing clinic for high risk patients utilizing auto-fluorescence bron-
choscopy and low dose spiral CT of the chest for early detection of
lung cancer where patients are screened, followed and biopsies per-
formed for pathologic and biomarker assessment. Therefore, studies
continue to evaluate the potential efficacy of calcitriol either as a
therapeutic or chemo-preventative agent and to determine the mech-
anisms of the anti-proliferative effects. Supported by NCI
CA112914, CA85142, CA67267, CA95045 and a DOD grant
PC040238.
2.01.05
EGFR Mutations: Predictors of Sensitivity and Resistance to
EGFR Tyrosine Kinase Inhibitors
Jänne, Pasi A., Dana-Farber Cancer Institute, Brigham and
Women’s Hospital and Harvard Medical School, Boston, MA, USA
Somatic mutations in the epidermal growth factor receptor (EGFR)
occur in 10-15% of all patients with non-small cell lung cancer
(NSCLC). They are more frequent in women, never-smokers, those
with adenocarcinoma and in patients of East Asian ethnicity. Both
retrospective and prospective clinical trials have confirmed that
patients with EGFR mutations treated with tyrosine kinase inhibitors
(TKIs) gefitinib or erlotinib have the highest response rate and time
to disease progression compared with any other subgroup of
NSCLC patients. Five recent prospective studies have demonstrated
response rates of 62-82% and a median TTPs of 9.4-13 months in
patients with EGFR mutations treated with either gefitinib or
erlotinib. Several recent studies have also demonstrated that there
are clinical differences amongst the two most common EGFR muta-
tions (exon 19 deletions and L858R). Patients whose tumors harbor
an exon 19 deletion have a significantly greater TTP and overall sur-
vival compared to patients with L858R when treated with either
gefitinib or erlotinib. The majority of patients with EGFR mutations
ultimately develop clinical resistance to EGFR TKIs. In 50% of
such patients, a secondary T790M mutation is observed which con-
fers resistance to gefitinib and erlotinib. Surprisingly, this mutation
can occur in a limited number of EGFR alleles (as most EGFR
mutant lung cancers also contain a concurrent amplification at the
EGFR locus) and be undetected by conventional sequencing tech-
niques. Strategies to overcome this resistance mechanism include
the use of irreversible EGFR inhibitors and HSP90 inhibitors both
of which are presently being evaluated pre-clinically and in several
clinical trials.
2.03.01
Spiral CT Screening For Lung Cancer: The Good, the Bad, and
the Ugly
Jett, James R., Mayo Clinic, Rochester, NY, USA
Pro Screening
In 2006 it is projected that there will be approximately 170,000 new
cases of lung cancer in the United States and only 15% of those
individuals will survive 5 years (1). The 5-year survival has been
relatively static for the past few decades. One of the major limita-
tions to improving 5-year survival is the fact that over 50% of
patients present to their physicians with advanced stage disease. In
the past decade, there has been increasing interest in the role of low-
dose spiral CT scan screening for early detection of lung cancer (2-9).
In three of these CT screening trials investigators obtained chest
radiographs within 3 months of the screening CT scans. The chest x-
ray missed 70-80% of the lung cancers detected by the CT (2,3,5).
The average size of the cancer detected by CT was 15 mm vs. 30
mm for screening chest x-ray detected cancer (9,10). Thus, it is clear
that screening with CT will detect smaller size lung cancers.
CT screening trials have reported a high rate of early stage cancers.
Henschke et al noted that 22 of 27 lung cancers (81%) were stage
IA (5). Similarly, Nana and associates detected 78% stage IA (7) and
Sobue and colleagues observed 69% stage IA (10). For prevalence
and incidence lung cancers, Swensen et al reported stage IA disease
in 69% and 59% respectively (9). In the United States the percent-
age of all newly diagnosed cancers with stage IA in the general pop-
ulation is approximately 25% (SEER Database). 
While there is some debate about size of cancer and the prognosis, a
number of publications have demonstrated better survival for stage
IA lung cancers <2 cm in maximum diameter versus those that are
2-3 cm in size (11,12).
To date there are no reported large Phase III randomized screening
trials of CT versus chest radiographs or observation alone. The
National Lung Cancer Screening Trial is such a randomized trial of
50,000 participants that will attempt to answer this question. Other
randomized screening trials are underway in The Netherlands (NEL-
SON trial) and France (DepiScan). The endpoints of these trials will
be to determine if screening with CT versus the control arm decreas-
es lung cancer mortality.
CON Screening
Screening with CT has detected a high rate of non-calcified nodules
(NCN). The Mayo Clinic trial detected NCN in 51% of participants
at baseline (4) and 73% of participants after 5 annual CT scans (9).
A study from Germany observed NCN in 43% of participants (6)
and a Canadian study observed 46% of participants with NCNs (8).
In the Mayo Clinic trial 61% of NCN were <4 mm in size and 34%
were 4-7 mm. Only 6% of NCN were 8 mm or greater and required
further investigation immediately. All NCN (7 mm and smaller)
require some follow-up CT evaluation even if it is at yearly inter-
vals. Our recommended follow-up interval is 1 year for nodules ≤ 4
mm and 6 months for 5-7 mm. 
In some participants the presence of NCN results in further diagnos-
tic testing. In a report by Pinsky et al, 12% of participants with an
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abnormal screening CT scan underwent biopsy and only a little over
half of these turned out to be cancer (14). Crestanello and colleagues
reviewed the number of thoracic surgery procedures performed in
the Mayo Clinic CT screening trial and noted that 10 of 55 surgeries
(18%) were performed for benign disease (15).
Interval lung cancers are cancers that develop between annual
screening CT scans. These are usually due to rapidly growing cancer
and are frequently small cell lung cancer. In the Mayo Clinic series
3 of 66 patients with lung cancer presented as interval cancers (9).
Diederich et al noted that 5 of 15 lung cancers in their study were
interval cancers presenting with symptoms. Interval cancers are
almost always advanced and incurable (16). 
Not all screen detected cancers are curable. Swensen et al reported
49 total deaths in their screening trial and 12 of these were from
lung cancer (9). Some of the lung cancers detected by CT screening
were stage III at the time of diagnosis. German investigators report-
ed 6 deaths due to lung cancer in their screening trial (16). It is
unrealistic to think that screening is going to prevent 80-90% of
lung cancer deaths.
Most controversial of all is the cost of screening for lung cancer.
Cost effective studies can only be determined after efficacy is
proven and to date that has not been established. Cost effective esti-
mates in the literature range from $2,500 to over $200,000 per year
of life saved (17,18,19). This wide variation is based on different
assumptions in the models employed. It is probably fair to say that
we do not have a good estimate of costs associated with CT screen-
ing. This is an important aspect of the NLST trial that will be evalu-
ated (13). 
While there are both proponents and opponents of CT screening for
lung cancer, there are currently no completed randomized control
trials that clearly evaluate the capability of screening to decrease
lung cancer mortality. These trials are in progress and the results are
anxiously awaited.
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2.03.03
Adjuvant Chemotherapy in Europe
Scagliotti, Giorgio V., University of Torino, S. Luigi Hospital,
Orbassano, Torino, Italy
Objective of the Presentation: To review the evidence and he state
of the art of adjuvant chemotherapy focusing on European studies
In the last fifteen years more than 5.000 patients with stage I-III
Non-Small Cell Lung Cancer (NSCLC) were enrolled in randomised
studies evaluating the benefit of adjuvant platinum-based
chemotherapy, and almost 50% of the patients were enrolled at
European institutions. Globally, the number of enrolled patients in
these studies is at least 4 fold higher than the number of patients
included in the British Medical Journal meta-analysis published in
1995. Some of these recently concluded adjuvant studies proved a
benefit for the post-operative treatment, ranging from 4% to 15%. In
some studies the overestimation of the treatment effect was poten-
tially related to the early termination of the study.
To get an average and more accurate estimation of the treatment
effect the Lung Adjuvant Cisplatin Evaluation (LACE) meta-analy-
sis was conducted and recently presented. The aim of the meta-anla-
ysis was to identify treatment options associated with a higher benefit,
or groups of patients benefiting more from adjuvant chemotherapy.
Individual patient data were collected and pooled from the five
largest trials (ALPI, ANITA, BLT, IALT and JBR10) of cisplatin-
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based chemotherapy in completely resected patients, conducted after
the NSCLC-meta-analysis. With a median follow-up of 5.1 years,
the overall HR of death was 0.89 (95% confidence interval [CI]:
0.82-0.96; p<0.005) corresponding to a 5-year absolute benefit of
4.2% with chemotherapy. There was no heterogeneity of chemother-
apy effect among trials. The benefit varied with stage (test for trend,
p=0.046) with the HR for stage I-A 1.41 [95% CI: 0.96-2.09], stage
I-B 0.93 [0.78-1.10], stage II 0.83 [0.73-0.95] and stage III 0.83
[0.73-0.95]. The effect of chemotherapy did not vary significantly
(test for interaction, p=0.10) with the associated drugs [0.84-1.14]). 
The LACE meta-analysis confirmed that cisplatin-based chemother-
apy improves survival in patients with NSCLC. This benefit
depends on stage and is greatest in patients with stages II and III.
This analysis confirmed that platinum-based adjuvant chemotherapy
may not benefit stage I-A patients.
2.03.04
Adjuvant Chemotherapy in Early Stage Lung Cancer -
Japanese Trials
Saijo, Nagahiro, National Cancer Center, Chiba, Japan
A prospective placebo controlled randomized trial conducted in
Japan demonstrated that oral administration of UFT in a postopera-
tive adjuvant setting yielded a significant improvement in the sur-
vival of patients with pathological stage I adenocarcinoma of the
lung (p=0.0465, HR=0.723), especially in stage IB (T2N0M0)
(p=0.005, HR=0.482). A meta-analysis of UFT involving more than
2,000 patients from 6 randomized controlled trials demonstrated a
survival benefit with UFT as compared with controls in patients
with completely surgically resected non-small cell lung cancer
(p=0.001, Hazard ratio=0.74).
A recent LACE meta-analysis showed a survival advantage in
patients with completely resected non-small cell lung cancer receiv-
ing platinum-based chemotherapy. However, this survival benefit
was observed only in patients with stage II & III, not in those with
stage IB. All randomized controlled trials including IALT, BR21,
CALGB, ANITA and ALPI found that the platinum-based regimen
failed to improve the survival of stage IB patients. It is unclear why
the results of cisplatin-based chemotherapy and UFT are discrepant.
In comparing patient characteristics between the LACE meta-analy-
sis and Japanese registry data, the Japanese study was noted to
include more elderly patients (≥70% 0. 9% vs 33%), more adenocar-
cinomas (sqamous vs adeno 49%/39% vs 33%/56%), and fewer
patients receiving pneumonectomy (31% vs less than 10%). The
clinical practice guidelines for lung cancer in Japan indicate that
adjuvant chemotherapy is recommended for patients with complete-
ly-resected P-stage IB to IIIA NSCLC. The recommendation grade
is B. UFT and platinum-based chemotherapy respectively are rec-
ommended for IB and II-IIIA patients. The biggest question is a
selection of some specific chemotherapy regimen. Among platinum-
based regimens, Cisplatin + Navelbine has most frequently been
used, though compliance with this chemotherapy tends to be poor.
For example, only 59% of patients received more than 3 cycles of
chemotherapy. Another problem is ambulatory use of cisplatin. In
Japan, there are two ongoing randomized controlled trials. The
WJTOG101 compares GEM alone vs UFT, and accrued 600 pts.
The data will be available within the next few years. Another
TORG0503 randomized phase II study compares paclitaxel + carbo-
platin vs docetaxel + cisplatin, and patients accrual contiues. We
have scheduled two randomized controlled trial: UFT vs S1 in stage
IB patients and platinum based chemotherapy and/or UFT in stage
II-IIIA patients.
2.04.01
Combining Staging with Therapy in Lung Cancer
Ancona, John; Blum, Matthew, Northwestern Memorial Hospital,
Chicago, IL, USA
Objectives: At the end of this session the attendant should be able to:
A. Understand the basic concepts of lung cancer staging and the use
of invasive and non-invasive studies used to determine stage.
B. Understand the staging concept rationale for surgery, chemother-
apy, and XRT and their combinations for the different stages of
lung cancer
C. Understand palliative options for treating advanced lung cancer
This lecture will focus on the treatment options for Non Small Cell
Lung Carcinomas. Determining the stage of the lung cancer, by PET
scan, CT scan, and invasive studies, will determine what treatment
options practitioners offer their patients. We will examine the role of
surgery, chemotherapy and radiation therapy and the success/failure
each has had in dealing with this disease. We will also discuss what
role combined modality treatment can offer patients. 
2.04.04
Case Scenarios in Head and Neck Malignancies
Stenson, Kerstin;1 DeHoyos, Alberto;2 Collazo, Susan;2 Salama,
Joseph1
1 University of Chicago, Chicago, IL, USA; 2 Northwestern
Memorial Hospital, Chicago, IL, USA
Objectives: After this presentation, the audience will better under-
stand the therapeutic decision making in patients with various
advanced head and neck malignancies.
Abstract: A brief introduction addressing the standard of care in
manageing patients with head and neck malignancies. The following
patients will be will then be presented. Treatment and management
of complications and potential problems will be discussed
Case #1: 54 y/o male patient with T4 oral cavity cancer with
obvious bone invasion.
Case #2: 61 y/o female with T2N2b carcinoma of the piriform sinus.
Case #3: 57 y/o man with high -grade parotid malignancy
Case #4 47 man with recurrent tongue cancer after local excision
and PORT for pathologic T2No carcinoma.
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2.05.01
Adjuvant Chemotherapy For Non-Small Cell Lung Cancer: A
Paradigm Shift
Shepherd, Frances A., Professor of Medicine, University of Toronto;
Scott Taylor Chair in Lung Cancer Research, Princess Margaret
Hospital, Toronto, ON, Canada
The poor survival rates following surgical resection for patients with
stage II and III disease have led several groups to investigate the
usefulness of adjuvant chemotherapy after complete or partial resec-
tion of NSCLC. The likelihood of adjuvant therapy prolonging dis-
ease-free or overall survival is based on a number of hypotheses
which include: 1) there is an inverse relationship between cell num-
ber and curability 2) when a tumour is small the growth fraction is
large and the fractional kill is greater than in larger tumours; 3)
drug-resistant cells emerge as tumour burden increases and therefore
therapy is most likely to work in the setting of minimal tumour bur-
den. There are data to support that clinically these hypotheses may
be valid in the adjuvant treatment of NSCLC. It is known from
numerous trials of induction chemotherapy in locally advanced
NSCLC that response rates are higher in earlier stage (Stage II-III)
disease than in metastatic (Stage IV) disease. Furthermore, in the
meta-analyses mentioned below there was a survival advantage for
patients receiving chemotherapy in early stage disease after
chemotherapy. Finally, in patients with other solid tumours (breast,
prostate, colon), chemotherapy and hormonal therapy, which may
have low response rates and are not curative in metastatic disease,
have been shown to improve disease-free and overall survival when
given adjuvantly.
The most active regimens result in responses in only 30 to 40 per-
cent of patients with advanced disease, and complete clinical
responses are rare. It is not surprizing, therefore, that a major sur-
vival advantage has not been seen in most of the prospective ran-
domised trials of adjuvant therapy to date. The results from several
prospective trials of adjuvant chemotherapy are summarized in
Table 3. The LCSG was formed in 1977 to evaluate the role of adju-
vant therapy after surgery for NSCLC. The trials undertaken by this
group are particularly important because all patients underwent
meticulous mediastinal node sampling at the time of surgery to
allow for precise staging. The first chemotherapy trial of the LCSG
evaluated postoperative cyclophosphamide, doxorubicin, and cis-
platin (CAP) or immunotherapy with bacillus Calmette Guérin
(BCG) in patients with completely resected stage II or III adenocar-
cinoma or large cell undifferentiated carcinoma. The recurrence rate
was significantly lower in the chemotherapeutic arm. The median
survival was approximately 7 months longer, and the 2 year survival
rate was also greater, although this did not reach statistical signifi-
cance by the two sided log rank test. This trial has been criticized
because it did not have a no therapy control arm.
In another trial, the LCSG also observed a benefit in patients with
incompletely resected tumours who received postoperative CAP and
radiotherapy compared with those treated with radiotherapy alone.
Once again, the median survival time was prolonged by approxi-
mately 7 months, but the 3 year survival rate was equal in both
arms. The last LCSG study evaluated the usefulness of CAP
chemotherapy following complete resection of early stage tumours
(T1N1 and T2N0) compared with no additional therapy. This study
was disappointing because no improvement was seen for patients
treated with CAP with respect to either the median survival or long
term survival time. The Finnish lung cancer group undertook a simi-
lar trial of adjuvant CAP chemotherapy in patients with early stage
(T1 3N0) NSCLC. In contrast to the last LCSG study reported by
Feld et al., this study did demonstrate a survival advantage for
patients in the chemotherapy arm at 5 and 10 years (P = 0.05). The
greatest benefit was seen in patients with T2N0 tumours, but
because of the small number of patients in this subgroup, the differ-
ence did not reach statistical significance (72.5 percent versus 50.3
percent; P = 0.15). The CAP regimen was expanded to include vin-
cristine and lomustine (COPAC) in a multicentre French trial. At a
minimum follow-up time of six years, no difference in either dis-
ease-free or overall survival was seen between the group who
received thoracic radiotherapy alone, or three courses of COPAC
followed by radiation. When these trials were designed up to 20
years ago, CAP chemotherapy was the most active regimen avail-
able for the treatment of non-small cell lung cancer. However, a
National Cancer Institute of Canada (NCIC) study demonstrated a
higher response rate and longer survival for patients with advanced
disease who received vindesine and high-dose cisplatin compared to
CAP. In a Japanese study, three cycles of vindesine and low-dose
cisplatin, 50 mg/m2 were administered, followed by one year of
tegafur and uracil. The control arms received either one year of
uracil alone or no therapy. The five-year survival rates for the
chemotherapy and uracil groups were 60.6% and 64.1% respective-
ly, compared to 49% for the no-treatment group (p=0.053, log-rank,
and p=0.044, Wilcoxon). A comparison of the overall survival of the
two treatment arms combined with that of the surgery alone group
showed a significant advantage for treatment (p=0.022). In another
Japanese trial limited to patients with completely resected stage III
tumours, post-operative vindesine and cisplatin was compared to no
further treatment. Their results were similar to those of the LCSG
trials in that the median survival was prolonged by approximately
six months, but long-term survival was not significantly improved
(5-year rates 41% and 35%). A US Intergroup trial , lead by the
Eastern Cooperative Oncology group randomized 488 patients with
completely resected Stage II or IIIA tumours to receive postopera-
tive etoposide and cisplatin plus thoracic radiotherapy or radiothera-
py alone. The median survival for the chemotherapy group was 38
months compared to 39 months for the radiation-alone group
(P=0.56).
The studies discussed above all used second generation chemothera-
py regimens. Although some of the trials demonstrated a definite
biologic effect for adjuvant chemotherapy, the survival gains were
modest at best, and frequently the benefit was reflected only in
median survival, without a long-term benefit. In addition, the CAP
generation of studies encountered significant problems with both
patient and physician compliance, with the result that only half of
the intended chemotherapy was actually administered in most of the
trials. Because most of the trials were relatively small, they lacked
the statistical power to show significant differences. To determine
whether small but meaningful survival gains could actually be
attributed to the administration of chemotherapy after surgery, a
large meta-analysis was performed by the Non-small Cell Lung
Cancer Collaborative Group. To evaluate the addition of chemother-
apy to surgery, 14 trials, which included 4357 patients, were studied.
The results for the use of long-term alkylating agents were negative
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with a combined hazard ratio of 1.15 (p= 0.005). However, for regi-
mens that contained cisplatin, the overall hazard ratio was 0.87
(p=0.08), with an absolute benefit from chemotherapy of three per-
cent at two years, and five percent at five years. When chemothera-
py was added to surgery plus thoracic irradiation, the benefits were
less, with an overall hazard ratio of 0.94 (p=0.46), and a two percent
survival benefit at both two and five years. 
Recent trials have been larger with the power to detect small, but
potentially clinically meaningful benefits. Unfortunately, many still
used second generation chemotherapy regimens. A large European
trial was conducted by the EORTC and the Adjuvant Lung Project
Italy (ALPI). Patients with completely resected stage I-IIIA tumours
were randomised to receive three courses of adjuvant mitomycin C,
vindesine and cisplatin or follow-up alone; radiation was optional.
No difference in survival was reported. The International Adjuvant
Lung Cancer Trial (IALT), which was initiated by the lung cancer
group at the Institut Gustave-Roussy in France, spanned at least four
continents, and was a trial of novel design. Patients with completely
resected stages I, II, and selected IIIA must have received a plat-
inum-based regimen, but the dose of cisplatin could range from 80-
120 mg/m2, and the second drug could be vinblastine, vindesine,
vinorelbine or etoposide according to availability of chemotherapeu-
tic agents in the country where the patient was being treated.
Patients must receive an adequate number of treatment cycles to
receive a total cisplatin dose of 300-400 mg/m2. Radiotherapy could
be administered at the discretion of the treating physicians. The trial
showed a significant survival benefit in favour of chemotherapy
with an absolute ~4% improvement in cure rate. The result of this
large trial is almost identical to that of the first meta-analysis done a
decade earlier!!
Three more randomised trials of adjuvant chemotherapy using 3rd-
generation regimens from North America and Europe have now
reported their results. The NCIC-CTG, ECOG, SWOG and CALGB
completed a trial of adjuvant cisplatin and vinorelbine for patients
with stage I (T2N0), and stage II (excluding T3N0) NSCLC. This
trial showed a significant survival advantage for patients treated
with chemotherapy. The median survival was prolonged by almost
two years and the overall hazard ratio for survival was 0.7 with an
absolute 15% improvement in survival at 5 years. Another study of
adjuvant vinorelbine and cisplatin was sponsored by Pierre Fabre in
France (ANITA-1). This trial also showed a significant survival
advantage for adjuvant chemotherapy with a hazard ratio of 0.79,
p=0.013. The CALGB closed its trial of adjuvant paclitaxel and car-
boplatin in T2N0 NSCLC early when an interim analysis suggested
a significant survival benefit for chemotherapy. The hazard ratio in
favour of chemotherapy was 0.62 and the absolute survival benefit
was 12% at 4 years. However, when the results of this trial were
updated at ASCO in June 2006, the overall survival difference was
no longer significant with a hazard ratio of 0.80, p=0.10, and an
absolute survival difference at 5 years of only 2%. The difference in
failure-free survival remained significant in favour of chemotherapy.
Although a 5% improvement in cure rate has been considered
enough to justify adjuvant chemotherapy for other tumour types,
neither surgeons, physicians nor patients considered this benefit to
be adequate to recommend adjuvant chemotherapy for NSCLC.
However, the results of the recent trials, particularly the two that
evaluated vinorelbine and cisplatin suggest that it will now be
mandatory to discuss adjuvant chemotherapy with lung cancer
patients who are fit enough to tolerate platinum-based treatment.
These two landmark studies are truly paradigm-shifting trials that
will change the way early stage NSCLC is treated in North America
and Europe. The survival benefit equals or even exceeds that which
is achieved with adjuvant chemotherapy in other tumour types, and
this treatment should no longer be withheld from patients with
NSCLC.
Table 1.
Summary of Adjuvant Chemotherapy Trials for NSCLC
Number HR (95% CI)
BMJ meta-analysis 1394 0.87 (0.74-1.02)
IALT 1867 0.86 (0.76-0.98)
ALPI 1209 0.94 (0.79-1.12)
E3590 488 0.93 (0.74-1.18)
BLT 381 1.02 (0.77-1.35)
NCIC JBR.10 482 0.70 (0.52-0.92)
CALGB 9633 330 0.80 (0.60-1.07)
ANITA 840 0.79 (0.66-0.95)
UFT meta-analysis 2003 0.74 (0.61-0.88)
LACE meta-analysis 6940 0.89 (0.82-0.96)
Vinorelbine/Cisplatin 2816 0.80 (0.70-0.91)
2.06.01
Targeting mTOR Signaling in Lung Cancer to Enhance
Therapeutic Efficacy
Khuri, Fadlo R.; Sun, Shi-yong, Winship Cancer Institute, Emory
University, Atlanta, GA, USA
The mammalian target of rapamycin (mTOR) signaling pathway
plays a critical role in promoting cell cycle progression and cell pro-
liferation, and is frequently up-regulated in many cancers including
non-small cell lung cancer (NSCLC). Rapamycin and its analogues,
such as RAD001 (everolimus), are highly specific inhibitors of
mTOR and are now in phase I - III oncology clinical trials. A recent
trial showed substantial efficacy for one such compound, CCI-779
(serolimus) in high risk, advanced renal call cancer. Akt, a survival
protein frequently activated due to ras mutations and overexpression
of growth factor receptors in human NSCLC, positively regulates
mTOR signaling via tuberous sclerosis complex 2 (TSC2), whereas
LKB1, a tumor suppressor gene, mutates with high frequency in
NSCLC, negatively regulates mTOR signaling. Thus, both Akt acti-
vation and LKB1 mutation may impact cell sensitivity or response
to mTOR inhibitors. The determination of the prognostic values of
key proteins (p-Akt, p-mTOR, p-70S6K, p-4E-BP1, p-S6) in the
mTOR axis in NSCLC will be carried out by obtaining tissue from
the NATCH (Neo-Adjuvant Trial of Chemotherapy Hope) and inte-
grating these biomarkers into a molecular prognostic model for
operable NSCLC. These biomarkers will subsequently be assayed in
a series of novel translational clinical trials evaluating RAD001 as
preoperative biochemical therapy in resectable NSCLC or in combi-
nation therapy with docetaxel in metastatic disease. Recent data
from our group demonstrate that downregulation of mTOR by
rapamycin and its analogues causes paradoxical upregulation of Akt,
and that inhibition of PI3K after mTOR inhibition substantially aug-
ments response to mTOR inhibitors. Our intention is to further
enhance the therapeutic exploitation of this pharmacologically
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enhanced oncogene addiction. Our hypothesis, that aberrant activa-
tion of mTOR signaling due to frequent Akt activation and LKB1
mutations in NSCLC impacts patient prognosis and serves as an
opportune target for effective treatment of NSCLC using mTOR
inhibitors and their combinations with chemotherapy and targeted
agents will be tested.
2.06.02
The Akt/mTOR Pathway in Lung Cancer Therapy
Papadimitrikopoulou, Vali, University of Texas MD Anderson
Cancer Center, Houston, TX, USA
The PI-3 kinase (PI3K)/Akt signaling represents a major cell sur-
vival pathway. Its activation has long been associated with malig-
nant transformation and apoptotic resistance. It is generally thought
that the mammalian target of rapamycin (mTOR) functions down-
stream of the PI3K/Akt pathway and many other signaling mole-
cules often deregulated in cancer cells, such as EGFR, HER2, IGF-
1R, PTEN, TSC1/2, Ras, Raf, Abl and the estrogen receptor, and it
is negatively regulated by LKB1, a serine/threonine kinase with
tumor suppressor activity. mTOR is a central controller of cell
growth, cell division and protein translation, primarily through two
distinct pathways:ribosomal p70 S6 kinase (p70S6K) and the
eukaryotic translation initiation factor 4E (eIF4E) binding proteins
(4E-BPs). This pathway is frequently altered in cancer either
through inactivating mutations of the LKB1 or constitutive activa-
tion of signalling of PI3K/Akt. Elevated PI3 kinase/Akt activity is
not only common in NSCLC but also promotes the survival of can-
cer cells in NSCLC and pharmacologic inhibition of PI3 kinase
leads to proliferative arrest in NSCLC cell lines while, in vitro stud-
ies have demonstrated that inhibition of Akt activity, by pharmaco-
logic or genetic means, greatly improves the cellular response to
treatment modalities commonly used to treat NSCLC, such as
chemotherapy and radiation.
mTOR inhibitors
Several mTOR inhibitors are currently under development including
rapamycin and its derivatives CCI-770 and RAD001 as well as
AP23573. mTOR inhibitors are active in preclinical models of
human lung cancer with direct inhibition of tumor growth and sup-
pression of angiogenesis . Sensitivity to mTOR inhibition with
RAD001 in tumor cells correlates directly with the level of activated
AKT. 
It has also been shown, that mTOR inhibition by rapamycin triggers
rapid and sustained activation of PI3K/Akt survival pathway in
human lung and other types of cancer cells such that combination of
mTOR targeted therapy with drugs that block PI3K/Akt activation
might also be reasonable.
The drug was well-tolerated in phase I studies with common adverse
events being rash and stomatitis in approximately 40% (grade 3 in
only 1% and 5% of patients respectively) of the patients . Dose-lim-
iting toxicities were stomatitis, neutropenia and hypoglycemia.
Pharmacodynamic studies based on inhibition of pS6kinase and
safety profile support phase II dosage of 10 mg/day or 50-70
mg/week. In addition reliable biomarkers of drug activity have been
indicated as pS6K and p-eIF4G . Tumor response and prolonged dis-
ease stabilization has been observed, notably in NSCLC. In addition,
clinical responses have been reported in NSCLC patients treated
with a rapamycin, CCI779, or AP23573.
In lung and other cancers that overexpress EGFR, resistance to
EGFR-targeted therapies may involve activation of alternative sig-
naling pathways which activate Akt and maintain signaling through
TOR(10). Combined inhibition of EGFR and mTOR signaling
enhanced in vivo anti-tumor activity in a glioblastoma multiforme
model. The rational combination of mTOR inhibition and EGFR
tyrosine kinase (TK) inhibition is pursued clinically with prelimi-
nary evidence of activity.
Clinical trials utilizing combinations of these agents with standard
chemotherapy as well as other signaling inhibitors (based on hints
provided by preclinical studies) are desired and are being planned.
2.06.03
Targeting Estrogenic Pathways for Lung Cancer Therapy
Siegfried, Jill M.;1 Traynor, Anne M.;2 Hershberger, Pamela;1
Belani, Chandra P.;3 Stabile, Laura P.1
1 University of Pittsburgh, SPORE in Lung Cancer, Pittsburgh, PA,
USA; 2 University of Wisconsin, Madison, WI, USA; 3 University of
Pittsburgh School of Medicine, Pittsburgh, PA, USA
Our previous work has shown that estrogen receptors are expressed
by lung tumors and estrogen functions as a proliferative signal,
alone and in combination with EGFR signaling. Evidence suggests
that ERβ is responsible for these effects. In a preclinical lung cancer
model, the combination of the anti-estrogen fulvestrant and the
EGFR tyrosine kinase inhibitor gefitinib was superior to either treat-
ment alone. We have carried out a Phase I clinical trial of the combi-
nation of monthly 250 mg IM fulvestrant and daily 250 mg oral
gefitinib in 22 post-menopausal women with Stage IIIB/IV NSCLC.
No unexpected adverse events were seen with the drug combination.
No treatment-related grade 3 or higher toxicities were observed.
Median overall survival was 46 weeks (range 7-80+ weeks). Median
progression-free survival was 12 weeks (range 4-80+ weeks). Three
partial responses were observed, median duration 73 weeks. All PRs
were in never smokers, one of whom had an EGFR mutation. Stable
disease was observed in 12 patients and disease progression in six.
High nuclear ERβ staining (≥ 60% of tumor nuclei positive) was
associated with better overall survival than lower ERβ staining (<
60% tumor nuclei positive). Combination of an anti-estrogen with
an EGFR TKI is safe and shows activity against NSCLC. Further
study will involve a Phase II clinical trial with the combination
erlotinib and fulvestrant compared to erlotinib alone. We have also
initiated studies of aromatase, the terminal enzyme in estrogen syn-
thesis, in NSCLC. RT-PCR analysis showed aromatase gene expres-
sion, confirmed by sequencing, in human bronchial epithelial cell
cultures, normal lung fibroblasts, and six NSCLC cell lines.
Immunoblotting also revealed aromatase protein in 77% of primary
NSCLC tumors. In an assay of conversion of testosterone to estro-
gen, the NSCLC cell line 273T (female) was found to produce
appreciable estrogen in 6 hr, compared to two male cell lines in
which no conversion to estrogen was detectable. These results sug-
gest targeting estrogen synthesis may also be useful in NSCLC.
Supported by SPORE grant P50 CA90440. 
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2.06.04
EGFR Inhibition in the Adjuvant or Stable Disease Setting
Kelly, Karen, University of Colorado Health Sciences Center,
Aurora, CO, USA
Maintenance therapy for nonsmall cell lung cancer (NSCLC) using
cytotoxic chemotherapy has not produced a survival benefit.
However, with the development of active, well tolerated, molecular-
ly targeted agents, re-evaluation of maintenance therapy has
emerged as a promising strategy in the adjuvant and stable disease
setting of lung cancer. The convenient, once a day oral administra-
tion of the EGFR small molecule tyrosine kinase inhibitors (EGFR-
TKIs), gefitinib and erlotinb are particularly attractive and both
agents are being explored in these settings and will be reviewed. In
advanced disease, gefitinib nor erlotinib plus chemotherapy pro-
duced a survival advantage over chemotherapy alone but subset
analyses suggested these agents may prolong survival in nonpro-
gressors after chemotherapy (1,2).
Southwest Oncology Group trial, S0023 was the first randomized
trial to report data on the role of an EGFR-TKI as a true mainte-
nance therapy (3). This phase III trial evaluated gefitinib versus
placebo after definitive chemoradiotherapy followed by consolida-
tion docetaxel in nonprogressing patients with stage III NSCLC. The
trial closed prematurely after an unplanned interim analysis showed
no potential for gefitinib to produce a superior survival outcome.
The explanation for this finding is unclear and the study is undergo-
ing further analysis.
In the adjuvant setting, the National Cancer Institute of Canada con-
ducted a randomized phase III trial of gefitinib versus placebo in
pathological stage IB-IIIA disease (JBR 19). It too closed prema-
turely with 500 patients enrolled. Data analysis is expected in 2009. 
Since these trials were initiated, retrospective biomarker studies
have identified promising predictive markers for response to EGFR
-TKIs including EGFR mutational analysis, immunohistochemistry
(IHC) and fluorescence in situ hybridization (FISH) (4-5). These
tests may be helpful in selecting the most appropriate patients for
anti-EGFR therapy. Prospective trials incorporating these predictive
markers have begun in many scenarios including as a maintenance
approach. For example, the RADIANT trial is an active, randomized
phase III trial of erlotinib or placebo following complete resection
and adjuvant chemotherapy in EGFR-IHC and/or FISH positive
patients with stage IB-IIIA NSCLC. 
References:
1. Herbst RS, Giaccone G, Schiller JH, et al: Gefitinib in combination with
paclitaxel and carboplatin in advanced non-small-cell lung cancer: A
phase III -INTACT 2. J Clin Oncol 22:785-794, 2004
2. Herbst RS, Prager D, Hermann R, et al. TRIBUTE: A phase III trial of
erlotinib hydrochloride (OSI-774) combined with carboplatin and pacli-
taxel chemotherapy in advanced non-small-cell lung cancer. 23:5892-
5899,2005.
3. Kelly K, Gaspar LE, Chanksy K, Albain KS, Jett J, Ung Y, Crowley JJ,
Gandara DR: SWOG 0023: A randomized phase III trial of
cisplatin/etoposide (PE) plus radiation therapy followed by consolidation
docetaxel then maintenance therapy with gefitinib or or placebo in
patients with locally advanced unrescetable stage III non-small cell lung
cancer (NSCLC). Lung Cancer 49(2s) 2005 (abstract #O-192a).
4. Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer -
Molecular and clinical predictors of outcome. N Engl J Med 353:133-
144,2005.
5. Bell DW, Lynch TJ, Haserlat SM, et al. Epidermal growth factor receptor
mutations and gene amplification in non-small-cell lung cancer:
Molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol
23:8081-8092,2005.
2.06.06
Bcl-2 as a Therapeutic Target in Small Cell Lung Cancer
Rudin, Charles M.; Hann, Christine L., The Sidney Kimmel
Comprehensive Cancer Center, Johns Hopkins University,
Baltimore, MD, USA
Bcl-2 is the first member of a large family of apoptotic regulatory
proteins. Bcl-2 is overexpressed in many cancers, and has been
implicated as both a contributor to malignant transformation and as
a determinant of therapeutic resistance. Bcl-2 upregulation has been
reported in the majority of small cell lung cancers (SCLC).
Inhibition of Bcl-2 production using antisense oligonucleotides
increased chemosensitivity in preclinical models of small cell lung
cancer. However, initial clinical trials using a Bcl-2 antisense
oligonucleotide with standard chemotherapy, both for chemorefrac-
tory disease and for previously untreated SCLC, demonstrated
response rates and survival data similar to that seen with chemother-
apy alone. Analyses performed in our laboratory on peripheral blood
mononuclear cells from patients in one of these studies demonstrated
no effect on intracellular Bcl-2 levels, suggesting that adequate target
suppression may not have been achieved with antisense in vivo.
As an alternative strategy for targeting Bcl-2 in small cell lung can-
cer, we have conducted a series of studies using a small molecule
inhibitor of Bcl-2, ABT-737, in SCLC lines in tissue culture and
established as murine xenografts. ABT-737 demonstrates remarkable
single agent cytotoxic activity against several SCLC both in vitro
and in vivo. Sensitivity to ABT-737 appears to correlate with cellular
expression of the target, Bcl-2. We are currently evaluating putative
mechanisms of acquired resistance to ABT-737 in recurrent
xenograft tumors, and exploring combinatorial therapies with ABT-
737 and standard cytotoxics for SCLC with intermediate sensitivity
to ABT-737 as a single agent.
A number of small molecule inhibitors of Bcl-2 have been devel-
oped and are beginning or will begin clinical evaluation in small cell
lung cancer soon. In addition to an orally bioavailable derivative of
ABT-737, these include AT-101 (R-(-)-gossypol), and GX15-070.
Development of these agents represents a promising direction in the
treatment of SCLC and other Bcl-2-dependent tumors.
3.01.01
Combined Modality Therapies in Head and Neck Cancer
Vokes, Everett E., University of Chicago, Chicago, IL, USA
The role of combined modality therapy in locally advanced head
and neck cancer has expanded in recent years. Concomitant
chemoradiotherapy is now a standard in the postoperative setting.
Similarly it is current standard therapy for patients with locoregion-
ally advanced unresectable head and neck cancer. Finally it can be
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used as initial therapy with the intent of allowing for subsequent
organ preservation in patients with resectable disease. Induction
chemotherapy has also been shown to prolong survival and remains
a therapeutic option for larynx preservation. Current issues regard-
ing combined modality therapy involve the addition of induction
chemotherapy to concomitant chemoradiotherapy. Randomized trials
are currently evaluating this approach. For example, in the DeCIDE
study at the University of Chicago patients receive either chemora-
diotherapy with docetaxel infusional flurouracil, hydroxurea and
twice daily radiation (DFHX) given every other week or initial
chemotherapy with two cycles of cisplatin, flurouracil and docetaxel
(TPF) followed by the identical chemoradiotherapy regimen. Similar
studies are ongoing at the other institutions. The integration of tar-
geted therapies into the combined modality therapy setting is also
undergoing evaluation. The use of the cetuximab with concurrent
radiotherapy has already been shown to increase survival compared
with radiotherapy alone. This approach therefore represents a possi-
ble approach for patients unable to undergo standard chemoradio-
therapy. Importantly, randomized trials are currently addressing
whether the addition of cetuximab to concurrent chemoradiotherapy
can lead to a further increase in local regional control and survival.
The use of antiangiogenic agents and novel chemotherapy agents in
the combined modality setting is also under investigation. 
It appears increasingly likely that current combined modality thera-
pies will be able to cure a majority of patients with local regionally
advanced head and neck cancer. As cure rates improve, increased
emphasis on reduction of acute toxicities as well as maintaining
long term speech and swallowing outcomes will be necessary.
3.01.03
The Role of Neck Dissection in Locally Advanced Squamous
Cell Carcinoma of the Head & Neck
Ridge, Drew, Fox Chase Cancer Center, Philadelphia, PA, USA
Presentation Objective: At the completion of this lecture the
attendee should be familiar with the management principles and
controversies surrounding neck dissection in the care of patients
with advanced head and neck cancer who are treated with primary
surgical management, as well as non-surgical “organ preservation.”
Abstract: Formal neck dissection continues to play an important
role in the care of patients with advanced squamous cell carcinoma
of the head & neck. This is true despite advances in the non-surgical
treatment of the disease, which involves many different primary
sites from the oral cavity to the thoracic inlet. Appreciation of man-
agement principles and current controversies is important.
Radiotherapeutic control of the tumor-free neck is outstanding, so
patients who undergo primary radiation treatment without neck dis-
ease do not need neck dissections.
When the primary cancer is addressed primarily with surgery, a
“staging” selective neck dissection confers important information
and usually guides recommendations surrounding adjuvant therapy.
Hence, even in the absence of clinical nodal disease, a neck dissec-
tion should be performed when surgical treatment at the primary site
is undertaken.
When a primary cancer is treated with surgery and malignant lymph
nodes are present, then a comprehensive node dissection as part of
combined modality therapy probably affords the best prospects for
long-term regional control.
Patients with cancers of the oropharynx, larynx, and hypopharynx
are increasingly treated without operations. Advances in combined
modality therapy for head and neck cancer seem to be reducing the
chance that even bulky nodal disease will recur in the neck, but
some such patients still need node dissection. Post-radiation neck
dissection is a safe procedure, and should be undertaken if tumor
remains in the neck some weeks after radiation has been completed.
It should be performed before wound healing problems increase
(usually within 12 weeks). Even in the hands of experienced sur-
geons long-term morbidity of neck dissection, such as swallowing
problems, cannot be ignored. However, post-radiation recurrences
are devastating, so thorough efforts to prevent them are justified.
3.01.04
Integration of EGFR Inhibition in Induction Chemotherapy
Strategies for Head and Neck Cancer
Kies, Merrill, The University of Texas M.D. Anderson Cancer
Center, Houston, TX, USA
Cetuximab is a chimeric human and murine monoclonal antibody
directed against the epidermal growth factor receptor. In an exciting
recent report, Bonner (N Engl J Med 354:567-78, 2006) and col-
leagues have conducted a prospectively randomized multinational
trial in which previously untreated patients with locally advanced
squamous cell carcinoma of the oropharynx, hypopharynx or larynx
received definitive radiotherapy with or without cetuximab. In this
phase III trial, 424 patients were entered and median duration of fol-
low-up was 38 months. Patients were randomized to receive radia-
tion alone or with concomitant cetuximab administered. With no
increase in severe-grade radiation-related mucocutaneous toxicity,
there was a statistically significant improvement in locoregional
control and overall 3-year survival (44% vs 57%) favoring the com-
bined therapy arm. This was the first demonstration of a survival
benefit in squamous carcinoma of the head and neck with use of
“molecular” therapy. We have completed a phase II trial with induc-
tion chemotherapy consisting of 6-weekly cycles of paclitaxel 135
mg/m2, carboplatin auc 2 and cetuximab 400 mg/m2 week 1 then
250 mg/m2 (Kies, ASCO 2006 Abs 5520). Previously untreated
patients with staging T0-4, N2b-3, M0, of any head and neck pri-
mary site were entered. Median follow-up is now 14 months.
Following induction chemotherapy, patients underwent “risk-based”
local therapy. Choice of surgery ± postoperative radiotherapy (RT),
RT, or concomitant chemoRT was based upon tumor stage and site
at diagnosis. Patient entry (2/05-11/05) has concluded with 47
patients (33 m, 14 f), median age 53 years and range 21-78.
Oropharynx was the dominant primary site, N=42. Toxicity was
acceptable. Sixteen (34%) pts had grade 3/4 leukopenia; 22(47%)
grade 3 folliculitis (median 5 cycles of cetuximab administered);
and 2(4%) serious hypersensitivity. All 42 evaluable pts achieved a
response in the primary site, 8 PR and 34(83%) CR. Forty-five of 46
evaluable patients achieved a nodal response, 33 PR and 12(26%)
CR. Overall, 11 of 45 (23%) pts were disease-free after CT. At this
early follow-up point, 3 pts have had 4 tumor recurrences, 2 local
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and 2 distant. Thus, control of distant disease is promising. Small
molecule tyrosine kinase inhibitors, such as gefitinib or erlotinib, are
also under investigation for use as single agents or as a component of
combination regimens. Phase II trial data are to be presented. Study of
tumor genomics and biomarkers is underway. These promising early
results predict the integration of molecular therapy into multimodal
treatment strategies. Current investigations are directed toward the
identification of active molecular drug combinations and dual
inhibitors which would affect EGFR and other signaling pathways.
3.01.05
Induction Chemotherapy in Locally Advanced SCCHN
Posner, Marshall R.; Wirth, Lori J.; Haddad, Robert I., Dana-Farber
Cancer Institute, Harvard Medical School, Boston, MA, USA
Cisplatin/5-fluorouracil (PF) has been the most effective regimen of
induction chemotherapy until 2006. Randomized trials and meta-
analysis have demonstrated unequivocally that PF-based induction
chemotherapy significantly improves survival by 5 % over 5 years,
reduces systemic metastases and permits organ preservation in local-
ly advanced SCCHN. Five-year survival in randomized trials with
PF has been less robust than the 8% seen with cisplatin-based
chemoradiotherapy (CRT). Differences in patient eligibility, trial
design, and the schedule of surgical intervention account for some
of the difference in results. Recent analysis of the RTOG 91-11 lar-
ynx preservation trial indicates an equal and significant improve-
ment in laryngectomy free survival with PF and CRT compared to
radiotherapy (XRT) alone, though no difference in overall survival
was seen. Recently, two randomized trials have shown that docetax-
el-PF (TPF) induction chemotherapy is significantly more effective
than PF. TAX 323 randomized unresectable patients to TPF or PF
followed by XRT and showed the TPF patients had a substantial
reduction in mortality, improved quality of life and less toxicity.
Because Phase II trials with TPF showed continued high rates of
local-regional failure despite reduced distant metastases, and ran-
domized trials of CRT have shown reduced local-regional failure but
no improvement in control of distant disease, a sequential model of
therapy was proposed. TAX 324 studied sequential therapy, combin-
ing induction chemotherapy, chemoradiotherapy and surgery and
compared TPF to PF followed by CRT with weekly carboplatinum.
TAX 324 reported impressive survival results in patients with local-
ly advanced disease receiving TPF with a 30% reduction in mortali-
ty compared to PF (p <0.006) and 62% of TPF and 48% of PF
patients surviving 3 years or more. With two highly positive trials,
TPF-based induction chemotherapy now replaces PF as the standard
of induction regimen and, based on TAX 324, sequential therapy
represents an acceptable treatment for patients with locally advanced
HNC. TPF-based sequential therapy versus chemoradiotherapy is
now being studied in multiple Phase III studies. 
3.02.02
Radiotherapy for Limited Stage Small Cell Lung Cancer -
Current Concepts
Bogart, Jeffrey A., Upstate Medical University, Syracuse, NY, USA
Objectives: 
1. Discuss the integration of thoracic radiotherapy and systemic
chemotherapy in limited stage small cell lung cancer (LSCLC)
2. Discuss considerations of thoracic radiotherapy dose, fractiona-
tion, and volume in LSCLC
3. Discuss ongoing and planned prospective trials in LSCLC
Although the integration of thoracic radiotherapy (TRT) with sys-
temic chemotherapy for the treatment of limited-stage small cell
lung cancer (LSCLC) has been widely studied, several critical issues
have not been resolved. Two meta-analyses, published in the early
1990s, confirmed that adding TRT to chemotherapy significantly
improved long-term survival in LSCLC, although the majority of tri-
als included in theses analyses did not employ modern standards of
systemic chemotherapy and TRT. More recently, INT 0096 demon-
strated that reducing the time to complete 45 Gy TRT to 3 weeks
(1,5 Gy BID) from 5 weeks (1.8 Gy QD), concurrent with cisplatin
based chemotherapy, improves outcomes in LSCLC. This was one
of the few studies documenting a change in TRT delivery could ulti-
mately impact survival. Nevertheless,due in part to practical consid-
erations and enhanced acute toxicity, the 45Gy BID TRT regimen
has not been widely adopted. Alternative strategies for increasing
the efficacy of TRT have been studied including high dose QD TRT
(CALGB), and concomitant boost TRT (RTOG). The relevant clini-
cal data from these studies will be discussed along the rationale for
proceeding with a prospective phase III study assessing TRT regi-
mens. The timing of TRT relative to chemotherapy is another hotly
debated issue, with several randomized studies yielding conflicting
results. Recent meta-analyses have suggested early initiation of TRT
is important when accelerated TRT is employed, and the relevant
clinical studies will be reviewed. In addition, considerations of mod-
ern radiotherapy planning including target volume determination,
normal tissue restrictions, and employing tissue heterogeneity cor-
rections will be presented. 
3.02.03
Novel Targets and Agents for Patients with Small Cell Lung
Cancer
Johnson, Bruce E., Dana-Farber Cancer Institute, Brigham and
Women’s Hospital, Harvard Medical School, Boston, USA
Presentation Objectives:
4. Recognize potential new targets that have been identified in
small cell lung cancer
5. Identify the new targeted agents that are undergoing trials in
small cell lung cancer
6. Assess the efficacy of the new targeted agents.
The introduction of new effective anticancer agents for small cell
lung cancer has been disappointingly slow during the past 2
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decades. The identification of novel targets and testing of potentially
effective targeted agents for patients with small cell lung cancer has
increased substantially in the past 5 years. The classes of targeted
molecules that are undergoing evaluation include antiangiogenic
agents, recombinant molecules, antisense bcl-2 inhibitors, and
inhibitors of the sonic hedgehog signaling pathway. The class of
agents that is undergoing the most extensive testing are the antian-
giogenic agents including bevacizumab (Avastin™, Genentech,
South San Francisco, CA), small molecule tyrosine kinase
inhibitors, and thalidomide. Bevacizumab is being studied in combi-
nation with etoposide and cisplatin or irinotecan and cisplatin for
patients with previously untreated extensive stage small cell lung
cancer in two different phase II trials. The small molecule tyrosine
kinase inhibitors, sorafenib and ZD2171, are being tested in phase II
trials for patients with relapsed small cell lung cancer. ZD6474 is
being tested in a maintenance setting in patients with small cell lung
cancer after they have achieved a partial or complete response to
treatment. Thalidomide is being evaluated with chemotherapy for
patients with extensive stage small cell lung cancer. The recombi-
nant molecule, BB-10901, is undergoing phase II testing in patients
with relapsed small cell lung cancer. G3139 (oblimersen sodium), a
phosphorothioate oligonucleotide, is complementary to the bcl-2
mRNA and has been tested in a randomized phase II study with
chemotherapy. The other novel target that has been identified is the
sonic hedgehog signaling pathway. Several lead compounds have
been identified but not yet started testing in humans. Investigators
are hopeful that these will provide new effective agents for treat-
ment of small cell lung cancer.
3.03.01
Oral Cancer Progression: Opportunities for Detection and
Prevention
Lingen, Mark W., University of Chicago, Chicago, IL, USA
Objective: To outline some of the current research investigating
ways to improve the clinical detection and the molecular diagnosis
of premalignant lesions of the oral cavity.
Head and neck squamous cell carcinoma (HNSCC) is an aggressive
malignancy that is the sixth most common neoplasm in the world.
Despite advances in treatment, the long-term survival has remained
largely unchanged for the last 50 years. Screening and early detec-
tion have been proposed to decrease the morbidity and mortality
associated with disease. However, the conventional visual detection
of premalignant oral lesions is problematic. This is in stark contrast
to skin lesions, where conventional visual screening for melanomas
has high rates of sensitivity and specificity. Possible explanations for
this discrepancy are that early oral lesions frequently do not demon-
strate the clinical characteristics of HNSCC and the clinical presen-
tation of premalignant lesions in the oral cavity is highly heteroge-
neous. Since the malignant potential of oral lesions cannot be accu-
rately predicted solely on the basis of its clinical characteristics, his-
tologic evaluation has been recommended for all suspicious lesions.
However, conventional biopsies rely on subjective histologic criteria
that are open to a wide range of interpretation. In addition, from a
molecular perspective, the use of histologic criteria does not consti-
tute early detection, because cytologic changes occur late in the
transformation process. Therefore, histologically benign appearing
lesions may have malignant potential while some dysplasias may
not progress and may even undergo regression. Therefore, histologi-
cal findings can only be used to indicate that a given lesion has
malignant potential, and cannot be used for the prediction of malig-
nant change. As such, improvements in the clinical visualization of
lesions in conjunction with additional diagnostic tools that allow for
molecularly based diagnostic predictions prior to and after the
development of cytologic atypia would greatly improve the potential
for early detection, prognostication, and intervention. Despite these
challenges, recent work by numerous investigators has identified
potentially new clinical and diagnostic tools that may aid in our
fight against HNSCC.
3.03.02
Novel Targets and Agents in SCCHN
Cohen, Ezra E., University of Chicago, Chicago, IL, USA
The first molecularly targeted agent was approved in SCCHN by US
regulatory authorities this year representing a major step forward in
the therapy of this disease. EGFR inhibition continues to be a major
focus of interest as new combinations and criteria for patient selec-
tion are defined. However, SCCHN is marked by several molecular
aberrations representing future targets for therapy. Current targets of
interest and potential agents in development will be discussed.
3.03.04
Recurrent Squamous Cell Carcinoma of the Head and Neck:
The Role of Re-irradiation and Chemotherapy – A North
American Perspective
Langer, Corey, Fox Chase Cancer Center, University of
Pennsylvania, Philadelphia, PA, USA
Recurrent squamous cell carcinoma of the head and neck (SCCHN)
or new second primary tumor (SPT) in a previous radiation field, if
not curable by surgery or radiation, is virtually always fatal. Chemo-
therapy alone yields median survival times (MST) of <10 months
and 1 year survival (OS) of d 35% at best.1-6 Re-irradiation alone,
except for patients with nasopharyngeal carcinoma,7 has not generally
been used in this setting because of prior relatively high radiation
dosage, and concerns about local tissue tolerance and catastrophic late
complications. Yet pre-clinical studies have demonstrated that soft tis-
sue can tolerate repeat doses of radiation as high as 90% of the origi-
nal dose, particularly if the second treatment is applied 6 weeks or
more after the completion of the firs treatment.7-10 Langlois has
shown that reduction in the size of the re-irradiation volume can
substantially decrease the probability of complications,11 and that
risk of toxicity is further reduced by split course approaches, as well
as smaller fraction sizes ~ 1.8 - 2.0 Gy per fraction. Regardless,
radiation alone is unlikely to confer durable survival in this setting.
On the other hand, concurrent re-irradiation and chemotherapy may
be a more viable strategy, particularly if we extrapolate the benefits
observed with combined modality therapy compared to RT alone in
treatment-naïve SCCHN patients. 12-14
Early Clinical Efforts:
Based on pilot trials at the University of Alabama15 and the
University of Chicago,16, 17 Spencer, Wheeler and colleagues
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mounted a Phase II trial under the aegis of RTOG (R-9610) evaluat-
ing concurrent split course hyperfractionated radiation with fluo-
rouracil infusion and hydroxyurea.18 Patients with unresectable,
locally relapsed, previously radiated SCCHN or SPT within a previ-
ous RT field received RT 1.5 Gy per fraction (fx) twice a day for 5
days every other week x 4 in combination with hydroxyurea 1.5 gm
2 hours prior to the second fraction of RT daily times 5, and 5FU
300 mg/m2 IV before second fraction of RT daily times 5. 
Between August 1996 and April 1999, 86 patients were accrued.
The median prior RT dose was 64.8 Gy. 25% had SPTs. Compliance
was fairly good, with 73% receiving all 4 cycles. Acute grade ≥3
mucositis occurred in 21%; grade ≥3 neutropenia was recorded in
24%. There were 6 treatment-related fatalities, 4 due to sepsis, 2 due
to tumor hemorrhage. Median survival was 8.8 months, with 1- and
2-year survival rates of 41.7% and 16.9%. 1-year survival was better
in those who relapsed 3 years or more after prior RT compared to
those who relapsed within 3 years (47.8% versus 36.4%, p=0.04).
Evaluating Paclitaxel and Cisplatin in the Salvage Setting:
Because cisplatin and paclitaxel are established radiosensitizers with
proven activity in SCCHN,2-5 investigators at Fox Chase Cancer
Center (FCCC) mounted a Phase I trial exploring the combination of
these agents with hyperfractionated RT.19 The upshot, FCCC 96-
006, employed a split course schedule to facilitate optimal integra-
tion of chemotherapy with RT, and allowed the integration of
hematopoietic growth factors (HGF) between cycles to avoid the
paradoxical toxicity noted with concurrent RT in HGF, and to poten-
tially mitigate both mucositis and myelosuppression. This study
established a maximum tolerated dose (MTD) of split course RT of
1.5 Gy per fraction twice a day x 5 days every other week for 4
cycles, in combination with cisplatin 15 mg/m2 daily x 5 days every
other week, and paclitaxel 20 mg/m2 daily times 5 days every other
week. In the absence of growth factor support, the second and sub-
sequent cycles were delayed a week or more almost routinely. With
growth factor support, 13 of 18 cycles at full dose were delivered on
schedule. The most common toxicities were grade 3 and 4 neutrope-
nia in 17% of enrollees, and grade 3 and 4 anemia in 23% of
patients. Grade 3 mucositis occurred in only 6%. Of 22 patients with
measurable, recurrent SCCHN, the overall response rate was 54%.
Local-regional freedom from progression was 10 months; one-year
progression free survival rate was 28%. Median survival was 9.5
months with 1-and 2-year rates of 41% and 27%, respectively.
Evolution of RTOG 9911
Based on these encouraging results, the RTOG launched a phase II
trial formally testing this regimen at its MTD in a multicenter set-
ting (RTOG 9911).20 Eligibility stipulated recurrent SCCHN or SPT
in a previous RT field. Patients received hyperfractionated (HFx) RT
(1.5 Gy per fraction BID x 5d every 2 wks x 4), plus cisplatin 15
mg/m2 IV daily x 5 and paclitaxel 20 mg/m2 IV , each daily x 5
every 2 weeks x 4. G-CSF was given days 6 through 13 of each 2
week cycle. 
105 patients were enrolled from 3/00 through 6/03; 23% had SPT.
Oropharynx (40%) and oral cavity (27%) were the predominant pri-
mary sites. Median prior RT dose was 65.4 Gy. 74% of patients
completed all 4 cycles of chemotherapy. Grade ≥ 4 acute toxicity
occurred in 28%, grade ≥ 4 acute hematologic toxicity in 21%.
Eight treatment-related deaths (8%) occurred: 5 in the acute setting,
3 late (including 2 carotid hemorrhages). Despite complications,
median survival was 12.1 months with 1- and 2-year survival rates
of 50.2% and 25.9%, respectively, results which generally exceed
those seen with chemotherapy alone. Patients with SPTs, or those
whose head and neck cancers relapsed more than 36 months after
prior treatment, fared no better than patients with recurrent disease
or those whose relapse occurred within 3 years of prior treatment.
These observations are discordant with our previous experience in
RTOG 961018 wherein those who relapsed more than 3 years after
prior radiation had a 12% absolute improvement in 1-year survival
rate and wherein a similar trend tended to favor those with second
primary tumors as opposed to recurrent disease
Future Directions
In most quarters, chemotherapy alone remains the standard of care
for patients with relapsed, incurable SCCHN. ECOG trials 13934
and 13955 tested cisplatin-based chemotherapy, in combination with
either paclitaxel or 5-fluorouracil. Of nearly 400 patients accrued,
153 had local disease, of whom 124 were previously treated with
radiation. The 2 year survival rate in this group was only 10.5%.4, 5
In contrast, of all patients enrolled onto RTOG 9911, 16% remain
progression-free beyond 2 years, and the prospect of long term sur-
vival, if not cure, is potentially within reach. Whether re-irradiation
and concurrent chemotherapy is superior to chemotherapy alone can
only be addressed by a properly conducted, prospective Phase III
trial. RTOG 0421 randomizes patients identical to those enrolled
onto RTOG 9911 to either split course, hyperfractionated radiation
with concurrent cisplatin and paclitaxel with G-CSF support, or to a
choice of three separate standard chemotherapy combinations: cis-
platin 75 mg/m2 every 3 weeks, in combination with either paclitax-
el 175 mg/m2, docetaxel 75 mg/m2, or 5 fluorouracil 1000 mg/m2
continuous infusion x 96 hours. 
Several other issues exist. The optimal dose of radiation in this set-
ting is still unknown. 60 Gy is likely insufficient, particularly since
the vast majority of these patients have relapsed after prior RT doses
that exceeded 60Gy, and more recent experiments have indicated
that soft tissue can tolerate a repeat dose as high as 90% of the orig-
inal if the second treatment is applied more than 6 weeks after the
first has concluded.11, 21 Ongoing studies are also evaluating the role
of targeted therapy in this setting, including angiogenesis inhibitors
and EGFr inhibitors, in combination with either RT alone or
chemotherapy and radiation. With the recent approval of C225 in
combination with RT in locally advanced SCCHN based on studies
demonstrating therapeutic superiority compared to RT alone22 and at
least one other study disclosing superior response rate in combina-
tion with cisplatin compared to cisplatin,23 this approach warrants
further attention. 
Still, considerable reluctance to investigate re-irradiation persists.
Fear of toxicity is not unrealistic. However, appropriate patient
selection, restricting this approach to patients with excellent per-
formance status should help mitigate this concern. In addition, it is
imperative that patients maintain adequate nutrition, and that those
whose nutritional integrity is compromised undergo appropriate G-
tube insertion. Finally, outside of a formal study, this therapeutic
strategy is not ready for routine implementation. This sort of
research is best conducted by a dedicated, multi-disciplinary team
with adequate experience and focus.
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3.05.01
Chemotherapy Plus Radiotherapy For Stage III NSCLC – Is
There An Optimal Regimen?
Eberhardt, Wilfried, Department of Internal Medicine, West German
Cancer Center, University Hospital of the University Duisburg-
Essen, Essen, Germany
Looking at currently available evidence for the treatment of stage III
non-small-cell-lung cancer, combinations of chemotherapy together
with radiation have become a standard approach. Recent evidence
has demonstrated, that concurrent application of chemotherapy and
radiotherapy within so called chemoradiation protocols can further
improve survival by an increase in local control. However, these
data from phase-III multicenter randomized trials were predominant-
ly based on cisplatinum-containing chemotherapy given simultane-
ously to standard fractionated radiotherapy. To date, the majority of
available multicenter trials have looked at cisplatin and etoposide
(PE) as well as cisplatin and vinca alkaloid together with radiation.
Cisplatin-combinations with newer agents like gemcitabine, pacli-
taxel or docetaxel have only been reported within multicenter, ran-
domized phase-II trials (eg. CALGB-trial). Multicenter randomized
data with carboplatin-based protocols could not clearly substantiate
favourable results with such a chemoradiation strategy, so far.
Recent results from a multicenter French randomized phase-II trial
have in principle shown feasibility of a cisplatin-based induction
chemotherapy plus concurrent chemoradiotherapy protocol. Here,
the concurrent chemotherapy regimen was cisplatin and the vinca
alkaloid vinorelbine. Multicenter SWOG-experience and the ran-
domized Intergroup-trial have demonstrated that concurrent PE
together with radiation followed by consolidation PE can currently
serve as a valid comparator. The promising multicenter experience
of SWOG, introducing consolidation docetaxel into this setting, is
currently being further investigated within the randomized Hosier
Oncology Group-trial. Mature results from this study will probably
solve the consolidation strategy issue.
As a conclusion, the most extensive database and evidence for
chemotherapy regimen in stage III currently exists for cisplatin-
based combinations with either etoposide or vinca alcaloid as the
second partner.
3.05.05
Addition of Targeted Agents to Multimodality Therapy for Stage
III NSCLC
Gandara, David R.;1 Gaspar, Laurie;2 Kelly, Karen;2 Crowley, John3
1 University of California Davis Cancer Center, Sacramento, CA,
USA; 2 University of Colorado Health Sciences Center, Aurora, CO,
USA; 3 Cancer Research And Biostatistics, Seattle, WA, USA; 
During the last few years, a wide array of novel, molecular-targeted
therapeutic agents (MTAs) have entered clinical investigation, many
in lung cancer. While a great majority of clinical trials have been
directed toward metastatic disease, stage III NSCLC presents both
increased opportunities, due to it’s potential curability, and increased
challenges regarding how to best integrate them into current treat-
ment paradigms with thoracic radiotherapy and chemotherapy.
Further complicating these issues is the fact that stage III NSCLC
represents a large and heterogeneous group of patients and several
clinically distinct substages. 
Treatment options for the majority of patients with stage III NSCLC
include combinations of chemotherapy and thoracic radiation, with
or without surgery. Randomized clinical trials and meta-analyses
support the conclusion that combined modality approaches employ-
ing platinum-based chemotherapy improve survival compared to
radiotherapy alone in patients with surgically unresectable stage III
disease. Conceptually, locally advanced lung cancer can be thought
of as a 2 compartment model: a local-regional compartment in the
chest, and a distant compartment harboring potential micrometas-
tases. Cancer must be eradicated in both compartments to achieve
long term survival. Combinations of chemotherapy and thoracic
radiation have been applied sequentially or concurrently; each
approach offers potential advantages and disadvantages for the
incorporation of MTAs. Sequential approaches to chemoradiothera-
py, in which chemotherapy precedes thoracic radiation, generally
improve outcome by reducing distant failure rates, with no improve-
ment in local control when compared with radiotherapy alone. In
contrast, in concurrent chemoradiotherapy strategies, chemotherapy
may play either a radiosensitizing role designed to improve local
control, or a cytotoxic role by eradicating distant micrometastases
or, both dependent on the timing and doses of chemotherapy
employed. Conceptually, MTAs may play a similar role to
chemotherapy, since in addition to addressing distant micrometas-
tases, MTAs may also possess radiosensiting properties that assist in
local control. 
This presentation will address the rationale for incorporating MTAs
into combined modality therapy in both stage III NSCLC, as well as
ongoing and developing clinical trials testing this therapeutic strategy.
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2.07.01
Randomized Phase II-III Trial of Concomitant CT/RT Versus
TPF Followed by Concomitant CT/RT in Locally Advanced
Squamous Cell Carcinoma of the Head and Neck (LASCCHN).
Results of the Phase II Part of the Study.
Ghi, Maria Grazia;1 Koussis, Haralabos;2 Buffoli, Alberto;3
Staffieri, Alberto;4 Mione, Carlo Alberto;1 Galligioni, Andrea;5
Lunghi, Francesco;6 Bonetti, Andrea;7 Zorat, Pier Luigi;8
Paccagnella, Adriano1
1 Ospedale SS Giovanni e Paolo, Venice, Italy; 2 Azienda
Ospedaliera IOV - Padova, Padua, Italy; 3 Azienda SM della
Misericordia, Udine, Italy; 4 Azienda Ospedaliera - Padova, Padua,
Italy; 5 Ospedale S. Chiara, Trento, Italy; 6 Ospedale Civile,
Monselice, Italy; 7 Azienda ULSS 21, Legnago, Italy; 8 Ospedale Cà
Foncello, Treviso, Italy
Background: Concomitant CT/RT is the standard treatment for
LASCCHN. The present study explores the efficacy of induction
chemotherapy followed by CT/RT vs CT/RT alone. 
Material and Methods: Pts with inoperable stage III-IVa, PS 0-1,
were randomized to CT/RT [2 cycles of Cisplatin 20mg/sqm days 1-
4, 5FU 800 mg/sqm 96 hours c.i. weeks 1 and 6 during RT (66-70
Gy)] (Arm A) or 3 cycles of neoadjuvant TPF (Docetaxel 75mg/sqm
day1, Cisplatin 80mg/sqm day1, 5FU 800mg/sqm 96 hours c.i) fol-
lowed by the same CT/RT (Arm B). Pts were stratified according to
tumor site, T stage and nodal status. Neck dissection was performed
in N2-N3 patients with pathological CR on primary tumor. The radi-
ological responses were evaluated by an Internal Committee accord-
ing to RECIST criteria.
Results: Pts/tumor characteristics are well balanced in the two arms.
Toxicities during induction TPF consisted primarily of G3-4 granu-
locytopenia 48.9% (febrile neutropenia:6.4%). Grade 3-4 toxicities
during CT/RT in arm A (CT/RT alone) and in arm B (TPF + CT/RT)
were mucositis (38.3% and 23.4%), dysphagia (19.2% and 10.6%),
skin reaction (12.7% and 14.9%); G3 weight loss (2.1% and 4.3%),
G3 dry-mouth (0% and 4.3%). TPF treatment seemed not to affect
the duration of CRT: 6.1wks (3.8-9.5) in arm A and 6.3 weeks (4.2-
8.7) in arm B. Preliminary efficacy results are available for 94 out of
101 randomized pts. At the end of the sequence of treatment, radio-
logical CR were 19.2% (95%CI 9.2-33.3) in CT/RT arm and 46.8 %
(95%CI 32.1-61.9) in TPF+CT/RT arm.
Conclusions: Three cycles of induction TPF are feasible and don’t
compromise subsequent concomitant CT/RT. The difference in CR
in favour of neoadjuvant CT followed by CT/RT justifies the follow-
ing phase III study. Final results will be presented at the meeting.
2.07.02
Aneusomy, Angiogenesis and Histology in Bronchial Biopsies
from Smokers at High Risk for Lung Cancer
Jonsson, Steinn;1 Varella-Garcia, Marileila;1 Miller, York E.;2 Wolf,
Holly J.;1 Lewis, Marina;1 Kennedy, Timothy C.;2 Keith, Robert L.;2
Hirsch, Fred;1 Franklin, Wilbur A.1
1 University of Colorado Health Sciences Center, Aurora, CO, USA;
2 University of Colorado Health Sciences Center, Denver, CO, USA
The development of Lung Carcinoma (LC) is accompanied by field
changes that may have prognostic importance. We compared histo-
logical dysplasia score, angiogenic squamous dysplasia (ASD) and
chromosomal aneusomy as predictors of prevalent or incident LC in
bronchial biopsies from 106 subjects with high-grade dysplastic
lesions or carcinoma in situ (CIS) obtained by LIFE bronchoscopy.
A 4-color FISH probe was used for aneusomy detection targeting
centromere 6, 5p15.2, 7p12 (EGFR) and 8q24 (CMYC). Three or
more copies for two or more of these DNA targets indicated an
aneusomic cell. 
The population included 83 males and 23 females with a mean age
of 63.1 years and a mean smoking history of 62.8 pack-years. There
were 30 individuals with invasive LC, 28 prevalent and 2 incident,
whereas 76 were LC free. Fourteen had CIS as the highest histologi-
cal grade, 42 had severe dysplasia (SD) and 50 had moderate dys-
plasia (MD). The strongest correlate with invasive LC was CIS by
histological examination 12/14 (OR=35.1). FISH analysis for MD
showed 38 normal / 12 abnormal (OR=0.33), severe dysplasia 27/15
(OR=0.97) CIS 2/12 (OR=9.94). Eighteen of 30 (60%) LC individu-
als had abnormal FISH analysis whereas 21 of 76 (27.6%) of LC
free individuals had abnormal FISH results (OR = 5.04). No associ-
ation between ASD and invasive LC was found. In those with ASD
5 of 13 with abnormal FISH had LC whereas 26 of 28 with normal
FISH analysis were LC free (OR=14.17).
CIS on histological examination is associated with the presence of
invasive LC. Abnormal FISH analysis in the presence of MD or SD
is associated with increased risk of invasive LC whereas normal
FISH analysis is associated with LC free status.
2.07.03
COX-2 Expression is a Positive Predictive Factor for Celecoxib
+ Chemotherapy in Advanced Non-Small Cell Lung Cancer
(NSCLC): CALGB 30203 
Edelman, Martin J.;1 Watson, Dorothy;2 Wang, Xiaolin;3 Morrison,
Carl;4 Kratzke, Robert A.;5 Jewell, Scott D.;4 Mauer, Ann M.;6
Green, Mark R.;7 Vokes, Everette E.;6 Masters, Gregory A.;8 Gajra,
Ajeet9
1 University of Maryland Greenebaum Cancer Center, Baltimore,
MD, USA; 2 Duke University, Durham, NC, USA; 3 CALGB
Statistcal Center, Duke University, Durham, NC, USA; 4 CALGB
Pathology Coordinating Office University of Ohio, Columbus, OH,
USA; 5 University of Minnesota, Minneapolis, MN, USA; 6
University of Chicago, Chicago, IL, USA; 7 Medical University of
South Carolina, Charleston, SC, USA; 8 Helen F. Graham Cancer
Center, Newark, DE, USA; 9 SUNY Upstate Medical/Syracuse
VAMC, Syracuse, NY, USA
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Background: Eicosanoid overexpression has been associated with
adverse prognosis. Specific inhibitors of two eicosanoid pathways,
COX-2 (celecoxib) and 5-LOX (zileuton) have been developed. We
hypothesized that eicosanoid inhibitors added to chemotherapy
could improve outcome. 
Methods: Patients (pts) with stage IIIb (pleural effusion)/stage IV
NSCLC, PS 0-2, no prior therapy were eligible. All pts received C
AUC 5.5 d1 + G (1000 mg/m2) d1, and were randomized to : A:
Zileuton (Z) 600 mg qid po, B: Celecoxib (CEL) 400 mg po bid C:
CEL and Z at the same doses. CEL and Z were administered with
chemotherapy and continued until progression.
Immunohistochemical (IHC) staining for COX-2 and 5-LOX was
evaluated by the number of cells 0 (0%), 1: (1-9%), 2:( 10-49%), 3:
(50-100%) and the intensity of staining (0-3). The expression index
was 0-9 = intensity (0-3) x percentage (0-3).
Results: 136 pts were treated (A: 44, B: 47, C: 45). M: 86, F: 50;
PS 0,1,2 = 38,85,13. There was no benefit in terms of PFS or OS.
107 blocks were submitted and 83 were adequate for IHC. In
patients who did not receive celecoxib, overexpression of COX-2
was a negative prognostic marker (index ≥ 4, HR = 2.683, p= .018;
index =9, HR = 4.155, p= .009). However, it was a positive predic-
tive marker. Pts with moderate to high COX-2 overxpression who
received celecoxib (Arms B,C) had better survival (index ≥ 4 HR
=.420, p=.039; =9 HR =.194, p=.006.) 5-LOX expression was nei-
ther prognostic nor predictive.
Conclusions: 1. Eicosanoid modulation in an unselected population
is not beneficial. 2. COX-2 overexpression is a negative prognostic
marker. 3. COX-2 overexpression is predictive of survival benefit in
pts who receive celecoxib +chemotherapy. 
2.07.04
A Phase II, Multicenter, Randomized Clinical Trial to Evaluate
the Efficacy and Safety of Bevacizumab in Combination with
Either Chemotherapy or Erlotinib, Compared with
Chemotherapy Alone for Treatment of Recurrent in Refractory
NSCLC
Herbst, Roy S.;1 O’Neill, Vincent J.;2 Fehrenbacher, Louis;3 Belani,
Chandra P.;4 Bonomi, Philip D.;5 Hart, Lowell L.;6 Melnyk, Ostap;7
Sandler, Alan B.;8 Lin, Ming;2 Bloss, Jeffrey D.2
1 The University of Texas M. D. Anderson Cancer Center, Houston,
TX, USA; 2 Genentech, South San Francisco, CA, USA; 3 The
Permanente Medical Group, Vallejo, CA, USA; 4 University of
Pittsburgh Cancer Institute, Pittsburgh, PA, USA; 5 Rush-
Presbyterian-St. Lukes Medical Center, Chicago, IL, USA; 6 Florida
Cancer Specialists, Fort Myers, FL, USA; 7 Bay Area Cancer
Research Group LLC, Concord, CA, USA; 8 Vanderbilt-Ingram
Cancer Center, Nashville, TN, USA
Background: Bevacizumab (B) is a recombinant, humanized anti-
VEGF MAb. Erlotinib (E) is a potent, reversible oral EGFR tyro-
sine-kinase inhibitor. Both compounds have demonstrated a survival
benefit in the treatment of NSCLC-Bevacizumab when added to
chemotherapy in the first line setting, and Erlotinib when given
alone in the 2nd/3rd line setting.
Methods: A multicenter, randomized phase II trial was conducted to
evaluate the safety of combining Bevacizumab with chemotherapy,
or with Erlotinib, and to make a preliminary assessment of the effi-
cacy as measured by progression-free survival. All patients had his-
tologically confirmed non-squamous NSCLC and had experienced
disease progression following one platinum-based regimen for
advanced stage disease. Randomization was on a 1:1:1 basis to doc-
etaxel or pemetrexed plus placebo vs. docetaxel or pemetrexed plus
Bevacizumab vs. Bevacizumab plus Erlotinib. Patients were treated
until documented disease progression or through 52 weeks.
Results: Between August 2004 and November 2005, 120 patients




Median, mo 3.0 4.8 4.4
Adjusted Hazard Ratio NA 0.66 0.72
(95% CI) (0.38, 1.16) (0.42 1.23)
Overall Survival
6-month rate (%) 62.4 72.1 78.3
Response Rate, n (%)
CR/PR 5 (12.2) 5 (12.5) 7 (17.9)
Drug discontinuation 10 (24.4) 10 (25.0) 4 (10.3)
due to AE, n (%)
SAEs, n (%) 22 (53.7) 16 (40.0 13 (33.3)
Grade 5 Drug-related 2 (4.9) 3 (7.5) 1 (2.6)
AEs, n (%)
Grade 3-5 Pulmonary 0 2 (5.0) 1 (2.6)
Hemorrhage
Conclusions: Observed data favor the addition of Bevacizumab to
either chemotherapy or Erlotinib over chemotherapy alone. No new
or unexpected safety signals were noted. The toxicity profile of the
Bevacizumab-Erlotinib combination is favorable when compared to
either chemotherapy-containing group. The Bevacizumab-Erlotinib
combination may represent an alternative to chemotherapy-based
treatment in this setting.
2.07.05
Efficacy and Safety of Sunitinib in a Multicenter Phase II Trial
of Previously Treated, Advanced Non-small Cell Lung Cancer
(NSCLC) 
Socinski, Mark A.;1 Novello, Silvia;2 Sanchez, Jose M.;3 Brahmer,
Julie A.;4 Govindan, Ramaswamy;5 Belani, Chandra P.;6 Atkins,
James N.;7 Gillenwater, Heidi H.;8 Tye, Lesley;9 Chao, Richard C.9
1 University of North Carolina, Chapel Hill, North CArolina, USA; 2
University of Turin, Turin, Italy; 3 Hospital Germans Trias I Pujol,
Barcelona, Spain; 4 Johns Hopkins University School of Medicine,
Baltimore, MD, USA; 5 Washington University School of Medicine,
St. Louis, MO, USA; 6 University of Pittsburgh School of Medicine,
Pittsburgh, PA, USA; 7 Southeastern Medical Oncology Center,
Goldsboro, NC, USA; 8 University of Virginia, Charlottesville, VA,
USA; 9 Pfizer Global Research and Development, La Jolla, CA, USA
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Background: Sunitinib malate (SU11248; SUTENT®) is an oral,
multitargeted tyrosine kinase inhibitor targeting VEGFR, PDGFR,
KIT, FLT3 and RET on tumor cells, tumor neovasculature and peri-
cytes. This open-label, two-stage, multicenter phase II trial evaluat-
ed the single-agent activity of sunitinib in refractory NSCLC. 
Methods: Eligibility criteria included confirmed diagnosis of
NSCLC, ECOG PS 0-1, no recent gross hemoptysis, no brain metas-
tases, previous treatment with 1-2 chemotherapy regimens, and ade-
quate end-organ function. Patients received sunitinib at 50 mg/day
po for 4 weeks followed by 2 weeks off treatment (6-week cycles). 
Results: 63/64 enrolled patients received sunitinib. Patients (65%
male; median age 60 years [range 33-86]) had adenocarcinoma
(64%), squamous cell carcinoma (22%), or other (14%); PS 0/1:
44%/56%; stage IIIB/IV: 10%/90%; prior regimens ≥2: 57% (range
1-4); median time since completion of prior regimen: 2.2 months
(range 0.3-16.7); median number of sunitinib cycles started: 2
(range 1-8). Sunitinib was generally well tolerated, with most side
effects mild to moderate. Grade 3/4 adverse events included fatigue
+ asthenia (22%/5%), pain + myalgia (14%/3%), dyspnea
(13%/0%), and nausea + vomiting (10%/0%). To date, there have
been 7 confirmed partial responses (11.1%; 95% CI: 4.6-21.6).
Stable disease ≥8 weeks has been observed in an additional 26
patients (41.2%). Median progression-free survival: 11.3 weeks
(95% CI: 10.0-15.7) and median overall survival: 23.9 weeks (95%
CI: 17.0-28.3).
Conclusions: Sunitinib has single-agent activity in previously treat-
ed patients with recurrent and advanced NSCLC, and is well tolerat-
ed in this population. A continuous dose schedule is under investiga-
tion at 37.5 mg/day po. Further trials are warranted and are ongoing
with sunitinib in combination with standard agents/regimens.
2.07.06
Preoperative Chemoradiotherapy Does Not Increase the Risk of
Complications for Pneumonectomy in Non-Small Cell Lung
Cancer Patients
Allen, Aaron;1 Mentzer, Steven;2 Sugarbaker, David J.;2 Mamon,
Harvey;1 Baldini, Elizabeth H.;1 Soto, Ricardo;1 Rabin, Michael S.;3
Jänne, Pasi A.;3 Bueno, Rapheal;2
1 Department of Radiation Oncology, DFCI/BWH, Boston, MA,
USA; 2 Division of Thoracic Surgery, Brigham and Women’s
Hospital, Boston, MA, USA; 3 Division of Medical Oncology, DFCI,
Boston, MA, USA
Purpose/Background: Trimodality therapy including concurrent
chemoradiation followed by surgery provides excellent outcomes for
operable Stage III NSCLC. The recent intergroup trial (0139)
showed an improvement in local control for trimodality therapy as
compared to chemoradiation alone. A survival benefit was not seen
secondary to a high level of post-operative mortality, primarily fol-
lowing pneumonectomy (26%). We examined the DFCI/BWH expe-
rience with trimodality therapy who underwent pneumonectomies.
Materials and Methods: The patient records of consecutive
patients undergoing chemoradiotherapy followed by pneumonecto-
my from 1994-2005 were retrospectively reviewed with IRB
approval. All patients underwent pneumonectomy at the BWH.
Neoadjuvant therapy was completed primarily at outside institutions.
93% of patients received weekly carboplatin/paclitaxel concurrent
with thoracic radiotherapy, the remainder received cisplatin/VP-16.
The median number of chemotherapy cycles was 3 (range 1-8).
Dose of thoracic radiotherapy was median 54 Gy ( range 30-60Gy).
All patients were followed from diagnosis to date of death or last
follow-up.
Results: 74 patients underwent trimodality therapy. Median age 58,
30 male and 44 female. 41% were adenocarcinoma and 59% squa-
mous. 34/74 (45%) were left sided cases and 40 ( 55%) were right
sided pnemonectomies. 36/74 were stage IIIA and 34/74 were IIIB.
Four patients underwent combined modality therapy after resection
of a single brain metatstasis. Thirty-day mortality was 4% (3/74).
The causes of death were PE, arrhythmia and ARDS. Ninety day
mortality was 7% (4/74), ARDS. All patients who died of complica-
tions related to surgery had undergone right-sided pneumonec-
tomies. Combined modality toxicity following surgery was seen in
11%. The causes were bronchopleural fistula three patients, DVT,
atrial fibrillation, heart failure, and hemothorax in one patient each.
Overall survival at one year was 64% and 40% at 2 years. The over-
whelming cause of death was disease progression.
Conclusion: Combined modality therapy is safe and effective. The
combination of concurrent chemoradiotherapy does not seem to
increase surgical complication when surgery is done at a high vol-
ume center with specialized thoracic surgeons. Right-sided pneu-
monectomies do appear to have more risk than left sided pneu-
monectomies.
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4.01.01
Skip Mediastinal Nodal Metasteses in the IIIA/N2 Non-Small
Cell Lung Cancer
Ilic, Nenad;1 Petricevic, Ante;1 Frleta Ilic, Nives;2 Arar, Dragan;3
Banovic, Josip;1 Kotarac, Slavica;3 Tripkovic, Andro1
1 University Surgical Hospital, Split, Croatia; 2 Oncology Dept.
Clinical Hospital, Split, Croatia; 3 Pulmology Dept. Clinical
Hospital, Split, Croatia
Objectives: To study the incidence and characteristics of mediasti-
nal nodal metastases without N1 nodal metastases (“skip N2 metas-
tases”) in patients with resected pIIIA/N2 non small cell lung cancer
(NSCLC).
Methods: A total of 322 NSCLC patients who undrewent R0 surgi-
cal resection with a systemic mediastinal nodal dissection in four
years time period (2000-2003) were retrospectively analyzed. The
85 patients (26%) at stage IIIA/N2 (pN2+) were grouped according
to their metastases status. Patinets data were statistically analyzed.
Results: Skip N2 metastases were found in 21 patients (25%) . The
postoperative survival for skip N2 disease was allmost the same as
that for pN2 disease with N1 nodal involvement. The incidence of
N2 metastases seemed to be more frequent in adenocarcinoma
patients (p>0.005), but skip N2 metastases were significantly higher
(p>0.001) in squamous cell carcinoma patients. Although skip
metastases involve more often upper mediastinal lymph nodes and
one station level, the difference was not found statistically signifi-
cant (p>0.227). Complications rate showed no difference between
analyzed groups of patients.
Conclusions: Sample mediastinal lymphadenectomy may not be
appropriate in surgery for NSCLC, because skip metastases were
found in 25% of the patients without N1 nodal involvement. Role of
intraoperatively sentinel lymph node dissection has yet to be proven.
4.01.02
Infusional Topotecan with Concurrent Radiation Followed by
Consolidation Etoposide Platinum and Docetaxel for Patients
with High Risk Unresectable Stage III Non-Small Cell Lung
Cancer
Seung, Steven;1 Fisher, Brenda;2 Ross, Helen J.2
1 The Oregon Clinic, Portland, OR, USA; 2 Earle A. Chiles
Research Inst., Portland, OR, USA
Background: Good PS patients (pts) with locally advanced NSCLC
treated with concurrent chemoradiotherapy have a 20-40% 3 year
survival. Treatment is arduous and poor PS or high risk pts often
cannot complete a full course of treatment. The optimal combination
of chemotherapy and radiation and the role of consolidation
chemotherapy are unknown. Despite response rates exceeding 50%,
most pts eventually progress with brain as the first site of relapse in
up to 30%. Continuous infusion chemotherapy is better tolerated
than intermittent chemotherapy combined with radiation and may
improve outcome in other locally advanced aerodigestive malignan-
cies, however it has not been studied extensively in NSCLC.
Topotecan is active in NSCLC, can safely be combined with radia-
tion, can be given by continuous infusion and penetrates the CNS
making it an attractive study agent in locally advanced NSCLC. 
Methods: In this pilot study, 20 pts were treated with infusional
topotecan 0.4 mg/m2/d with 3D conformal radiation to 63 Gy both
delivered M-F for 7 weeks. Pts without progressive disease under-
went consolidation chemotherapy with etoposide and platinum for
one cycle to take advantage of upregulation of topoisomerase II by
topotecan. Two cycles of docetaxel consolidation followed. Study
endpoints include response, time to progression, survival, toxicity
and development of CNS metastases. 
Results: All pts have completed induction chemoradiotherapy. 12/20
have completed consolidation. 17/20 pts had a PR and 1/20 SD after
induction chemoradiation. 1 pt developed CNS metastases 228 days
after study entry and is alive with disease at 541 days. 3 pts had pul-
monary emboli. Therapy has been well tolerated with 1/20 grade
4 lymphopenia. Grade 3 hematologic toxicity was seen in 17/20 pts.
Other grade 3 toxicities include esophagitis (3/20), esophageal stric-
ture (2/20), pneumonitis (6/20), fatigue (6/20), weight loss (1/20). 
Conclusion: Continuous infusion topotecan with radiation is well
tolerated and shows evidence of activity in the management of poor
risk patients with unresectable stage III NSCLC. Survival data will
be presented at the meeting.
4.01.03
Survivin and BCL-XL Genes Expression as Predictive Factor in
IIB and IIIA Non-Small Cell Lung Cancer.
Karczmarek-Borowska, Bozenna;1 Filip, Agata A.;2 Wojcierowski,
Jacek;2 Korszen-Pilecka, Iwona2
1 Oncology Center of Lublin Land, Lublin, Poland; 2 Dept. of
Human Genetics, Medical University of Lublin, Lublin, Poland
Lung cancer is the most common tumor in men; growing incidence
of this tumor in women is observed recently. Increased expression of
anti-apoptotic genes involving BCL-XL and Survivin correlates with
poor prognosis.
The aim of the study: BCL-XL and Survivin expression estimation
in locally advanced NSCLC, and its impact on survival assessment.
Methods: Group of 60 consecutive patients was examined. The
stage according to TNM was: IIB - 43.3%, IIIA - 56.7%. Squamous
cell carcinoma was recognized in 76.7%. Patients were treated with
cisplatin + vepesid at day 1 - 3, every 21 days. In patients that
showed response to the chemotherapy according to WHO (CR and
PR) after 2 regimens, one more regimen was administered and the
were qualified to surgery. BCL-XL and Survivin expression was
examined by means of in situ hybridization.
Results: Expression of BCL-XL was found in 60% of cases, and
Survivin in 58.3%. In 45% co-expression of both genes was
observed. Survivin (+) and BCL-XL (-) expression was found in
13.3% of cases, Survivin (-) and BCL-XL (+) in 15%, Survivin (-)
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and BCL-XL (-) in 27.6%. In 76.2% of patients with Survivin
expression the response to the chemotherapy was found (CR+PR).
In patients with and without Survivin expression the percentage of
5-years survival was 14.3% and 60%, respectively. In patients with
and without BCL-XL expression the 5-years survival was 19.4%
and 54.2%. In patients with co-expression of both the 5-years sur-
vival was 14.8% (median 11 months). The 5-years survival in the
case of Survivin (+) and BCL-XL (-) was 12.5%, for Survivin (-)
and BCL-XL (+) patients - 33.3% (median 25 months in both
groups), while for Survivin (-) and BCL-XL (-) it was 75% (median
60 moths).
Conclusions:
1. Positive expression of both genes examined stands for poor
prognostic factor.
2. In patients with only one gene expression present the median
survival was longer than in patients with co-expression of both
genes analyzed.
3. It appears that Survivin expression is more valuable predictive
factor in NSCLC.
4.01.04
Feasibility and Accuracy of Pretherapeutic Mediastinal Lymph
Node Staging By Video-Assisted Mediastinoscopic
Lymphadenectomy (VAMLA)
Witte, Biruta; Huertgen, Martin; Wolf, Michael, Dept. of Thoracic
Surgery, Katholisches Klinikum Koblenz, Koblenz, Germany
Background: Exact mediastinal staging of lung carcinoma by sys-
tematic mediastinal lymphadenectomy is neither new nor controver-
sial, and usually done at thoracotomy together with lung resection.
Video-assisted mediastinoscopic lymphadenectomy (VAMLA) offers
the possibility to carry out a systematic mediastinal dissection mini-
mally-invasive, and pretherapeutically.
Objective: To assess feasibility and accuracy of video-assisted
mediastinoscopic lymphadenectomy (VAMLA) in the mediastinal
staging of lung carcinoma.
Methods: prospective observation study with a standardized data-
base.
Results: From 2000 to 2005, 170 patients underwent VAMLA for
radiologically (CT-scan) staged N0-N1 lung carcinoma. The median
duration of VAMLA was 70 min (range, 30-170 min), and the medi-
an sample weight 7,5 gr (range, 2-24 gr). 11 complications (6,4%)
were observed: 6 temporary recurrent nerve palsies, 2 venous bleed-
ings, 2 chylothoraces, 1 mediastinitis. Mediastinal involvement was
detected by VAMLA in 30 patients (17,6%). 120/170 patients under-
went subsequently a thoracotomy for lung resection, and mediastinal
reexploration was carried out. At open reexploration, we found rem-
nants of lymphatic tissue in 28 patients, and involved nodes over-
looked by VAMLA in 2 patients. So, the sensitivity of VAMLA is
93,8%, and the specifity 100%.
Conclusion: VAMLA is a feasible and comparatively accurate
method of mediastinal staging. Compared with open mediastinal
exploration, the advantages of VAMLA are the minimal-invasive
approch, the pretherapeutic availability, and, particularly in left-
sided tumors, the improved access to contralateral mediastinal
nodes. VAMLA may be valuable in multimodal, especially neoadju-
vant treatment protocols.
4.01.05
Clinical Outcome of First-Line Four Cycle-Chemotherapy in
Advanced Non-Small Cell Lung Cancer: A Prospective
Observational Study
Lee, Young Seok; Jang, Seung Hun; Kim, Dong Gyu; Eom, Kwang-
seok; Jung, Ki-suck, Division of Pulmonary, Allergy and Critical
Care Medicine of Hallym University Medical Center, Anyang, South
Korea
Objectives: Though guidelines for advanced non-small cell lung
cancer (NSCLC) proposed 3-6 cycles of first-line chemotherapy,
many institutes are still performing 6-cycle chemotherapy. This
study is aimed to evaluate the clinical outcomes of first-line 4-cycle
chemotherapy for NSCLC.
Methods: First-line chemotherapy was limited to 4 cycles. All
patients receiving at least one cycle of treatment were evaluated for
survival and toxicity, and all patients receiving at least two cycles
were evaluated for response.
Results: Between October 2003 and October 2005, forty seven
patients were treated with chemotherapy. Patients’s characteristics
were as follows: male 68.1%, female 31.9%; median age 63 year-
old, range 33-78; ECOG performance status 0-1: 70.2%, 2: 29.8%;
squamous 38.3%, adenocarcinoma 34.0% and unspecified 27.7%;
clinical stage IIIA 6.4%, IIIB 29.8% and IV 63.8%. In total, 150
cycles were administered with mean number of 3.2 ± 1.1 per patient.
57.4% of patients could receive the planned 4 cycles. 89.4% of
patients were treated with the regimen of gemcitabine 1,250mg/m2
on Day 1, 8 plus cisplatin 60 mg/m2 on Day 1. The overall survival
period was 13.6 months (95% CI 12.2-15.0), and the 1-year survival
rate was 58.5%. The time-to-progression (TTP) of the first-line ther-
apy was 4.3 months (95% CI 3.9-4.7). The response rate was as fol-
lows: CR 0%, PR 40.0%, SD 35.0%, PD 22.5% and unevaluated
cases 2.5%. 70.2% of patients received second-line treatment and
40.4% received third-line treatment.
Conclusion: The overall survival of first-line four-cycle chemother-
apy was not inferior to 6-cycle chemotherapy compared with histori-
cal controls (median survival 8.8-11.0 months, and TTP 4.9-6.3
months). TTP tended to be shorter than that of 6-cycle chemothera-
py, but second-line or more after therapy could be possible in larger
portion of the patients. This seemed to overcome the disadvantage
of shorter TTP.
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Every-2-Week Docetaxel plus Platinum In Advanced Non-Small-
Cell Lung Cancer Patients: Response Rate and Quality of Life
Assessment
Wu, Haiying; Dai, Wenqing; Liu, Junling, Department of Medical
Oncology, Cancer Center, Sun Yat-sen University of Medical,
Guangzhou, China
Purpose: The aim of this study is to evaluate the efficacy, toxicity
and quality-of-life(QOL) of docetaxel plus platinum drugs given
every-2-week in chemotherapy naïve patients with advanced
NSCLC.
Method: Docetaxel at a dose of 75 mg/m2combined with carbo-
platin at a dose of 300 mg/m2 or cisplatin at a dose of 25 mg/m2/d
for 3 days were administered by intravenous infusion.
Chemotherapy was repeated every 2 weeks with prophylactic use of
G-CSF. QOL was assessed by EORTC QLQ-C30 (Chinese Version
3) and QLQ-LC13 at baseline, one day before next cycle and after
the completion of chemotherapy.
Results: A total of 47 chemotherapy naive patients with advanced
NSCLC received chemotherapy. The total response rate was 40.5%,
with the response rate of docetaxel plus cisplatin being 35.7%G and
the response rate of docetaxel plus carboplatin being 50.0%G (no
statistical significant p=0.374). The major toxicity included myelo-
suppression, nausea and vomiting, alopecia, myalgia and arthralgia,
and fatigue. The physical function of the patients was improved
after chemotherapy. Symptoms such as cough, dyspnea, hemoptysis
and shoulder pain were relieved after chemotherapy. Global QOL
was not deteriorated after chemotherapy. The improvement of QOL
for patients with stable disease was similar to that of responders.
Conclusions: The biweekly combination chemotherapy with doc-
etaxel and platinum is feasible and effective for patients with
advanced NSCLC. The toxicity of this regimen is well tolerated by
patients. The symptoms and QOL have been improved significantly
after chemotherapy. This regimen merits further study.
4.01.07
Prognosis of Rehabilitational Potential in Lung Cancer Patients
Ulyanov, Andrey V.; Bukenow, Akhat M.; Shauyenov, Ergaly S.;
Malyshev, Nikolay V.; Smeshuk, Vladimir V., Karaganda State
Medical Academy, Karaganda, Kazakhstan
The incidence rate of lung cancer in Kazakhstan has a tendency to
the steady growth and for today the Republic takes the third place
among the CIS countries, after Russia and Belarus. According to
International Association of Cancer Research (Lyon, 2000),
Kazakhstan takes the seventh place worldwide on the incidence rate
of lung cancer among men (60.5 per 100 000 of population).
In the majority of the CIS countries physical disability due to malig-
nant neoplasms takes the second place (17%) in the general struc-
ture of physical disability. Among invalids with an oncologic pathol-
ogy the percent of working invalids grows from 24.6% in 2000 up
to 31.9% in 2004, and respectively number of idle invalids decreas-
es from 75.4% in 2000 to 68.1% in 2004.
It was performed the analysis of lung cancer patients (by question-
ing) and level of vital activity restrictions for 5 year period according
to medical-social examination (MSE) in the Karaganda area for the
period from 2001 to 2005. For the specified period there were exam-
ined 241 patients, primary - 191 (82.2 %), repeated - 50 (17.8 %).
Average age of the examined patients was - 55.1 years, 150 patients
(62.2%) - before 60 years and 91 patients (37.8%) - after 60 years.
Lung cancer patients, referred on primary MSE, in 97.1% had locally
advanced disease, and in 38.6% - plural regional and distant metas-
tases. Distant metastases were taped in 32.8% (79 patients), accompa-
nying diseases of various character were taped in 68% (164 patients),
among them - 51.8% (85 from 164) had combined pathology.
According to the performed correlation analysis, the rehabilitational
potential authentically depends on the age of patient (p<0.0003), the
clinical form of lung cancer (p<0.03), the stage of disease
(p<0.00001), the volume of surgical treatment (p<0.02).
Therefore, for the rehabilitational potential, determining the further
physical disability, age of patients and stage of disease are the most
significant factors.
4.01.08
Clinical Outcomes of First-Line Four Cycle-Chemotherapy in
Advanced Non-Small Cell Lung Cancer. A Prospective
Observational Study
Lee, Young Seok; Jang, Seung Hun; Kim, Dong Gyu; Eom, Kwang-
seok; Jung, Ki-suck, Division of Pulmonary,Allergy and Critical
Care Medicine of Hallym University Medical Center, Anyang, South
Korea
Objectives: Though guidelines for advanced non-small cell lung
cancer (NSCLC) proposed 3-6 cycles of first-line chemotherapy,
many institutes are still performing 6-cycle chemotherapy. This
study is aimed to evaluate the clinical outcomes of first-line 4-cycle
chemotherapy for NSCLC.
Methods: First-line chemotherapy was limited to 4 cycles. All
patients receiving at least one cycle of treatment were evaluated for
survival and toxicity, and all patients receiving at least two cycles
were evaluated for response.
Results: Between October 2003 and October 2005, forty seven
patients were treated with chemotherapy. Patients’ characteristics
were as follows: male 68.1%, female 31.9%; median age 63 year-
old, range 33-78; ECOG performance status 0-1: 70.2%, 2: 29.8%;
squamous 38.3%, adenocarcinoma 34.0% and unspecified 27.7%;
clinical stage IIIA 6.4%, IIIB 29.8% and IV 63.8%. In total, 150
cycles were administered with mean number of 3.2 ± 1.1 per patient.
57.4% of patients could receive the planned 4 cycles. 89.4% of
patients were treated with the regimen of gemcitabine 1,250mg/m2
on Day 1,8 plus cisplatin 60 mg/m2 on Day 1. The overall survival
period was 13.6 months (95% CI 12.2-15.0), and the 1-year survival
rate was 58.5%. The time-to-progression (TTP) of the first-line ther-
apy was 4.3 months (95% CI 3.9-4.7). The response rate was as fol-
lows: CR 0%, PR 40.0%, SD 35.0%, PD 22.5% and unevaluated
cases 2.5%. 70.2% of patients received second-line treatment and
40.4% received third-line treatment.
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Conclusion: The overall survival of first-line four-cycle chemother-
apy was not inferior to 6-cycle chemotherapy compared with histori-
cal controls (median survival 8.8-11.0 months, and TTP 4.9-6.3
months). TTP tended to be shorter than that of 6-cycle chemothera-
py, but second-line or more after therapy could be possible in larger
portion of the patients. This seemed to overcome the disadvantage
of shorter TTP.
4.01.09
Reversal of Risk Upon Quitting Smoking
Dresler, Carolyn M.; Leon, Maria E.; Straif, Kurt; Baan, Robert;
Secretan, Beatrice, International Agency for Research on Cancer,
Lyon, France
The International Agency for Research on Cancer convened a
Working Party (WP) in March 2006 to assess the evidence on the
reversal of risk upon quitting smoking. 17 experts from 8 countries
convened to assess this reversal of risk relative to smoking-related
cancers, cardiovascular disease and chronic obstructive lung disease.
The WP examined the scientific evidence to answer 3 questions: 1.
is the risk for disease lower in former smokers than in continuing
smokers; 2. what is the time course of the reduction in risk with
continued abstinence, and 3. does the risk return to that of never
smokers after long periods of abstinence? The assessment by the
WP experts concluded that published studies showed a lower risk of
lung cancer within 5-9 years and progressively diverges with longer
periods of cessation. A substantially lower risk for lung cancer
results with cessation in middle age compared to stopping at an
older age. However, the absolute annual risk for developing lung
cancer does not decrease after cessation. The risk for laryngeal can-
cer decreases steeply with cessation - reducing approximately 60%
within 10-15 years after cessation. There remains an increased risk
for lung and laryngeal cancer in former smokers compared to never
smokers. The relative risk for oral and pharyngeal cancers decreases
with increasing duration of abstinence compared with continuing
smokers and remains higher compared with never-smokers until the
second decade of abstinence but reaches the level of never-smokers
thereafter. There are significant health benefits with cessation that
accrue with increasing duration of abstinence for lung and head &
neck cancers. 
4.01.10
A Phase II Trial of VNP40101M (Cloretazine) for Patients with
Relapsed or Refractory Small Cell Lung Cancer
Greco, F. Anthony;1 Gettinger, Scott;2 Blumenschein, George;3
Axelrod, Rita;4 Haigentz, Missak;5 Guarino, Michael;6 Mekhail,
Tarek;7 Allain, Elmira;8 Geller, Robert B.;8 Spigel, David9
1 The Sarah Cannon Research Institute, Nashville, TN, USA; 2 Yale
University School of Medicine, New Haven, CT, USA; 3 MD
Anderson Cancer Center, Houston, TX, USA; 4 Thomas Jefferson
University, Philadelphia, PA, USA; 5 Montefiore Medical Center,
Bronx, NY, USA; 6 Christiana Care Health System, Newark, DE,
USA; 7 The Cleveland Clinic Foundation, Cleveland, OH, USA; 8
Vion Pharmaceuticals, Inc., New Haven, CT, USA; 9 The Sarah
Cannon Research Center, Nashville, TN, USA
Background: Alkylating agents have demonstrated activity in small
cell lung cancer (SCLC), and have been an integral component of
standard induction regimens. As a result, alkylating drugs are among
the options considered for second-line therapy. Cloretazine(r)
(VNP40101M) is a novel alkylating agent of the sulfonylhydrazine
class, selected for clinical development based on its broad anti-
tumor activity in preclinical models. It undergoes an initial activa-
tion step to form 90CE and a carbomoylating methylisocyanate
species. 90CE yields a chlorethylating group that attacks the O6
position of guanine in DNA. 
Methods: Eligible patients (pts) have either sensitive-relapse or
resistant disease after treatment with a standard cytotoxic regimen.
Pts have measurable or evaluable disease, life expectancy at least 2
months and ECOG PS 0-2. Cloretazine(r) is given intravenously
over 15-30 minutes at a dose of 125 mg/m2/week, weekly x 3, every
6 weeks. Pts are assessed for response at the end of each cycle and
retreated to progression or toxicity. Results: 27 patients (median age
67, range 48-86) have been treated with Cloretazine(r).
Demographic characteristics include M:F =19(70%)/8(30%); PS
0/1/2 = 6(22%), 13(48%), 8(30%); sensitive-relapse/resistant =
14(52%)/13(48%). Of 21 pts evaluable for response, 2 sensitive-
relapse and 1 resistant pt achieved PR; 4 sensitive-relapse and 1
resistant pt had SD; 7 sensitive-relapse and 6 resistant pts showed
PD. Eight pts of 21 received subsequent cycles. Grade 3-4 thrombo-
cytopenia was seen in nearly 50% of the first 14 pts evaluable for
toxicity. 
Conclusions: Cloretazine(r) is well tolerated and shows promising
activity in this patient population. Due to significant thrombocytope-
nia , the protocol has been amended to reduce the weekly dose to
100 mg/m2/week in an effort to maintain a regular schedule of treat-
ment. Accrual is ongoing.
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4.01.11
Pilot Study of Weekly Chemo-Hormono-Immunotherapy
Including Cisplatin (C), Epirubicin (E), Medroxyprogesterone
Acetate (MPA) + rhuIL-2, Followed By Docetaxel (T) Plus
Cisplatin  in Patients With Stage IIIB-IV Non-Small-Cell Lung
Cancer (NSCLC)
Mantovani, Giovanni; Massa, Elena; Madeddu, Clelia; Gramignano,
Giulia; Astara, Giorgio; Dessì, Mariele; Cherchi, Maria V.; Serpe,
Roberto, Department of Medical Oncology, University of Cagliari,
Cagliari, Italy
The study purpose was to evaluate the effectiveness of a combina-
tion chemotherapy regimen of C and E plus MPA, rhu-IL-2 and
antioxidants followed by T and C in stage IIIB-IV patients (pts)
NSCLC. Quality of life and CACS symptoms were also evaluated.
As July 2006, 16 chemotherapy-naive pts (12 M, 4 F, mean age 59.2
years, 1 patient (6.3%) had Stage IIIB and 15 patients (93.7%) had
Stage IV) have been enrolled. Treatment: 9 cycles of C 40
mg/m2/week plus E 40 mg/m2/week, both i.v. day 1, rhu-IL-2 1.8
MIU/day s.c., MPA 1 g/day orally plus antioxidants, followed by 9
cycles of C 40 mg/m2/week plus T 30 mg/m2/week. At the end of 9
weeks pts with CR, PR or SD were further treated with C (40
mg/m2/week, d1) plus T (30 mg/m2/week, d1) for 3 weeks followed
by a week rest (1 cycle) for a total of 3 cycles. Pts with PD were
treated with T alone (30 mg/m2/week, d1). After the first 9 weeks,
13 pts were assessable for response: no CR was observed, PR was
achieved in 4 pts (30.2%; ORR 30.2%), SD in 5 pts (38.6%) and PD
in 4 patients (30.2%) for an overall disease control of 68.8%. The
toxicity was mainly hematological: grade 3/4 neutropenia 46.1%,
anemia 7.7% and thrombocytopenia 7.7%. There were no toxic
deaths. Weight, LBM and ECOG PS did not change significantly
during treatment, while IL-6 decreased significantly. After the first 9
weeks of treatment, 11/13 patients were eligible for the treatment (T
+ C). At the end 6 patients completed the treatment and were evalu-
able for response: 3 SD and 3 PD were observed; 1 patient was
ongoing and 4 patients died in PD for an overall disease control of
27.3%. Grade 3 neurotoxicity was 33.3%. Overall QL did not show
significant changes. The study is in progress.
4.01.12
Morphological Analysis of Preinvasive Bronchioloalveolar
Carcinoma with Central Sclerosis
Itaya, Toru;1 Kameya, Toru;2 Ito, Ichiro;2 Kondo, Haruhiko1
1 Shizuoka Cancer Center Division of Thoracic Surgery, Shisuoka,
Japan; 2 Shizuoka Cancer Center Division of Pathology, Shizuoka,
Japan
Hypothesis: Localizing bronchioloalveolar carcinoma (BAC) with
foci of collapse of alveolar structure (central sclerosis) has been
thought to be preinvasive peripheral adenocarcinoma with 100% 5
year survival. In view of the ambiguity concerning the criteria for
stromal invasion of the peripheral adenocarcinoma, the intensive
morphologic analysis of the putative preinvasive lesions may estab-
lish morphologic criteria for non-invasiveness and invasiveness.
Methods: Twelve BACs with central sclerosis or collapse of alveolar
structure of small adenocarcinoma were analyzed morphologically by
high resolution computed tomography (HRCT), H&E, Elastica-van-
Gieson stain, and immunostains for blood and lymphatic capillaries
and Ki-67 and p27/Kip1 immunostains for tumor cell growth rate.
Results: All tumors showed ground-glass opacity with central con-
solidation by HRCT. The central zone of tumor consisted of sclero-
sis with absence of tumor cells and of proliferation of blood and
lymphatic capillaries. In elastic fiber staining the tumor showed; 1)
lepidic growth with a complete preservation of elastotic framework,
2) the presence of granulation tissue in the intraalveolar space sur-
rounded by elastotic framework in the sclerosis and 3) the progres-
sive disappearance of tumor cells lining inner alveolar wall.
Labeling indices of Ki-67 and p27 for tumor cells showed that pro-
liferation activity is greater in the periphery than that in the center.
Conclusions: A complete preservation of elastotic alveolar frame-
work represents non-invasiveness, whereas the disruption of the
framework represents invasiveness of bronchioloalveolar carcino-
mas with central sclerosis. The center of non-invasive tumor is at
regression stage, whereas the periphery is not.
4.01.13
Phase II study of Safety and Efficacy of the MDR Inhibitor VX-
710 Combined with Doxorubicin and Vincristine in Patients
with Small Cell Lung Cancer
Gandhi, Leena;1 Harding, Matthew;2 Neubauer, Marcus;3 Langer,
Corey;4 Crawford, Jeffrey;5 Moore, Melvin;6 Ross, Helen;7 Einhorn,
Lawrence;8 Johnson, Bruce E.;9 Lynch, Thomas J.10
1 Dana Farber Cancer Institute, Massachusetts General Hospital,
Boston, MA, USA; 2 Vertex Pharmaceuticals, Incorporated,
Cambridge, MA, USA; 3 US Oncology, Overland Park, KS, USA; 4
Fox Chase Cancer Center, University of Pennsylvania,
Philadelphia, PA, USA; 5 Duke University, Durham, NC, USA; 6
Georgia Cancer Specialists, Decatur, GA, USA; 7 Earle A. Chiles
Research Institute, Portland, OR, USA; 8 Indiana University School
of Medicine, Indianapolis, IN, USA; 9 Dana Farber Cancer
Institute, Brigham and Women’s Hospital, Boston, MA, USA; 10
Massachusetts General Hospital, Boston, MA, USA
Background: Tumors with multidrug resistance (MDR) frequently
show upregulation of efflux proteins including the MDR protein
(MRP-1) and P-glycoprotein (Pgp). MDR represents a major obsta-
cle to successful chemotherapy treatment and can be reversed in Pgp
or MRP-1-expressing cells by the MDR inhibitor VX-710. A phase
II study was designed to evaluate the safety, tolerability, and effica-
cy of VX-710 in combination with doxorubicin and vincristine in
patients with relapsed small cell lung cancer (SCLC).
Methods: Eligible patients had progressive SCLC more than 60
days after an initial response to 1st-line chemotherapy. Stage I safety
evaluation was done with planned expansion to a second stage if 9
responses were confirmed in the first 35 patients. Patients were
treated every 21 days until progression or intolerable adverse events
(AEs). Severe neutropenia was noted in the first 15 pts, so the proto-
col was amended to include prophylactic G-CSF or ciprofloxacin.
Interim analysis was performed after 36 pts were treated. 
Results: 36 pts were enrolled from 1998 to 2000. Neutropenia was
the major toxicity, occurring in 26/36 (72%) patients. Neutropenia
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was more severe (30% vs. 20% grade 4) and developed earlier (58%
vs. 38% in cycle 1) among the 15 patients enrolled prior to an
amendment requiring neutropenia prophylaxis versus those enrolled
afterward. Four patients died on study or within 30 days of termina-
tion: 2 from infections likely related to therapy and 2 from disease
progression. Seven of 36 total patients (19%) had partial responses;
6 of these sustained responses through 6 cycles of treatment, with
one of these responses lasting 3 years. Three additional patients had
unconfirmed responses and 4 patients had stable disease. The medi-
an survival for the 36 patients was 6 months.
Conclusions: The addition of VX-710 to doxorubicin and vin-
cristine therapy did not significantly enhance anti-tumor activity or
survival in this study. Hematologic toxicity caused 2 patient deaths
from neutopenic fever. Although there were some durable responses,
response criteria were not met to proceed with stage 2. 
4.01.14
Sarcomatoïd Lung Tumors
Venissac, Nicolas;1 Pop, Daniel;1 Lassalle, Sandra;2 Khelef,
Sabrine;1 Hofman, Paul;2 Mouroux, Jérôme1
1 Thoracic Surgery Department, Pasteur Hospital, Nice, France; 2
Clinic and Experimental Pathology Department, Pasteur Hospital,
Nice, France
Background: We studied the histological, clinical and prognostic
characteristics of the lung sarcomatoïd tumors(LST), a new defined
WHO classification entity.
Methods: We included retrospectively all files of patients admitted
in our surgical department between 1991-2005 with “a carcinoma
with pleomorphic, sarcomatoïd or sarcomatous elements” according
to WHO classification. Pathologic samples were re-examined in all
cases.
Results: Forty-nine patients were included (37 men, mean age 62
years). The majority were smokers (92%) and symptomatic (82%).
The tumors had 7cm in mean diameter (long axis). The CT-scan
showed necrosis in 67% of tumor and Pet-scan an intense enhance-
ment (SUV=16-25). Histology identified: pleomorphic carcinoma -
36 cases, pure spindle cells carcinoma - 8, pure giant cells carcino-
ma - 2, carcinosarcoma - 2, pulmonary blastoma - 1. Thirty-eight
patients were operated (surgical group). The pT were:
T2/T3/T4=23/13/2 and pN: N0/N1/N2=29/7/2 and M1 (prevalent
cerebral metastases) in 2 patients. Post-operative mortality was 7,8%
(3 patients) and major morbidity in 11% (4 patients). Another 18
patients were dead because of recurrences. Induction and/or adju-
vant chemotherapy was done in 12 patients and adjuvant radiothera-
py in 5. The 5-years survival rate was 37% negatively influenced by
size of tumors > 7cm (p=0,0004) and the disease free interval <
6months (p=0,0025). The medical group (11 patients) were staged
IIIB/IV=4/7 cases. The 1-year survival rate was 25% (all being
deceased at 18months).
Conclusion: The LST are rare, heterogenous tumors. They are
peripheral, symptomatic and necrotic discovered in locally advance
stage. The surgery allows prolonged survival, slightly inferior to
other types of lung cancer. The early recurrences or the “non-surgical”
tumors have a quickly unfavourable prognosis. They seemed to be
not influenced by chemotherapy perhaps in relation with their com-
posite characters. 
4.01.15
Surgery for Lung Cancer in Elderly
Venissac, Nicolas; Pop, Daniel; Sibon, Stephanie; Khelef, Sabrina;
Mouroux, Jérôme, Thoracic Surgery Department, Pasteur Hospital,
Nice, France
Background: The OMS estimations showed increasing life-
expectancy in time and two-fold increased in number of patients
having a cancer. We evaluate prospectively the morbid-mortality of
the octogenarian patients operated for lung cancer (LC)
Methods: The LC operated patients from 02.1997-11.2005 were
included in prospective way. They were noted: medical past, preop-
erative assessment, therapeutic methods, morbi-mortality up to 3
months after surgery and 5-year survival.
Results: Forty-eight interventions were done among 47 patients (35
men), mean age 81years. Medical history: cancer-10, pulmonary-10,
cardio-vascular-25, diabetes-2, nephrectomy-3. After cardio-respira-
tory assessment (pulmonary function study, VO2max, blood gases,
heart echography), the patients were classified ASA: 1/2/3=8/22/18.
The resections were: 4 pneumonectomy, 37 lobectomy, 2 bi-lobecto-
my, 2 wedge resection, 3 exploring thoracotomy (6%). One patient
was operated 2 times (metachronous cancers). Widened resection
was done 10 times: chest wall in 5, angioplasty in 1, parietal pleura
in 1, adjacent lobe in 3). Two preoperative incidents were noted, tra-
cheal or bronchial tear repaired promptly. R0 exeresis was noted 45
times. Mostly were squamous carcinoma in 25 cases and adenocar-
cinoma in 12 cases. Uneventful post-operative course was noted 11
times (23%). The complications were: 15 confusional syndrome, 14
pneumopathy, 9 atrial fibrillation, 4 hemothorax (2 unclotting thora-
cotomy), 1 upper digestive haemorrhage. Two patients died shortly
after (4%) and 2 in the 1st trimester. The pTNM stages were: IA-3,
IB-17, IIA-1, IIB-13, IIIA-6, IIIB-4. Median hospital times was 13 b
6 days. Survivals at 1 and 5 years were 70% and 35% respectively.
Conclusion: The group of octogenary account for 5% of patients
operated in the same period. The post-operative mortality authorize
surgical treatment among necessarily selected patients. Some of
complications modified our per-operative strategy (adapted analge-
sia, oncogeriatry assessment). 
4.01.16
The role of an Endobronchial Ultrasound (EBUS) in Staging of
Lung Cancer
Skwarski, Kristopher M.; McCafferty, John; Matthews, Jenny, Royal
Infirmary of Edinburgh, Edinburgh, UK
Accurate staging in lung cancer determines prognosis and treatment
plans. Up to 20% of patients with lung cancer present in early stages
(I-II) allowing surgical treatment. CTPET has high negative predict-
ed value (97%) in predicting mediastinal nodal malignancy but it
has only moderate positive predictive value (75%) and does not pro-
vide a histological diagnosis. Mediastinoscopy remains a gold stan-
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dard in evaluation of mediastinal lymphnodes (LN) but the sensitivi-
ty varies from 70 - 95%, requires general anaesthetic and usually it
is done only once. Providing an adequate tissue sample from medi-
astinal LN is crucial to determine the treatment. Real-time
Endobronchial Ultrasound FNA with Doppler facilities (EBUS) pro-
vides an alternative for mediastinoscopy in staging of lung cancer. It
allows an easy access to mediastinal and hilar LN (stations: 2, 3, 4,
7, 10, 11). This procedure is performed as an out-patient in conjunc-
tion with bronchoscopy with conscious sedation. We have per-
formed 150 EBUS procedures and analysed 125 cases. There were
64 positive aspirations for malignancy. The most frequently (in
order) sampled LN, were: level 7, 4, 10, 11, 2 and 3. EBUS was
negative in 61 cases. There were 5 true negative results. 51 primary
tissue diagnoses were obtained and 70 potential mediastinoscopies
were avoided. There were no complications. Calculated sensitivity
was 92% with accuracy 95%. In conclusion EBUS, in conjunction
with CTPET, should be considered as a safe and an effective alter-
native for mediastinoscopy in the staging algorithm of lung cancer.
Once this procedure is fully established, it is predicted that approxi-
mately 70% of mediastinoscopies would be avoided. Moreover, we
predict that EBUS would have a future role in the re-staging of
patients with lung cancer (stage IIIA) after neoadjuvant therapy.
4.01.17
No Difference of Progression-free Survival Depend on the Past
Chemotherapeutic History in Patients Treated by Gefitinib;
TMU Experiences
Saijo, Takamoto; Tsuboi, Masahiro; Nagase, Seisuke; Ohira, Tatsuo;
Hirano, Takashi; Kato, Harubumi, Department of Thoracic Surgery
& Oncology, Tokyo Medical University, Tokyo, Japan
Purpose: In the present study, we examined whether the therapeutic
efficacy of gefitinib treatment according to previous chemotherapy
status was different.
Patients and Methods: A total of 202 NSCLC patients, who started
gefitinib treatment in our hospital between July, 2002 and August,
2005, were investigated, retrospectively.
Results: Their median age at gefitinib treatment was 67 years. 87
patients were female. 122 patients had positive smoking history. 75
patients received previous chest surgery, and 55 patients received
previous thoracic radiotherapy. Only 10 patients received gefitinib
as first line chemotherapy. 113 and 79 of patients received gefitinib
as second line chemotherapy and as third line or more chemothera-
py, respectively. The median follow-up time was 19 months.
Response rate was 15%, and disease control rate was 75%. The
median survival time (MST) and 1-year survival rate was 14.0
months and 52.6%. Adenocarcinoma, previous chest surgery and
previous thoracic radiotherapy were correlated with higher antitu-
mor response. Histological typing and performance status were inde-
pendent prognostic factors for overall survival. Response rate was
14.2% for “second line or less chemotherapy” group, as opposed to
16.2% for “third line or more chemotherapy” group. No significant
difference about response rate was observed between them. The
MST was 14.0 months for “second line or less chemotherapy”
group, as opposed to 13.0 months for “third line or more chemother-
apy” group. The median progression-free survival time was 6.0
months for “second line or less chemotherapy” group, as opposed to
6.0 months for “third line or more chemotherapy” group. No signifi-
cant difference on outcome was observed between them. Past
chemotherapeutic history was not associated with outcome. 
Conclusion: Suggesting that, the therapeutic efficacy of gefitinib
according to previous chemotherapy status was not different.
Analysis of EGFR mutation, FISH and IHC in these series will be
added till the conference.
4.01.18
A Phase I-IIa Dose Ranging Study of Pemetrexed plus
Cetuximab in Patients (pts) with Recurrent Non-Small Cell
Lung Cancer (NSCLC): Analysis of the Completed Phase I
Portion of HOG-LUN04-79
Bedano, Pablo M.;1 Edelman, Martin;2 Nattam, Sreenivasa;3
Waterhouse, David;4 Shen, Jianzhao;5 Yu, Menggang;5 Harvey,
Jayme;6 Vinson, Jake;6 Bottema, Brian;6 Hanna, Nasser1
1 Indiana University School of Medicine, Indianapolis, IN, USA; 2
University of Maryland, Greenbaum Cancer Center, Baltimore, MD,
USA; 3 Ft Wayne Oncology and Hematology, Fort Wayne, IN, USA;
4 Oncology Hematology Care, Cincinatti, OH, USA; 5 Indiana
University School of Medicine, Division of Biostatistics,
Indianapolis, IN, USA; 6 Hoosier Oncology Group, Indianapolis,
IN, USA
Background: Pemetrexed (P) & cetuximab (C) are independently
active in NSCLC. These agents were combined in this phase I/II
study.
Methods: 1˚ endpoint of phase I was to determine the maximum
tolerated dose (MTD) of P + C. Eligible pts had relapsed-NSCLC, ≥
1 prior regimen, PS 0-2, adequate heme, liver & renal function.
Following a loading dose of C 400 mg/m2 IV on week 1, pts
received subsequent weekly C 250 mg/m2. P was given beginning
on week 2 and repeated q3wks in sequential dose escalation cohorts,
following a standard 3+3 design . Dose limiting events (DLE) for
phase I were defined as need for dose modifications or delays based
on grade 3/4 toxicities. 
Results: Of the 13 pts available for phase I portion, median age was
64 (range 37-68), 5 females (38%) and 8 males (62%); 8 PS 0
(62%), 5 PS 1 (38%). Median number of prior regimens 2 (range 1-
6). A total of 31 cycles were administered (range 1-5). Toxicity is
summarized in table.
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Conclusions: P 750 mg/m2 & C 250 mg/m2 d 1, 8 & 15 was select-
ed as the phase II dose.
Table: Toxicities associated to different dose
levels of pemetrexed and cetuximab
Level 1 Level 2 Level 3 Level 4
(n=3) (n=3) (n=4*) (n=3)
P 500 P 600 P 750 P 900
mg/m2 mg/m2 mg/m2 mg/m2
DLE 0 0 0 3
G 3/4 Heme Tox
-Neutropenic fever 0 0 0 1
G 3/4 Non-hemeTox
-Transaminitis 0 1 (after cycle 2) 0 1
G 3/4 Non-hemeTox
-Acneform Rash 0 1 (after cycle 2) 0 1
Abbreviations: P=pemetrexed; DLE=dose liming events
*One patient registered but never treated
4.01.19
Toxicity of Stereotactic Body Radiation Therapy for Centrally-
located Early Stage Lung Cancer: To Treat or Not to Treat
McGarry, Ronald C.;1 Tudor, Kathy;1 Timmerman, Robert2
1 Department of Radiation Oncology, Indiana University,
Indianapolis, IN, USA; 2 University of Texas Southwestern, Dallas,
TX, USA
Stereotactic body radiation therapy for Stage I non-small cell lung
cancer (NSCLC) is being widely investigated as a treatment option.
In small series, it has been suggested that tumors proximal to the
mediastinum have a higher risk of toxicity.
70 medically inoperable patients with clinically staged 1a/1b (<7cm)
NSCLC were entered on a prospective trial of SBRT. Patients with
T1 tumors received 60 Gy and T2 tumors received 66 Gy in three
fractions. Toxicity grading was confirmed by an independent data
safety monitoring committee. 
At two years, severe toxicity was noted in 17% of patients with
peripheral tumors vs. 46% for proximal tumors. 22/70 patients had
proximal tumors and of these, 9 had grade 3-5 toxicities “possibly”
treatment-related including 5 pneumonias/respiratory decline, 1
pleural effusion, 1 pericardial effusion, 1 apnea and 1 hemoptysis. In
contrast, 6 of the 48 remaining patients with “peripheral” cancers
had grade 3-5 toxicities. 13/22 patients with proximal tumors had
hilar masses included in the high dose radiated region. Only 4 of
these were found to have “collapse” of lobes of lung which is
important to differentiate from radiation fibrosis. No obvious pattern
relating treatment location to toxicity was found. The observed toxi-
cities were similar in the remaining 48 patients with peripheral
tumors. For the entire study population, local control at two years is
95% with a median overall survival of 32.6 months and two-year
overall survival of 54.7%. 
It is unclear why, in this small series, the survival of these frail
patients with “proximal” tumors was lower than the “peripheral”
tumors. Significant observed toxicities seem to occur with higher
frequency in proximal cancers but are difficult to predict and direct-
ly link to the treatment.
4.01.20
Phase I/II Study of Inhaled Doxorubicin Combined with
Platinum Based Therapy for Advanced NSCLC
Otterson, Gregory A.;1 Villalona-Calero, Miguel A.;1 Ellerton, John
A.;2 Westaway, David;3 Gerber, Mirjam;3 Murren, John4
1 Ohio State University, Columbus, OH, USA; 2 Southern Nevada
Cancer Research Foundation, Las Vegas, NV, USA; 3 Zivena, Inc.,
Columbus, OH, USA; 4 Yale University, New Haven, CT, USA
We have previously demonstrated the feasibility of administering
inhaled doxorubicin. The drug was administered via a novel device
that allowed for reproducible deposition into small airways while
minimizing aerosol from the environment. Dose deposited was cal-
culated after a Tc99m deposition test. Maximum tolerated dose was
determined to be 7.5 mg/m2 administered every three weeks. Dose
limiting toxicity (DLT) was pulmonary. This trial was performed to
determine the safety and preliminary efficacy of combining a stan-
dard platinum-based doublet (docetaxel and cisplatin) with inhaled
doxorubicin. Since intravenous chemotherapy had not previously
been combined with inhaled doxorubicin, we started with a phase I
study. The initial dose of inhaled doxorubicin was 6.0 mg/m2. 43
patients were accrued to this trial, though 6 were never treated (3
had uneven drug distribution on technetium deposition, 1 withdrew
consent, and 2 had persistent neurologic symptoms from brain
metastases). Six patients were initially treated at the 6.0 mg/m2 dose
without DLT, and subsequently eight patients were treated at the 7.5
mg/m2 dose. After two developed pulmonary DLT (>20% drop in
PFT parameters), the remainder of patients were treated at 6.0
mg/m2. 29 patients were treated at the phase II dose. Toxicity was
modest and primarily associated with intravenous chemotherapy
(myelosuppression, diarrhea, nausea/vomiting) though at least one
patient had delayed pulmonary toxicity following six cycles of treat-
ment requiring transient corticosteroids and oxygen. 26% of patients
had partial responses, with 48% having stable disease for up to eight
cycles. Median time to progression amongst those treated at the
phase II dose was 33 weeks. We conclude that this combination of
docetaxel and cisplatin administered intravenously with inhaled dox-
orubicin is safe and that time to progression appears promising. 
4.01.21
Biweekly Pemetrexed/Gemcitabine in Previously Untreated
Stage IIIB/IV Non-Small Cell Lung Cancer: Updated Results of
a Phase II Study
Spigel, David R.; Greco, F. A.; Simons, Lisa; Yardley, Denise A.;
Burris, Howard A.; Hainsworth, John D., Sarah Cannon Research
Institute, Nashville, TN, USA
Background: Pemetrexed (P) and gemcitabine (G) are safe and
active non-small cell lung cancer (NSCLC) therapies when adminis-
tered every 3 weeks. Biweekly scheduling was studied in this phase
II trial. 
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Methods: The primary objectives were to assess the safety and
response rate (RR) of P/G in chemotherapy-naïve patients (pts) with
stage IIIB/IV NSCLC. Pts received P 500mg/m2 IV and G
1500mg/m2 IV every 2 weeks for 8-12 cycles. Pts also received
folate and B12 therapy. Pts were restaged after 4 cycles. Entry crite-
ria included: measurable disease, ECOG 0-2, and informed consent.
Results: Seventy-one pts were enrolled. The median follow-up is
9.5 months. The median age was 66 years (41-85); male/female,
65%/35%; ECOG 0,1,2: 20%/66%/14%; and histology: adenocarci-
noma (34%), large cell (25%), squamous (13%), mixed or not speci-
fied (28%). The median number of cycles was 6 (1-12). Grade
(G)3/4 non-hematologic toxicity included: dehydration (6%), fatigue
(25%), and dyspnea (20%). G3/4 hematologic toxicity included:
neutropenia (45%), anemia (10%), and thrombocytopenia (6%).
G3/4 febrile neutropenia occurred in 10%. There were no treatment-
related deaths. Complete/partial responses for all pts: 1 pt/15 pts,
respectively, for an overall RR of 23% (95% CI 13%-33%). Thirty-
nine percent of pts had stable disease, and 21% had disease progres-
sion (12 pts were unevaluable.) Median and 6-month progression-
free survival were 4.3 months and 45%, respectively. Actuarial 1-
year overall survival (OS) was 35%. The median OS has not been
reached.
Conclusion: Biweekly administration of P/G appears to be well-tol-
erated with activity comparable to other first-line NSCLC regimens.
Further study addressing whether biweekly scheduling could be an
effective strategy to shorten overall treatment duration warrants ran-
domized design.
4.01.22
The Erlotinib Expanded Access Program (EAP) in Non-Small-
Cell Lung Cancer (NSCLC) – Initial Safety Results in German
Patients
Reck, Martin;1 Eberhardt, Wilfried;2 Schneider, Claus-peter;3 von
Pawel, Joachim;4 Spengler, Werner;5 Gütz, Sylvia;6 Schütte,
Wolfgang;7 Laack, Heinz-eckart;8 Ko, Y-d;9 Schott von-Römer,
Kathrin;10
1 Hospital Grosshansdorf, Department of Thoracic Oncology,
Grosshansdorf, Germany; 2 University Hospital Essen, West
German Cancer Center, Essen, Germany; 3 Central Clinic Bad
Berka, Department of Pneumology, Bad Berka, Germany; 4
Asklepios Clinic Munich-Gauting, Asklepios Clinic, Gauting,
Germany; 5 Clinic Schillerhoehe, Department of Internal Medicine,
Gerlingen, Germany; 6 City Hospital Sanct George, Robert-Koch-
Clinic, Leipzig, Germany; 7 City Hospital Martha-Maria,
Department of Internal Medicine II, Halle-Doelau, Germany; 8
University Hospital Hamburg, Department of Internal Medicine,
Medical Clinic II, Hamburg, Germany; 9 Johanniter Hospital,
Department of Internal Medicine, Bonn, Germany; 10 University of
Heidelberg, Clinic for Thoracic Diseases, Heidelberg, Germany
Background: Erlotinib (Tarceva(r)) is an orally active, potent, selec-
tive inhibitor of HER1/EGFR tyrosine kinase. In the BR.21 phase
III trial, erlotinib significantly prolonged survival, delayed symptom
progression, and improved quality of life compared with best sup-
portive care in patients with advanced NSCLC.1 The EAP is an
open-label, non-randomized, multicenter phase IV trial.
Methods: Patients with advanced (stage IIIb/IV) NSCLC, who
failed or were unsuitable for chemotherapy, received oral erlotinib
(150mg/day) until disease progression or unacceptable toxicity. 
Results: To date, 1,219 patients have been enrolled in 54 centers in
Germany. Median patient age: 64 years (range 31-91). Baseline
demographic/clinical characteristics (%): male/female (60/40); non-
smoker/current or former-smoker (23/77); ECOG PS 0/1/2/3
(22/50/23/5); stage IIIb/IV (20/79); adenocarcinoma/squamous
cell/large cell/BAC (51/29/7/6). Patients received erlotinib as first-
(17%), second- (40%), or third-line treatment (40%). Data on extent
of erlotinib exposure will be presented. Complete safety data were
available for 690 patients. Unexpected erlotinib-related adverse
events (AE) were rare (no single event in >1% of patients). As
expected, rash was common (68% all grades; 12% grade 3/4). 3% of
patients withdrew because of gastrointestinal (GI) AEs (2% grade
3/4:), 2% due to skin AEs (1% grade 3/4). Serious AEs were mainly
GI disorders (n=18). Only 10% of patients had dose reductions to
100mg and 1% to 50mg, mainly due to rash (78%) and diarrhea
(19%). Analyses of response, survival and assessments of predictive
biomarkers are ongoing.
Conclusions: Interim results with erlotinib from this real-world
clinical setting in a large number of unselected patients with
advanced NSCLC confirm the tolerability seen in clinical trials. The
favorable side-effect profile of erlotinib allowed full dose adminis-
tration (150mg/day) in the majority of patients.
1. Shepherd F, et al. 2005. NEJM;353:123-32.
4.01.23
One-Year Analysis of Lung Cancer Cases in Ceara Cancer
Hospital – Fortaleza-CE-Brazil
Sant’Ana, Rosane O.;1 Matos, Juliana A.;1 Ribeiro, Ronaldo A.;2
1 Hospital Do Câncer Do Ceará – ICC, Fortaleza, Brazil; 2
Hospital Do Cancer Do Ceara/ Universidade Federal Do Ceara-
UFC, Fortaleza, Brazil
Lung cancer is the most common cancer. In Brazil the incidence is
17,875 for men and 9,320 causes for women in 2006. Tabagism is
the principal risk factor for lung cancer ( 90% of man and 50% of
women). Despite treatment the letality of lung cancer is high with
five-year survival in developing coutries of 7 and 10%. lung cancer
is divided in two groups: non-small cell lung cancer (NSCLC) and
small cell lung cancer (SCLC). Although the multidiciplinary (sur-
gery, radiotherapy and chemotherapy) aproach is the main therapy
for NSCLC the mortality rates have kept high for two decades. For
stages IIIB and IV the treatment is paliative including chemotherapy
with or without radiotherapy. 
Material And Metods: In this work we retrospectively evaluated
stages IIIB and IV patients with NSCLC admitted to Ceara Cancer
Hospital in the the year of 2005 regarding to age, sex incidence,
KPS, tabagism, lost of weight, histologig type, metastatic site,
response rates and toxicity to treatment and median survival.
Results: Data from 112 patients were available. Most of these were
men (59%) and stage IV (59.8%). About of 82% were tabagist of
these 55,4% had adenocarcinoma and 29.3% had squamous cell his-
tology. Median age was 63 years (range 38-83). Most of patients
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related loss of body weigth above 10% (53.6%) and the median KPS
was 70% (range: 50-100%). Bones were the most frequent site of
distant metastasis (26.8%), followed by lung (19.4%) and CNS (9%)
and most of patients had 2 or more metastatic sites. Only 10 patient
didn’t receive chemotherapy and most of chemotherapy regimes
included two drugs. The incidence of grade 3 and 4 toxicity was
7,2%. There was clinical benefit of treatment and median survival
was 10,4 months (range 4-61m), 13,3m for IIIB and 8,6% for IV
stage patients (86 patients available for survival analysis).
Conclusions: The following study sugest that our NSCLC cases
have similar charactheristics from world historical series and have
clinical benefit with low grade 3 and 4 toxicities.
4.01.24
A Novel Geometric Technique for Treatment of Locally-
Advanced Non-Small Cell Lung Cancer Using Three-
Dimensional Conformal Radiotherapy
Chen, Sea; Strauss, Jonathan B.; Kirk, Michael C.; Zusag, Thomas
W., Department of Radiation Oncology, Rush University, Chicago,
IL, USA
Introduction: We describe a novel 3D-conformal radiotherapy tech-
nique for the treatment of locally-advanced non-small cell lung can-
cer (NSCLC). We compare this to the conventional technique of
AP/PA followed by off-cord opposed oblique fields. 
Methods: Patients with Stage III NSCLC treated at our institution
receive a PET scan, pulmonary function tests, and a quantitative
ventilation-perfusion scan to guide radiotherapy planning. Tumor
motion is measured under fluoroscopy. Gross target volumes are
delineated utilizing PET/CT fusion and adjusted for motion before
expansion to planning target volumes. 
An initial 4-field orientation of AP, PA, ipsilateral posterior oblique,
and ipsilateral anterior oblique is defined in the treatment planning
system. Custom blocking is then linked directly to the planning tar-
get volume plus a margin, with spinal cord blocking in the posterior
oblique field. The beam weights, wedges, and angles are adjusted
for the final treatment plan prescribed to 60Gy, limiting spinal cord
dose to 45Gy. 
In the conventional technique, AP/PA fields were planned to 44Gy.
Then off-cord obliques were planned to 60Gy. Custom blocking was
used for the same targets, but no wedges were used. 
We compared plans developed with our technique to the convention-
al technique in our patients, measuring the ipsilateral lung V20Gy
(volume receiving 20Gy), and target V95% (volume receiving 95%
of prescription dose). In our comparison, neither technique used
elective nodal irradiation. 
Results and Conclusion: Our technique decreases contralateral
lung V20Gy, while increasing average target V95% from 95% to
99%. In addition, it yields the advantages of (1) lower biologically
effective lung dose for equivalent irradiated lung volumes, (2)
decreased spinal cord dose if the patient is operable at 44-46Gy, and
(3) use of the same fields on each treatment day. 
4.01.25
Phase II Trial of Fixed Dose Rate (FDR) Gemcitabine (G) in
Combination with Oxaliplatin (O) in the 2nd Line Treatment of
Patients with Advanced and Metastatic Non-Small Cell Lung
Cancer
Raez, Luis E.;1,2 Bepler, Gerold;2 Lopes, Gilberto;2 Blaya,
Marcelo;2 Lobo, Crhistopher;2 Macintyre, Jessica;2 Farfan, Nancy;2
Flores, Aurea;2 Walker, Gail2
1 Sylvester Cancer Center, Miami, FL, USA; 2 University of Miami,
Miami, FL, USA
Background: FDR G may be more efficacious than standard infu-
sion G. The synergy between G and platinum agents has been well
documented before. The combination of G and O has demonstrated
a good toxicity profile in several solid tumors.
Methods: A phase II trial was designed to assess the efficacy and
tolerability of G 1,000 mg/m2 over 100 min in combination with O
100 mg/m2 over 2 hours both given on days 1 and 15 of each 28-day
cycle. Patients with NSCLC were eligible if they had progressed
after first line treatment. Functional Assessment of Cancer Therapy-
Lung (FACT L) was measured. 
Results: Nineteen patients have been enrolled: 12 men, 17 White
(15 Hispanic), 2 Black Histologic subtypes were as follows: adeno-
carcinoma, 10 patients; NSCLC not otherwise specified 5; squamous
cell carcinoma, 3. Six patients had an ECOG performance status
(PS) of 0 and 13 had a PS of 1. Two patients were never smokers. A
total of 45 cycles have been administered (median 2, range 1 to 4).
Two patients died on study from disease progression leading to res-
piratory and multi-organ failure. The following Grade 3 and 4
adverse events were seen in one patient each: fatigue, dyspnea, fever
(without neutropenia), dehydration, and anemia. Eighteen patients
are available for assessment of response. One patient had a con-
firmed partial response (6%) and another six had stable disease
(33%).
Conclusion: Preliminary results combining FDR G and O are well
tolerated. Response rate in the second line treatment of patients with
advanced NSCLC, thus far, has been disappointing. . Enrollment
will continue to a total of 30 patients. QOL data and correlative
studies will be very presented in the meeting.
4.01.26
Identification Of Patients Potentially Benefiting From
Concomitant EGF-R Inhibition And Chemotherapy:
CHALLENGE Trial: Erlotinib Followed By
Gemcitabine/Cisplatin ± Erlotinib Induction In Patients With
NSCLC IIIA/B Monitored by Microarray Analyses
Overbeck, Tobias R.;1 Danner, Bernd;1 Doerge, Hilmar;1 Wenleder,
Stefan;1 Hemmerlein, Bernhard;1 Meller, Johannes;1 Wolf, Jürgen;2
Schirren, Juergen;3 Wolf, Martin;4 Griesinger, Frank1
1 University of Goettingen, Germany; 2 University of Cologne,
Germany; 3 Wiesbaden, Germany; 4 Kassel, Germany
Background: Induction therapies have been shown to potentially
improve long term survival. As <30% of pts respond with favorable
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pathologic tumor regression to chemotherapy there is an urgent need
to increase effectivity of CTx. Although erlotinib and CTx combina-
tions have failed in unselected patients to improve response rates
and survival, they might be synergistic in specific subgroups. Tumor
profiling might be helpful in identifying further subgroups with high
response rates to erlotinib and erlotinib/CTx. 
Methods: Primary aim of the CHALLENGE phase II trial is to
determine pathological response rate of CTx ± erlotinib and to cor-
relate this with genetic tumor markers. This trial plans to recruit 116
pts with pathologically proven N2/N3 NSCLC. Fresh lymph nodes
and/or primary tumor samples are taken for tumor profiling. Pts are
staged with CT, PET, and are induced for 6 weeks with erlotinib 150
mg/d p.o. Erlotinib response is assessed by CT and PET. CT non-
progressers receive combined erlotinib/CTx, CT-progressors only
CTx (3 cycles of gemcitabine/cisplatin). After 3 cycles, pts are
restaged by CT and PET and are evaluated for surgery. Resection
specimens are studied for pathologic response and are subjected to
microarray analyses and further tumor profiling. Adjuvant radiother-
apy and 1 year erlotinib maintenance therapy (in erlotinib respon-
ders) is given post-op. 
Results: As of yet, 33 pts have been screened, at this time data from
14 pts are available, 7 cN2/N3 pts dropped out because of non-
involved lymph nodes (5/7), lymph node without reach (1/7) and
M1 status by PET (1/7). 7 pts were registered and started induction
therapy with erlotinib. 4/7 pts were erlotinib non-progressors in CT.
7/7 pts have been resected, 3 after erlotinib-erlotinib/CTx, 4 after
erlotinib-CTx, 6/7 R0, 1/7 R1. 
Conclusions: This is the first prospective tumor profiling study in
NSCLC III where material is ascertained before induction therapy.
Tumor profiling data as well as imaging and metabolic response
data after erlotinib therapy might have the potential to identify fur-
ther subgroups benefiting from EGF-R inhibitor therapy.
4.01.27
Consolidation Docetaxel after Concurrent Chemoradiotherapy
with Carboplatin and Irinotecan in Unresectable Stage III
NSCLC
Bastos, Bruno; Roman, Eloy; Negret, Lawrence; Takita, Cristiane;
Lobo, Christopher; Lopes, Gilberto; Farfan, Nancy; Karr, M; Rocha-
Lima, Caio; Raez, Luis, University of Miami - Sylvester Cancer
Center, Miami, FL, USA
Purpose: To verify the role of docetaxel as consolidation therapy
with the expectation that the chemoradiation portion using carbo-
platin and irinotecan will improve the response rate with less toxici-
ty that the conventional, but less commonly used, cisplatin/etoposide
regimen used in the SWOG 9019 and SWOG 9504 studies.
Methods: Treatment included Carboplatin: (AUC=2) and
Irininotecan: 30mg/m2, weekly with concomitant radiation therapy,
and Docetaxel: 75 mg/m2 every 3 weeks for 3 cycles after CRXT.
The daily administered dose of radiation was 1.8 Gy, 5 days a week
for 5 weeks, (25 fractions equaling 45 Gy) to the primary tumor site
and mediastinum (primary planning target volume). After 45 Gy, the
primary tumor and involved nodal sites (secondary planning target
volume) was boosted at 2 Gy per day to 18 Gy. The total dose given
was 63 Gy in 35 fractions. Evaluation of response has been done
with RECIST criteria. 
Results: Median age is 55 years (range: 42-78). 23 patients were
enrolled of which 74% are male, 74% are white, 57% are Hispanic,
and 65% had an ECOG Performance Status of 1, 61% are stage
IIIB. We documented 22 grade 3/4 adverse events (AE): Pneumonia
(17%), radiation pneumonitis (13%), neutropenia (13%), esophagitis
(5%). Data for response is available in 18 patients. Partial Response
in 10 pts (56%), stable disease in 6 pts (33%). 2 pts are ineligible
for response. Preliminary median survival is around 19 months. 
Conclusions: Consolidation docetaxel after concurrent chemoradio-
therapy with Carboplatin and Irinotecan in unresectable Stage III
NSCLC is feasible and generally tolerable, and results compare
favorably with the best known trials in stage III NSCLC
4.01.28
Pemetrexed and Carboplatin Plus Bevacizumab as First-Line
Therapy For Advanced Non-Squamous Non-Small Cell Lung
Cancer: Encouraging Preliminary Results
Sanft, Tara B.;1 Patel, Jyoti D.;2 Hensing, Thomas;3 Villaflor,
Victoria;4 Hart, Eric;5 O’Keeffe, Patricia;5 Obasaju, Coleman;6
Bonomi, Philip7
1 Internal Medicine Residency Program, Feinberg School of
Medicine at Northwestern University, Chicago, IL, USA; 2 Division
of Hematology/Oncology, Feinberg School of Medicine of
Northwestern University, Chicago, IL, USA; 3 Evanston
Northwestern Healthcare, Evanston, Il, USA; 4 Rush University
Medical Center, Chicago, IL, USA; 5 Northwestern University,
Chicago, IL, USA; 6 Lilly Pharmaceuticals, Chicago, IL, USA; 7
Rush University, Chicago, IL, USA
Background: Pemetrexed is a multi-targeted antifolate with activity
in NSCLC as a single agent and in combination with carboplatin.
Bevacizumab improves response and survival in combination with
carboplatin and paclitaxel in patients with non-squamous NSCLC.
Given the positive response rates and favorable toxicity profile, the
combination of pemetrexed and carboplatin plus bevacizumab is
being investigated. 
Methods: This single cohort, phase II study evaluates the safety and
efficacy of the combination of pemetrexed and carboplatin plus
bevacizumab in patients with untreated advanced non-squamous
NSCLC. Eligibility requires ECOG PS 0-1, Stage IIIB(pleural effu-
sion)/IV non-squamous NSCLC, no evidence of CNS metastases, no
anticoagulation. Treatment consists of pemetrexed 500mg/m2 iv
over 10 minutes, carboplatin AUC 6 iv over 30 minutes, and beva-
cizumab 15mg/kg iv over 30-90 minutes. Treatment is repeated
every 21 days for 6 cycles. Patients with SD or PR continue peme-
trexed 500mg/m2 and bevacizumab 15mg/kg every 21 days until
POD or toxicity. All patients receive folic acid, vitamin B12, and
steroid prophylaxis. 
Results: From 8/2005-5/2006, 24 (planned 50) patients were
enrolled. One patient enrolled refused treatment. Characteristics:
median age: 63 (41-72), M/F: 52%/48%. Median number of cycles:
6 (1-15). Of the 23 patients undergoing treatment, 20 have been
assessed for response. Eleven (55%) have PR, eight (40%) have SD,
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one (5%) had POD. One refused treatment after 3 cycles. Two expe-
rienced toxicities requiring removal from study (DVT, thrombocy-
topenia). Three patients (15%) experienced grade 3/4 toxicities:
DVT, thrombocytopenia, anemia, fatigue and infection. 
Conclusions: Treatment with pemetrexed and carboplatin plus beva-
cizumab has shown a favorable response in advanced NSCLC.
Given the demonstrated tolerability and efficacy, this regimen war-
rants further investigation. Supported by Genentech Inc and Lilly
Pharmaceuticals.
Translational Research - Lung Cancer
4.02.01
Public Health Importance of Lung Cancer Prevalence and
Mortality in Croatia
Poliæ-Vi√intin, Marina;1 Tripkoviæ, Ingrid;2 Kukulj, Suzana;3
Èulig, Josip1
1 Zagreb Institute of Public Health, Zagreb, Croatia; 2 Institute of
Public Health, Split-Dalmatia County, Split, Croatia; 3 Jordanovac
University Hospital for Lung Diseases, Zagreb, Croatia;
Aim: To assess the prevalence and mortality of tracheal, bronchial
and lung (TBL) cancer in Croatia, the most common stage of dis-
ease at diagnosis, and patterns of its occurrence.
Background: In Croatia, TBL cancer is the most common localiza-
tion of carcinoma in men and third most common localization in
women. 
Methods: The method of descriptive epidemiology was employed
to analyze data on new cases of and deaths from TBL carcinoma
according to age, sex, and stage of disease, with special reference to
new cases recorded during the 1978-2002 period. The Croatian
Cancer Registry was used as the source of data. Crude rates and age
standardized rates calculated against standard European population
were used.
Results: The prevalence of TBL cancer has been on a steady
increase, especially in men where the incidence increased from
67.5/100,000 in 1978 to 109.3/100,000 2002. In 2002, there were
2908 new cases of (standardized rate 53.0) and 2597 deaths from
(standardized rate 46.8) TBL cancer. The ratio of numbers of deaths
to new cases in men and women were 0.90 and 0.86. According to
age, TBL cancer was the most common in men aged 40-79, and sec-
ond in those aged >80. In women, the incidence also increased with
age to be the third most common cancer in those aged 70-79.
According to stage of disease, in 2002 localized TBL cancer was
diagnosed in 320 (11.8%), regional lymph node involvement in 662
(24.4%), and distal metastases in 746 (27.5%) patients, yielding
poorer staging indicators than those for total of all-seat cancers.
Conclusions: Both total and sex specific incidence and mortality of
TBL cancer are on an increase. The late diagnosis and high mortali-
ty rate point to the need of upgrading non-smoking campaign.
4.02.02
Strong Combined Expression of pAKT and pMAPK in Lymph
Node Metastasis in Patients With Locally Advanced Non-Small-
Cell Lung Cancer (NSCLC)
Jacobs, Jan;1 Korfee, Sönke;2 Gauler, Thomas;2 Cortes-Incio, D.;2
Krbek, Thomas;1 Seeber, S.;2 Stamatis, Georgios;1 Eberhardt,
Wilfried2
1 Department of Thoracic Surgery, Ruhrlandclinic, Essen, Germany;
2 Department of Internal Medicine, West German Cancer Center,
University Hospital of the University Duisburg-Essen, Essen,
Germany
Introduction: Overexpression of pAKT or pMAPK has been postu-
lated as a surrogate for resistance and poor prognosis in cancer
patients. The prognostic value of these parameters in patients with
locally advanced NSCLC is still unknown. We determined the
expression of activated (phosphorylated) AKT and MAPK by
immunohistochemistry (IHC) in tumor-involved lymph node metas-
tasis in patients (pts) with NSCLC stage IIIA/IIIB undergoing
neoadjuvant chemoradiotherapy.
Material and Methods: Lymph nodes were sampled by medi-
astinoscopy. Treatment consisted of induction-CTX with cisplatin
and paclitaxel followed by chemoradiation and definitive surgery. To
evaluate the pAKT and pMAPK expression, lymph nodes were
examined by IHC. IHC staining was semi-quantitatively assesed by
DAKO HercepTest(r) criteria.
Results: n = 50 pts; male/female 35/15; age 35-69ys; IIIA/IIIB
23/27; subtypes: squamous cell carcinomas 44%, adenocarcinomas
34%, large cell carcinomas 22%. IHC-results: strong combined
expression (DAKO 2+ and 3+) of pAKT and pMAPK in 30 pts
(60%), strong expression of pMAPK alone in 12 pts, strong expres-
sion of pAKT alone in 6 pts, no expression of pAKT and pMAPK in
2 pts. 16 pts (53.3%) with combined strong expression showed
objective response (OR) to induction CTX; 7 pts (58.3%) with
expression of pMAPK alone and 4 pts (66.6%) with expression of
pAKT alone showed OR. The 2 pts without pAKT or pMAPK being
expressed showed both OR.
Conclusions: Combined expression of pMAPK and pAKT in lymph
node metastasis is observed in a considerable percentage of our
patients with locally advanced NSCLC. The combined expression of
these parameters was not a predictive factor for clinical response to
cisplatinum based induction chemotherapy. The high rate of samples
with co-expression of both factors lets us speculate, that in a consid-
erable number of tumors, different and independent cancer signal
transduction pathways are activated simultaneously. This may
explain the existing clinical difficulties in tailoring molecular target-
ed therapies to individual patients based on the interruption of one
signal transduction pathway alone.
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4.02.03
Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitor
AZD2171 and Fractionated Radiotherapy in Mouse Models of
Lung Cancer
Lu, Bo, Vanderbilt University, Nashville, TN, USA
The VEGF receptor tyrosine kinases are being explored as targets
for anti-angiogenic cancer therapy. Radiotherapy also inhibits tumor
growth and affects vasculature. We investigated the combination of
the potent VEGFR-2 tyrosine kinase inhibitor AZD2171 and ioniz-
ing radiation in cell culture and mouse models of lung cancer. We
show that ionizing radiation induces expression of phosphorylated
VEGFR-2 (Flk-1) in endothelial cells, and that this phosphorylation
is inhibited by AZD2171. HUVEC cells become more sensitive to
radiation after treatment with AZD2171 as determined by clono-
genic assay. Matrigel assay showed an additive decrease in in vitro
tubule formation with AZD2171/radiation combination treatment.
H460 cells were used for a xenograft model in nude mice. Von
Willebrand factor (vWF) staining of xenograph tumors also showed
a large decrease in tumor vascular density after combination treat-
ment. H460 tumor growth delay was enhanced in the combination
treatment group versus treatment with drug or radiation alone. In
conclusion, AZD2171 sensitizes lung tumor xenografts to radiation
and inhibits angiogenesis in both in vitro and in vivo models. When
used as a radiation enhancer, AZD2171 has the potential to improve
tumor growth delay. Further in vivo studies and clinical trials are
needed to determine the potential of combination therapy with
AZD2171 and radiation.
4.02.04
Circulating Non-Small Cell Lung Cancer (NSCLC) Cells
Correlate With CXCR4 Expression and Survival in Patients
With NSCLC
Reckamp, Karen L.;1 Figlin, Robert A.;2 Burdick, Marie D.;3
Dubinett, Steven M.;4 Elashoff, Robert M.;4 Strieter, Robert M.3
1 University of California, Los Angeles and the Greater Los Angeles
VA Healthcare System, Los Angeles, CA, USA; 2 City of Hope
National Medical Center and Beckman Research Institute, Duarte,
CA, USA; 3 University of Virginia, Charlottesville, VA, USA; 4
University of California, Los Angeles, Los Angeles, CA, USA
The CXC chemokine, CXCL12, and its receptor, CXCR4 promote
metastases of a variety of solid tumors including NSCLC. This con-
cept supports the notion that expression of CXCR4 on tumor cells
may represent a critical biomarker for their propensity to metasta-
size. A study was performed on 28 patients with non-small cell lung
cancer (NSCLC) who were seen at the UCLA Medical Center
between October 2004 and March 2006. Each specimen was
processed to isolate buffy coat cell populations. Of 28 patients with
blood samples, 13 had stage IIIB or IV NSCLC, and these samples
were evaluated for circulating malignant cells. The number of circu-
lating NSCLC tumor epithelial cells was measured using intracellu-
lar staining for anti-human cytokeratin 14, 15, 16, and 19 and FACS
analysis. Dual color analysis of pan-cytokeratin (pCK) positive cells
using an antibody against the chemokine CXCR4 receptor was also
performed and quantified by FACS. There was an increase in pCK
positive cells in the circulation of patients with NSCLC, as com-
pared to normal control subjects. Patients with 2,500 or more
pCK+/CXCR4+ cells/ml, had a significant decrease in overall sur-
vival. Patients with pCK+/CXCR4+ > 2,500 cells/ml had a median
survival of 12.5 weeks (6-16), while patients with pCK+/CXCR4+ ≤
2,500 cells/ml had a median survival of 45 weeks (15-84). Plasma
was also assayed for markers of angiogenesis, cytokines and
chemokines, and this analysis will be reported. In future studies, we
will confirm the prognostic significance of pCK+/CXCR4+ cells,
and evaluate the mechanisms that are involved in the regulation of
CXCR4 expression on tumor cells. This could lead to targets to
modify expression of this receptor that impacts on NSCLC metas-
tases and survival. 
Supported by NIH P50CA90388, CA87879, GLAVAHS Career
Development Award, and the STOP Cancer Memorial Award.
4.02.05
Evaluation of EphA2 Receptor Tyrosine Kinase Expression and
Function in Lung Cancer.
Choong, Nicholas W.;1 Stricker, Thomas;1 Seiwert, Tanguy Y.;1
Kagzi, Yasmin;1 Ramnath, Nithya;2 Tretiakova, Maria;1 Husain,
Aliya;1 Salgia, Ravi1
1 University of Chicago, Chicago, IL, USA; 2 Roswell Park Cancer
Institute, Buffalo, NY, USA
Background: The Eph receptor tyrosine kinases and their mem-
brane-bound ligands, the ephrins, are overexpressed and may be
functionally important in many cancers. We investigated the expres-
sion and role of EphA2 in lung cancer.
Methods: The expression of EphA2 in a lung cancer tumor tissue
microarray was examined using immunohistochemistry and in lung
cancer cell lines using Western blotting and immunofluorescence.
The functional role for EphA2 was investigated by assessing the
activation status of the receptor and the effect of ephrinA1 on lung
cancer cell motility, adhesion and invasion. Small hairpin RNA
(shRNA) was used to determine the effect of suppressing EphA2
expression on lung cancer cell proliferation.
Results: 197 individual tumors were evaluated and EphA2 overex-
pression was found in 60% of lung cancers compared to only 10%
of normal lung tissue. All non-small cell lung carcinomas had simi-
lar rates of EphA2 overexpression but the receptor was overex-
pressed in only 30% of small cell lung carcinomas. The expression
of EphA2 was higher at metastatic sites compared to primary
tumors. EphA2 was activated and phosphorylated through stimula-
tion by ephrinA1 in lung cancer cells which resulted in up-regula-
tion of p130cas and talin. Time-lapse videomicroscopy of EphrinA1
stimulated lung cancer cells showed a rapid but transient change in
cell morphology. The adhesion of lung cancer cells to vitronectin
was reduced with EphrinA1 stimulation but was unchanged with
fibronectin and collagen surfaces. Prolonged stimulation of EphA2
resulted in a reduction in invasiveness of lung cancer cells.
Suppression of EphA2 expression resulted in significant reduction in
cell proliferation after 48 hours (p=0.005).
Conclusion: We show that EphA2 is overexpressed in lung cancer
cells. EphA2 seems to be functionally important in regulating cell
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invasion, adhesion and motility in lung cancer cells. These charac-
teristics may play an important role in tumor metastasis. Hence,
EphA2 represents a novel target for the development of molecular
therapeutics against lung cancer.
4.02.06
Glycolytic Inhibition with 2-Deoxy-glucose (2-DG) in Patients
with Lung and Head and Neck (H/N) Cancers
Raez, Luis E.;1,4 Langmuir, Virginia;2 Papadopoulos, Kyriakos;3
Ricart, Alejandro;3 Tolba, Kalhed;4 RochaLima, Caio;4
Schlesselman, James;5 kroll, Stew;6 Collowick, Allan;6 Rosenblatt,
Joseph;4 Lampidis, Theodore4
1 Sylvester Cancer Center, Miami, FL, USA; 2 Threshold
Pharmaceuticals, San Frnacisco, CA, USA; 3 Institute for Drug
Development, San Antonio, TX, USA; 4 University of Miami, Miami,
FL, USA; 5 University of Pittsburg, Pittsburg, PA, USA; 6 Threshold
Pharmaceuticals, San Francisco, CA, USA
Background: We demonstrated in mouse xenografts that the combi-
nation of chemotherapy with 2DG is feasible and increases respons-
es against tumors (CancerRes; 2004 64:31-4). 
Methods: To determine the maximum tolerated dose (MTD) of
daily oral doses of 2DG given alone and in combination with week-
ly docetaxel (DC) in patients (pts) with advanced malignancies who
had relapsed after chemotherapy, and to evaluate the pharmacokinet-
ics (PK) of 2DG alone and in combination with weekly DC. 2DG
was administered orally once daily for 7 days every other week
starting at a dose of 2 mg/kg, and DC was administered at 30mg/m2
for 3 of every 4 weeks. A modified accelerated titration design was
used where single subjects were enrolled at each dose level and dose
increases were 100% until dose-limiting toxicity (DLT) occurred.
Cohorts of 3-6 pts were then enrolled at dose increases of 40%. 
Results: To date 21 pts have been enrolled at 2DG doses up to 88
mg/kg/day. 5 pts had lung cancer (4 NSCLC + 1 SCLC); and anoth-
er 6 pts had H/N cancers. One pt discontinued for DC-related senso-
ry neuropathy. Single cases of DLT occurred - asymptomatic
(64mg/kg) and symptomatic (88 mg/kg) Grade 3 hyperglycemia.
The MTD has not been reached. 2DG is rapidly absorbed (Tmax
0.5-1h) with a half-life of 5-10h. 2DG exhibits linear PK following
single and multiple doses with minimal accumulation after multiple
doses at 63 and 88 mg/kg. 2DG PK and DC PK do not alter each
other. One of 18 evaluable pts with breast cancer had a partial
response (PR). Another 8 pts achieved disease stabilization (SD)
among them: 2 of 4 pts with NSCLC, 2 of 6 pts with H/N cancers, 1
pt with thyroid cancer, and 1 of 3 pts with adenoidcystic carcinoma.
The others were unknown primary and a breast lymphoma. 
Conclusions: The combination of 2DG and DC appears to be fea-
sible and safe with no evidence of PK interactions. Evidence of
anti-tumor activity was observed in patients with NSCLC and H/N
cancers. 
4.02.07
Overcoming Cisplatin and VP-16 Resistance by Inhibiting
mTOR in Small Cell Lung Cancer Patients
Bastos, Bruno;1 Wu, C;2 Wangpaichitr, M;2 Robles, Carlos;2
Savaraj, Niramol2
1 University of Miami - Sylvester Cancer Center, Miami, FL, USA; 2
VA Miami Medical Center, Miami, FL, USA
Purpose: Although small cell lung cancer (SCLC) is known to
respond well to chemotherapy, relapse is inevitable and salvage ther-
apy remains poor. This is most likely due to development of drug
resistance. In this report, we have found that cisplatin or VP-16
resistant SCLC cells lines become sensitive after the addition of
mTOR inhibitor
Methods and Results: Cisplatin resistant cells share certain com-
mon characteristic features, i.e. increase in ribosomal proteins and
elongation factors. Thus, we hypothesize that by blocking the trans-
lation of these proteins, one should be able to restore cisplatin sensi-
tivity. We demonstrated that CCI-779 at 10 ng/ml can increase the
growth inhibition of cisplatin by 2.5-6 fold. Cells treated with CCI-
779 decreased the amount of 4E-BP phosphorylation and p-
70S6kinase phosphorylation as well as lower the amount of elonga-
tion factor. In VP-16 resistant cell lines, CCI-779 at 10 ng/ml is also
able to restore sensitivity. To confirm that inhibition of mTOR is the
important target, we have designed siRNA to inhibit mTOR which
yielded similar results to that of mTOR inhibitor. 
Clinical Translation: We propose a Phase I-II pilot study that will
select three group of patients: Group one: patients with partial
response after cycle 1-2 of cisplatin + VP-16 and no further
improvement after cycle 3-4; Group two: pts with Stable disease
(SD) after cycle 1-2 and Group three: patients with progression of
disease (PD). Protocol: CI-779, 25 mg Intravenously (IV) once a
week + EP regimen q 3weeks. In Phase I and II studies CCI-779 at
dose of 25 mg IV has been well tolerated. The response rate will be
defined by RECIST criteria and the toxicity will be defined by NCI
criteria. (Supported by VA Reearch fund).
4.02.08
Therapeutic Targeting of c-MET in Lung Cancer Cell Lines and
in Vivo Mouse Models
Nallasura, Vidya; Ramasamy, Jagadeeswaran; Seiwert, Tanguy;
Janamanchi, Varalakshmi; Loganathan, Sivakumar; Zumba, Osvaldo;
Surawska, Hanna; Trevor, Reichman; Krishnaswamy, Soundararajan;
Salgia, Ravi, University of Chicago, Chicago, IL, USA
Objective: To determine therapeutic inhibition of c-Met in lung can-
cer cell lines and to establish mouse models to determine specific
inhibition of lung cancer in vivo. 
Design: Specific inhibition of small cell lung cancer (SCLC) and
non-SCLC (NSCLC) cell lines was determined with c-Met small
molecule inhibitors (SU11274 and PHA665752). Also, xenograft
nude mouse models were established to determine the activity of
these small molecule inhibitors in lung cancer. MRI scans and
Doppler Ultrasound was utilized to determine the tumor growth
characteristics and angiogenesis. 
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Results: Utilizing several SCLC cell lines and small molecule
inhibitors against c-Met, we show that there was significant inhibi-
tion of cell growth and viability on c-Met mutated cell lines as com-
pared to wild-type cells, and no effect on non-c-Met expressing cell
lines. Also, there was specific inhibition of phosphorylated c-Met
(on tyr1003 in the juxtamembrane domain, and on
tyr1230/1234/1235 in the catalytic domain) and downstream cell
survival pathway AKT. This was similarly observed in the various
NSCLC cell lines tested. To determine the effects of these small
molecule inhibitors, we determined the growth characteristics of
SCLC and NSCLC in xenograft nude mouse models. We observed
that in H69 SCLC cell lines and in H441 NSCLC cell lines engraft-
ed into the nude mouse, there was robust growth. In response to the
PHA665752, we saw specific inhibition of SCLC and NSCLC cell
growth with decreased tumor burden. Using MRI scans, we show
specific regression of tumor growth in the treated mice. Also, there
was decreased angiogenesis. This was confirmed with a Doppler
scan, as well as histologically with specific CD31 staining of blood
vessels.
Conclusions: c-Met is an important therapeutic target in lung can-
cer. We have established specific cell line models as well as nude
mouse models for small molecule inhibitor testing. This can be now
tested and generalized with other novel targeted inhibitors.
4.02.09
HSP27 Is a Novel Therapeutic Target In Non-Small Cell Lung
Cancer With Particular Implications For Migration and
Metastasis
Seiwert, Tanguy Y.;1 Bracht, Lynn K.;2 Janamanchi, Varalakshmi;1
Jagadeeswaran, Ramasamy;1 Husain, Aliya;1 Padilla, Mary;1 Li,
Qiang;3 Tan, Dongfeng;4 Ramnath, Nithya;3 Salgia, Ravi1
1 University of Chicago, Chicago, IL, USA; 2 University of
Goettingen, Goettingen, Germany; 3 Roswell Park Cancer Institute,
Buffalo, NY, USA; 4 University of Texas, Houston, TX, USA
Purpose: HSP27 is a chaperone protein with anti-apoptotic and pro-
motility properties. We investigated the role of HSP27 in non-small
cell lung cancer (NSCLC) and it’s potential as a therapeutic target.
Methods: NSCLC tissue microarrays (TMA) were stained for
HSP27/ Phospho-HSP27 (IHC). Cell motility in HSP27 lentivirus
transfected A549 NSCLC cells was compared with control-sequence
transfected cells using Time Lapse Video Microscopy (TLVM).
HSP27 was suppressed with specific siRNA and antisense (OGX-
427). Normal human bronchial epithelial cells (NHBE) were used as
controls. Cell growth was determined by Cyquant assay. PI3K was
inhibited with Wortmannin/ LY290042.
Results: HSP27 and Phospo-HSP27 were overexpressed in 65% and
61% of tumor tissues. HSP27 expression was higher in 30% of
matched metastases compared to the primary tumor, and was lower
in only 3% (p<0.0001). HSP27 was overexpressed in 92% of Stage
IIIB/IV tumors compared to 65% in Stages I-IIIA (p=0.048).
Preliminarily HSP27 expression did not correlate with survival
(N=163), although a trend was seen.
HSP27 overexpressing cells showed markedly increased cell migra-
tion compared to control transfected cells. HSP27 suppression with
specific siRNA and OGX-427 antisense lead to growth inhibition
and tumor cell death. There was no toxic effect on NHBE cells. In
addition HSP27 suppression with OGX-427 HSP27 specific anti-
sense inhibited cell motility and membrane ruffling. PI3K inhibition
(Wortmann/LY290042) abrogated the pro-motility effects of HSP27
overexpression.
Conclusions: HSP27 is a novel target for NSCLC with a prominent
role in migration/ cell motility. HSP27 function is PI3K dependent.
Increased HSP27 expression in NSCLC metastases suggests a role
of HSP27 in the metastatic process. HSP27 inhibition leads to cell
death and abrogation of cell motility/membrane ruffling. A phase I
trial of OGX-427 is scheduled to start this year.
4.02.10
Mutations and Functional Analysis of c-Met in Lung Cancer
Krishnaswamy, Soundararajan;1 Janamanchi, Varalakshmi;1 Kanteti,
Rajani P.;1 Seiwert, Tanguy Y.;1 Ramnath, Nithya;2 Szeto, Livia;1
Ferguson, Mark;1 Vokes, Everett E.;1 Husain, Aliya;1 Salgia, Ravi1
1 University of Chicago, Chicago, IL, USA; 2 Roswell Park Cancer
Institute, Buffalo, NY, USA
The c-Met proto-oncogene encodes a transmembrane tyrosine kinase
receptor that mediates multiple functions such as migration, prolifer-
ation and differentiation by binding to hepatocyte growth factor
(HGF). Dysregulation of c-Met through overexpression or mutation
has been shown to play an important role in human cancers.
NIH3T3 cells stably transfected with c-Met carrying various muta-
tions exhibit prolonged c-Met phosphorylation and signal transduc-
tion following HGF stimulation and enhanced in vitro and in vivo
tumorigenicity when compared with cells expressing wild-type Met.
c-Met inhibitors specifically targeting the mutant isoform have been
reported to reduce tumor size and decrease metastasis. Furthermore,
inherited mutations in Met are known to contribute to the develop-
ment of gastric and renal cancer in humans. Higher incidence of
cancer in Rottweiler dogs has been related to a breed-specific herita-
ble G966S mutation in Met occurring in 70% of the members. We
have been systematically studying the mutations for c-Met in lung
cancer. We have in particular identified that there are germline muta-
tions of c-Met in non-small cell lung cancer and small cell lung can-
cer. Some of the mutations may also be important in the metastatic
mechanisms. In particular, we have identified mutations of c-Met in
the semaphorin, juxtamembrane, tyrosine kinase, and IPT domains.
In determining germline versus somatic mutations, we have evaluat-
ed tumor specimens as well as adjacent normal lungs and/or lym-
phocyte DNA. All c-Met missense mutations for which adjacent
normal or lymphocyte DNAs were available have proved to be
germline. We have also evaluated EGFR and K-ras mutations in the
context of c-Met mutations. In contrast to c-Met, all EGFR muta-
tions turned out to be somatic. In conclusion, c-Met mutations, most
of which are germline may be more widespread and racially biased
than previously known. We also show that the juxtamembrane
domain mutations lead to altered signal transduction and also
enhanced cell motility. We will further investigate the role of other
mutations. Ultimately, our goal is to arrive at novel therapeutics
against c-Met. 
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4.02.11
Strategies To Target C-Met Receptor Tyrosine Kinase Oncogenic
Pathway in Lung Cancer
Jagadeeswaran, Ramasamy; Zumba, Ozvaldo; Ahmed, Salman;
Jagadeeswaran, Sujatha; Bindokas, Vytas; Salgia, Ravi, University
of Chicago, Chicago, IL, USA
Lung cancer is a devastating illness with poor prognosis. In order to
significantly impact this disease, novel biological and biochemical
signaling mechanisms must be determined and ultimately targeted.
We have previously shown that the c-Met receptor tyrosine kinase
(RTK) is deregulated and important in lung cancer. The c-Met proto-
oncogene encodes a transmembrane tyrosine kinase receptor (c-Met)
for the ligand hepatocyte growth factor (HGF), a multifunctional
protein involved in normal cellular homeostasis as well as in cancer
and metastasis. Of the many cancer and normal cell lines studied by
immunoblotting, there was differential activation of c-Met signaling
in most of the lung cancer cell lines but not in normal cell lines.
HGF caused increased phosphorylation of the c-Met receptor tyro-
sine kinase, and further up-regulated downstream phosphorylation of
phospho AKT and ERK1/2 in a dose-responsive and kinetic fashion
in lung cancer cell lines. Also Reactive oxygen species such as
H2O2 induces phosphorylation of c-Met receptor tyrosine kinase,
and further up-regulated downstream signaling in lung cancer cells
in a growth factor independent manner. We further analyzed cell
lines for c-Met signaling and inhibition using invitro survival, apop-
tosis and colony formation assay. We have also studied the inhibi-
tion of c-Met using RNA interference, Anti c-Met Fab antibody,
small molecule inhibitors and antioxidants and observed in vitro the
reduction of cell growth, viability and colony formation. In addition,
HGF, ROS induced c-Met phosphorylation and basal level activated
c-Met as well as downstream targets such as phospho AKT [S473]
and anti-phospho ERK1/2 [T185Y187] were effectively inhibited in
the cancer cells with c-Met inhibition. It would be interesting to
selectively target the c-Met oncogenic pathway in cancer cells and
arrive at novel therapeutics.
Basic Research – Head and Neck Cancer
4.03.01
Filipino Patients with Locally Advanced Nasopharyngeal
Carcinoma Treated with Concurrent Chemotherapy and
Radiation Therapy At the Cancer Institute, St. Luke`s Medical
Center
Bautista, Janet B.; Caguioa, Priscilla B.; Li, Rubi K.; Panuncialman,
Gina V.; Dy, Carlos; Gorospe, Charity V.; Gorospe, Agnes E., St.
Luke`s Medical Center, Quezon City, Philippines
Purpose: Nasopharyngeal carcinoma (NPC) is a rare neoplasm in
most countries, but occurs in high frequencies among Chinese and
Filipino men. Studies on Concurrent chemoradiation done in the
United States and Taiwan have shown it to be more effective for
locally advanced nasopharyngeal carcinoma. This study aims to
determine the characteristics of Filipino patients with locally
advanced NPC treated with concurrent chemotherapy and radiation
therapy in terms of age, sex, histology, stage, chemotherapeutic and
radiation treatment protocols and to determine the clinical response
and toxicity profiles of these patients.
Methodology: Records of patients with AJCC Stages III, IVA and
IVB NPC treated with concurrent chemoradiation within a two-year
period were reviewed. Patient characteristics such as age, sex, his-
tology were collected and tabulated. Clinical responses were deter-
mined via the WHO criteria.Toxicities were graded using the NCI
Common Toxicity Criteria. 
Results: Thirty-one patients were included in the study. Majority
was male with a mean age of 44. Most had undifferentiated carcino-
ma histology. Toxicities were grade 2-3 mucositis, grade 2-weight
loss, grade 1-2 neuropathy and grade 1 anemia. The Intergroup 0099
protocol was mostly used; other protocols were the Cisplatin-5FU-
RT protocol by Cheng, weekly cisplatin-RT protocol by Chan, and
concurrent Carboplatin-FU-RT for 3 cycles without adjuvant
chemotherapy. Only 1 of the 31 patients was unable to complete
radiation treatment while 65% completed treatment according to
protocol. Response rate was 84% with 19% having complete
response.
Conclusion: Filipino patients with locally advanced NPC fit the
profiles of their Asian counterparts and respond well to concurrent
Chemoradiation with tolerable toxicity profiles. It is recommended
that further studies be done on these patients to measure overall sur-
vival and progression free survival. 
4.03.02
Anti-Tumor Effects Of Combinatorial Chemotherapy With
Tumor Specific Replicating Adenovirus In Head & Neck
Squamous Cell Carcinoma
Cho, Byoung Chul;1 Yun, Chae-ok;2 Kim, Joo-hang3
1 Yonsei Cancer Center, YonseiUniversity College of Medicine,
Seoul, Korea; 2 Institute for Cancer Research, Yonsei Cancer
Center, Yonsei University College of Medicine, Seoul, Korea; 3
Yonsei Cancer Center, Yonsei University College of Medicine, Seoul,
Korea
Combination therapy of chemotherapeutic agents, cisplatin and 5-
fluorouracil has been used as a standard therapy for advanced head
and neck squamous cell carcinoma (HNSCC). Gene attenuated repli-
cation competent adenoviruses are being developed as novel anti-
tumor therapeutics. Clinical trials with the ONYX-015 (E1B 55kDa-
deleted) adenovirus in combination with chemotherapeutic agents
have demonstrated a synergistic antitumor effect. However, most of
replicating adenoviruses have their E1B 19kDa gene intact. Because
the E1B19 protein is an anti-apoptotic agent, adenoviruses retaining
their E1B 19kDa gene may interfere with action of some chemother-
apeutic agents, resulting in attenuating the overall potency of these
combination treatment. E1B 19kDa-deleted adenovirus, Ad-mTERT-
∆19, which encodes the E1A gene driven by the uniquely modified
m-hTERT promoter, elicited enhanced viral replication and cyto-
pathic effects in a cancer cell-specific manner. For the aim of
improving the therapeutic efficacy for HNSCC cancer, we investi-
gated the value of different combinations of various chemotherapeu-
tic agents combined with Ad-mTERT-∆19. We assessed the cytotox-
ic activity of each combination in four different HNSCC cancer cell
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lines, utilizing MTT assay. Our results show that the combination
therapy with Ad-mTERT-∆19 and chemotherapeutic agents led to
improved cytotoxic effect compared with a virus or chemotherapeu-
tic agents alone treatment. The induction of apoptosis was also syn-
ergistically increased in cancer cells treated with Ad-mTERT-∆19
and chemotherapeutic agents, demonstrated by FACS analysis and
TUNEL assay. Furthermore, combination therapy with Ad-mTERT-
∆19 and chemotherapeutic agents exhibited superior anti-tumor
effect in FaDu head and neck tumor in vivo compared with either
agent alone. Overall, this study presents strong evidence for a syner-
gistic effect when treatment of Ad-mTERT-∆19 is combined with
chemotherapeutic agents. 
4.03.03
Expression of MT1 and MT2 Isoforms is Associated With
Increased Calcium and ERK Activation in Anaplastic Thyroid
Cancer
Chen, George G.; Liu, Zhimin; Shum, Cathy K.; Vlantis, Ac; van
Hasselt, Ca, The Chinese University of Hong Kong, Hong Kong,
China
Metallothioneins (MTs) are a family of small cysteine-rich multi-
functional stress proteins that bind with high affinity transition metal
ions. In human, there are four distinct MTs. The MT-1 protein com-
prises many subtypes encoded by a set of MT-1 genes. A hallmark
of the MT-1 and MT-2 genes is their rapid transcriptional induction
by transition metals such as cadmium. The known functional
MT1and MT2 isoforms are MT-1A, -1B, -1E, -1F, -1G, -1H, -1X,
and -2A. The present study was designed to explore transcription
induction of these functional MT-1 and MT-2 isoforms by cadmium,
and the possible involvement of intracellular calcium ([Ca2+]i) in
the cadmium-induced transcription of functional MT-1 and MT-2
isoforms in anaplastic thyroid carcinoma ARO cells. In this study
we demonstrated that cadmium could induce transcription of all 8
functional MT-1 and MT-2 isoforms in ARO cells in a time-depend-
ent manner at nontoxic dose by using real time PCR. However, the
transcriptional level of MT-1B and MT-1E induced by cadmium was
much lower, compared to the other 6 isoforms, suggesting that MT-
1A, -1F, -1G, -1H, -1X, and -2A were the main cadmium-induced
functional MT isoforms in ARO cells. Cadmium exposure caused
the rapid elevation of [Ca2+]i and moderate phosphoreylation of
ERK1/2. The selective ERK inhibitor (PD98059) significantly sup-
pressed the transcription of these main cadmium-induced functional
MT isoforms. Buffering of the calcium response with 1,2-bis-(2-
aminophenoxy)-ethane-N, N, N', N'-tetraacetic acid tetrakis
(BAPTA) blocked cadmium-induced transcription of these main
cadmium-induced functional MT isoforms. The pretreatment of
ARO cells with BAPTA inhibited the phosphoreylation of ERK to a
level that was close to the control. These results suggest that a com-
mon pathway, which is initiated by the rapid elevation of [Ca2+]i
and followed by calcium-mediated activation of ERK, is involved in
the transcriptional activation of the main cadmium-induced func-
tional MT isoforms in ARO cells. 
4.03.04
Identification of Molecular Biomarkers for Premalignant Oral
Lesions
Hasina, Rifat;1 Sigari, Farhad;1 Blair, Elizabeth;1 Stenson, Kerstin;1
Kuo, Winston;2 Lingen, Mark W.1
1 University of Chicago, Chicago, IL, USA; 2 Harvard Medical
School, Boston, MA, USA
The current criteria for identifying pre-malignant lesions of the oral
cavity require the identification of nuclear and/or cellular atypia.
However, since morphological or cytological changes occur late in
the molecular process of transformation, histologically benign
appearing lesions may have malignant potential. Conversely, even
severely dysplastic oral lesions can undergo spontaneous regression.
Thus, histologic findings cannot clearly predict malignant change. A
method for detecting molecularly premalignant lesions at an early
stage and for predicting the likelihood of their malignant progres-
sion is required. Our hypothesis is that molecular profiling in con-
junction with multi-tiered high throughput validation will greatly
improve diagnostic prediction compared to the cellular pattern
recognition currently used. Our goal is to identify a panel of bio-
markers that will allow for the identification of molecularly prema-
lignant lesions as well as histologically dysplastic lesions that are
more likely to progress to cancer. Accordingly, gene expression pro-
filing of more than 23,000 genes on the Affymetrix gene chip plat-
form was done on laser capture microdissected keratinocytes from
biopsies of 11 normal mucosal tissue and 50 patients with HNSCC
to define a set of genes with marked alteration in expression in the
course of carcinogenic transformation. A number of potential bio-
markers were identified and are currently undergoing a two-step val-
idation process, which includes RTQ-PCR and immunohistochemi-
cal evaluation. The validation of such biomarkers may provide us
with the ability to detect premalignant lesions at an earlier stage as
well as to better predict the biology of histologically dysplastic
lesions. Finally, the identification of specific sets of genes whose
expression is altered during oral cancer development may provide
crucial insights into the basic biology of cancer progression.
Basic Research - Lung Cancer
4.04.01
Urinary 8-OHdG Level as an Oxidative Stress Marker in Lung
Cancer Patients
Yano, Tokujiro; Shoji, Fumihiro; Koga, Tadashi; Shiraishi, Takeshi;
Orita, Hiroyuki; Kohno, Hitoshi, Saga Prefectural Hospital
KOSEIKAN, Saga, Japan
Objective: Reactive oxygen species are suggested to contribute to
carcinogenesis by oxidative DNA damage. The urinary excretion
rate of the oxidized nucleoside 8-hydroxydeoxyguanosine (8-OHdG)
has been validated as a biomarker of the rate of oxidative DNA
modification. In this study, we investigated the relationship between
urinary level of 8-OHdG and clinical factors in lung cancer patients.
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Patients and Methods: Eighty-one preoperative patients with nons-
mall cell lung cancer were enrolled into the present study. They con-
sisted of 49 men and 32 women, aging from 38 to 82 with a mean of
67.5. The subjects collected 24-h urine samples that were analyzed
for 8-OHdG content by ELISA.
Results: The urinary excretion rate of 8-OHdG in smokers was sig-
nificantly higher than that in never-smokers (7.4 ng/kg/h vs. 5.7
ng/kg/h, p<0.03). Especially, 8-OHdG excretion rate of current
smokers was higher than that of quitters longer than 1 month.
Excluding current smokers, the urinary excretion rate of 8-OHdG
did not relate to age or gender, but advance of the disease stage. The
mean urinary 8-OHdG level of patients with stage II to IV diseases
was significantly lower than that of patients with stage I disease. On
the other hand, urinary excretion rate of isoprostanes, that were end
product of lipid peroxidation was similar between those patients.
Conclusion: Smoking significantly increases the urinary excretion
rate of 8-OHdG, giving direct evidence that cigarette smoking caus-
es an increased rate of oxidative DNA modifications. In patients
with advanced stages, the capacity to repair oxidative DNA modifi-
cations might be impaired to some extent.
4.04.02
Treatment For Apical NSCLC
Porhanov, Vladimir A.; Poliakov, Igor S., Cardio-thoracic Surgery
Center, Krasnodar, Russia
Pancoast tumors are observed in less than 2% patients with lung
cancer. Approximately in 80% patients tumor invades subclavian
vessels, in others bone structures. At radical tumor resection 5-year
survival rate varies from 10 to 70%.
Since 1989 till February 2005, 61 patients with apical lung cancer
(ALC). Mean age was 59 years. Right tumor was in 35 cases, and
left tumor C in 26. Vessel invasions were in 43 (70%) patients and
they required resection with further grafting. Bone structures inva-
sion (vertebrae, sternum, clavicle, first ribs) were in 58 (95%).
Tumor located in the anterior apex in 27 (44%), posterior apical
localization in 34 (56%). Posterior-lateral approach was applied in
39 (63%), cervico-sterno-thoracotomy - in 19 (31%), sterno-thoraco-
tomy in various variants was used in 3 (6%). There were 5 pneu-
monectomies (8%), 39 lobectomies (63%), 17 segmentectomies
(27%). Subclavian artery grafting was performed in 34 (55%), SVC
in 7 (11%). Mean length of arterial graft was 4,5 cm. 
There were 2 cases (3%) of arterial bleeding with blood loss ≥ 800
ml; spinal liquid leakage was observed in 2(3%) following vertebral
resection. Intraoperative mortality was nil. Postoperative mortality
was 9%. Main reasons of death were graft thrombosis and cerebral
stroke, upper extremity gangrene. Total 5-year survival with complete
resection (R0) was 34%. None survived with incomplete resection.
Surgery for ALC is well tolerated by patients; it has rather low com-
plication and mortality rates with satisfactory survival rates.
Treatment for apical cancer should be considered as a combined
treatment.
4.04.03
Radiation Dose Escalation in Patients with Regionally Advanced
Non-Small Cell Lung Cancer Facilitated by the Use of the
Cytoprotectant Amifostine
Nichols, Romaine C.;1 Neuenfeldt, Lisa M.;1 England, Gregory J.;2
Mahmood, Syed K.;3 Nanfro, John J.;4 Malamud, Fernando C.;5
Sweetser, Matthew G.;6 Varner III, John C.;1 Gainer, Christopher D.1
1 Bay Medical Regional Cancer Center, Panama City, FL, USA; 2
Coastal Cardiovascular Surgeons, Panama City, FL, USA; 3 Bay
Oncology Center, Panama City, FL, USA; 4 Northwest Florida
Hematology and Oncology, Panama City, FL, USA; 5 Panhandle
Cancer Center, Panama City, FL, USA; 6 Gulf Coast Cancer
Treatment Center, Panama City, FL, USA
Purpose: Retrospective review of a cohort of patients receiving
higher than standard radiotherapy doses (>60Gy) with weekly
chemotherapy and daily subcutaneous amifostine for regionally
advanvced non-small cell lung cancer.
Methods and Materials: From January 2002 through December
2004, 19 patients (13 male, 6 female) with AJCC stage III non-small
cell lung cancer (14 stage IIIA, 5 stage IIIB) were treated with dose
escalated radiotherapy, weekly chemotherapy (Paclitaxel 50mg/m2,
Carboplatin AUC 2) and daily subcutaneous amifostine(500mg).
Maximum central axis dose ranged from 68.4Gy to 76Gy. The medi-
an dose was 72Gy. Karnofsky scores ranged from 70 to 100. The
median age was 62 years. Complete dose volume histograms were
available for 10 patients. Pulmonary doses were estimated based on
the 3D conformal treatment plans for the remaining 9 patients. The
average lung volume receiving greater than 20Gy was 31% (range
10% to 42%). 
Results: All patients have been followed for a minimum of 18
months. The 2 year survival is 38%. No patient experienced signifi-
cant (grade III or worse) acute or late pulmonary or esophageal toxi-
city. 18 of the 19 patients received at least 6 of the planned 8 weekly
chemotherapy doses. An average of 24.5 500mg vials of amifostine
were delivered to each patient (range 2 to 40). The most common
reasons for amifostine discontinuation included hypotension, nauea
and skin / injection site reactions. 
Conclusions: In spite of high radiotherapy doses delivered and rela-
tively large pulmonary volumes irradiated, the lack of significant
pulmonary toxicity suggests that amifostine may offer meaningful
cytoprotection. The encouraging survival data suggests that dose
escalated radiotherapy with chemotherapy is a reasonable manage-
ment strategy for this group of patients. 
4.04.04
Establishment of Lung Cancer Transgenic Animal Models with
Type-Specific P53 Mutants for Experimental Therapeutic
Studies
Villalona-Calero, Miguel A.; Wenrui, Duan; GAO, Li; Wu, Xin;
Otterson, Gregory, The Ohio State University, Columbus, OH, USA
More than 50% of lung cancers contain p53 mutations. Two major
types comprise the mutations described to date: Type I (contact) and
Type II (conformational). Differences include higher oncogenic
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potential for the Type II mutation, and conservation of some wild
type activity for Type I. 
To create lung cancer animal models with the major mutation types,
the human Type I (R273H) or the Type II (R175H) p53 mutant genes
were placed under the control of the human surfactant protein C
(SPC) promoter to selectively express the mutant gene in lung tissue. 
Results: Both p53types expressed in a lung-specific manner per
Immunohistochemistry and Western-blot. Type I transgenics (n=122)
were sacrificed at different ages. Lung tumors occurred as follows:
1/21 at 4-6 months, 1/20 at 7-9 months, 2/34 at 10-12 months, and
13/47 at 13-15 months. Among 160 Type II mice, 1/14 had tumors
at 4-6 months, 6/23 at 7-9 months, 14/59 at 10-12 months and 20/64
at 13-15 months. Tumors were adenocarcinomas, and in contrast to
inhaled-carcinogen models, no adenomatous formation preceding
the carcinomas was observed.
Among age-matched non-transgenic littermates (n=109) no tumors
were observed at 4-6 (n=20) and 7-9 months(n=22), and in two mice
each in the 10-12 (n = 31) and 13-15 (n=35) months. Tumor forma-
tion rate was statistically significantly different at 13-15 months
(Type I) compared to control (p=0.022) and for Type II at 7-9
months, (p=0.011); p=0.021 at 10-12 months, and p=0.0034 at 13-15
months, t-test).
Conclusions: p53 mutant mice have an earlier tumor onset com-
pared to non-transgenic littermates and the tumors are more aggres-
sive in Type II transgenics, as had been suggested by increased
oncogenic potential in vitro. Since these animal models develop dis-
crete single lung adenocarcinomas, they should provide valuable
models for evaluating the effect of a mutant type on response to
treatment interventions and to devise potential prevention strategies.
4.04.05
Regulation of cancer growth in HNSCC and NSCLC conferred
by TCF21
Smith, Laura T.;1 Lin, Mauting;1 Brena, Romulo M.;1 Lang, James
C.;1 Schuller, David E.;1 Otterson, Gregory A.;1 Morrison, Carl D.;1
Smiraglia, Dominic1 J.;2 Plass, Christoph1
1 The Ohio State University, Columbus, OH, USA; 2 Roswell Park
Cancer Institute, Buffalo, NY, USA
Background: Identification of tumor suppressor genes has classical-
ly been determined by their locations within common regions of loss
of heterozygosity (LOH). Losses along chromosome 6q have been
clinically associated with HNSCC and NSCLC, including tumor
aggressiveness. However, the putative tumor suppressor gene had
not been identified. By combining DNA methylation analysis along
6q23-q24, we were able to identify TCF21 as the important gene
targeted for inactivation in HNSCC and NSCLC.
Results: Restriction Landmark Genomic Scanning was used to iden-
tify and confirm methylation events in primary HNSCC (n=15) and
NSCLC (n=24) samples. Loss of TCF21 was observed in 86% and
67% of NSCLC and HNSCC samples, respectively. Methylation
was confirmed in the promoter of TCF21 via bisulfite sequencing.
The tumor suppressive function of TCF21 was evaluated in vitro via
colony formation and growth curve assays. Exogenous expression of
TCF21 in A549 was able to reduce tumor volume in nude mice by
four fold. Immunohistochemical analysis demonstrated no nuclear
staining of TCF21 in all NSCLC tumors examined, while normal
airway epithelium strongly expresses.
Conclusions: TCF21 is known to function in early development as
regulating mesenchymal to epithelial transition (MET). The reverse
process of epithelial to mesenchymal transition (EMT) has been
demonstrated as being an important mechanism allowing for malig-
nancies derived from epithelium, such as HNSCC and NSCLC, to
become more invasive, altering cellular properties affording the can-
cer cell the ability to become migrant or metastatic. Therefore, we
have shown that loss of TCF21 occurs commonly in HNSCC and
NSCLC, and that this loss causes changes in expression patterns
known in mesenchymal and epithelial cells, supporting our hypothe-
sis that TCF21 is a novel tumor suppressor gene frequently targeted
by DNA methylation for silencing.
4.04.06
In Vitro Schedule Dependent Synergy of the Aurora Kinase
Inhibitor (AKI) VE-465 and Anti-Tubulin Agents in Non-Small
Cell Lung Cancer (NSCLC)
Edelman, Martin J.; Wilson, Melinda; Sausville, Edward A.; Burger,
Angelika, University of Maryland Marlene and Stewart
Greenebaum Cancer Center, Baltimore, MD, USA
Background: Aurora kinases are a family of proteins responsible
for correct chromosomal orientation and separation during mitosis.
Overexpression of aurora kinase B in NSCLC is common and asso-
ciated with poor prognosis. AKIs are now entering clinical trials. We
hypothesized that combining an AKI with antitubulin agents would
be synergistic and schedule dependent. Furthermore, as both fami-
lies of agents affect targets important for successful completion of
mitosis, the mechanism of cell death might relate to enhanced apop-
totic susceptibility during mitosis or mitotic catastrophe. AE-465 is a
nonspecific AKI that is similar to MK-0457 (VX-680), currently
undergoing clinical evaluation.
Methods: A549 cells were plated on 96 well plates. VE-465, pacli-
taxel or vinorelbine were added at fixed ratios of the IC50. All expo-
sures to drug were for 24 hours. After exposure, agents were
removed and cells grown until controls were 90% confluent. Cell
survival was determined by the MTT assay. Evaluation of drug
interaction was accomplished by median effect analysis and deter-
mination of the combination index (CI). Antagonism, additive and
synergistic interactions are concluded for CI >1,= to 1 o r <1,
respectively. Flow cytometry and immunofluorescence was per-
formed at the single agent’s IC50 and with the combinations at opti-
mal concentrations. 
Results: VE-465 and paclitaxel demonstrated marked synergy when
paclitaxel was administered prior to VE-465 (CI <1). When AE-465
preceded or was administered concurrently with paclitaxel, there
was antagonism (CI > 1). Concurrent administration of VE-465 with
vinorelbine was synergistic while vinorelbine preceding VE-465 or
the reverse sequence was antagonistic. Flow cytometry of paclitaxel
followed by AE465 demonstrated increased numbers of cells with
>4n DNA content with relatively little sub-G1 population, consistent
with disordered progression through mitosis rather than immediate
apoptosis. The latter is supported by immunofluroescence
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microscopy demonstrating giant multinucleated cells. Antitubulin
agents or AE-456 alone showed the morphology typical for the
effects of the single agents. 
Conclusion: 1. AKI and antitubulin agents demonstrate schedule
dependent synergy. 2. Disordered progression through mitosis
appears to precede cell death. 3. This information should be consid-
ered in the design of clinical trials. 
4.04.07
Activation of Extracellular Signal-Regulated Kinase and
Nuclear Factor kappaB Mediates Lung Cancer Cell
Proliferation Induced By 4-(N-Methyl-N-nitrosamino)-1-(3-
pyridyl)-1-butanone (NNK)
Chen, George G.;1 Li, Mingyue;1 Yip, Johnson;1 Lee, Tak W;1 Wu,
Tangchun;2 Mok, Tony S.;1 Yim, Anthony P.1
1 The Chinese University of Hong Kong, Hong Kong, China; 
2 Huazhong University of Science and Technology, Wuhan, China
4-(N-Methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone (NNK), the
tobacco-specific nitrosamine, induces lung cancer in all animal
species tested and contributes significantly to the development of
smoking-related lung cancer. In present work, we studied how ERK
and nuclear factor kappaB (NF-kB) activiation regulated protein
expression in human lung cancer cells NCI-H23 treated by NNK.
Results showed that NNK stimulated cell proliferation, up-regulated
NF-kB expression, helped to translocate p65 into the nucleus and
induced the NF-kB DNA binding activity and ERK activation. The
further study found that both U0126 (a specific inhibitor of ERK)
and SN50 (a specific inhibitor of NF-kB) blocked most of NF-kB
transcriptional activity in the cell treated by NNK. Unlike U0126,
NNK-mediated increased ERK activation was not affected by SN50.
ERK activation appeared to have a role upstream of NF-kB in NCI-
H23 cells treated by NNK. The levels of HO-1, p21, c-IAP-2 as well
as Bcl-2 were up-regulated by NNK in a time-dependent manner. In
contrast, the expression of Bad was down-regulated. Inhibition of
ERK and NF-kB activation led to the suppression of NNK-mediated
these proteins expression, indicating that NNK may regulate cell
proliferation through an ERK- and NF-kB-dependent pathway. In
conclusion, the activation of ERK and NF-kB is involved in NNK-
mediated changes in HO-1, p21, c-IAP-2, Bcl-2 and Bad, which are
in favor of the proliferation and growth of lung cancer cells.
4.04.08
Compatibility Study Between Cisplatin and Gemcitabine: pre-
Requiste for a Clinical Study Combining These Two Drugs in
the Intrathoracic Hyperthermic Chemotherapy of Pleural
Mesothelioma (ITHC)
Venissac, Nicolas;1 Pop, Daniel;1 Leo, Francesco;1 Renée, Nicole;2
Mouroux, Jérôme;1 Milano, Gerard2
1 Thoracic Surgery Department, Pasteur Hospital, Nice, France; 
2 Oncopharmacology laboratory, “Antoine Lacassagne” Center,
Nice, France
Background: The multimodal treatment of pleural mesothelioma
included single-drug ITHC. Intravenous two-drugs chemotherapy is
more effective. We studied “in vitro” compatibility of cisplatin and
gemcitabine reproducing the per-operative conditions of ITHC.
Methods: The cisplatin concentrations used were 50µg/ml and
200µg/ml respectively; the gemcitabine concentrations used were
625µg/ml and 2500µg/ml respectively. The study in hyperthermia
was done by immersing the pockets for one hour in 42°C bath. The
pure and mixed drugs solutions were mesured by HPLC before and
after immersion with a precise time schedule.
Results: No precipitate was found in any bottle at any time. The
gemcitabine concentrations remained stable in time, after hyperther-
mia, whether at low or high concentrations, pure or mixed, with
standard deviation of 7-53,3µg/ml and the variability factor between
0,4-3,46%. The cisplatin concentrations remained stable in time,
after hyperthermia, whether at low or high concentrations, pure or
mixed, with standard deviation of 0,79-3,41µg/ml and the variability
factor between 0,9-6,85%. The pH of the mixed solutions was low
(between 2,82-3,14) and remains stable in time with pH standard
deviation of 0,008-0,049 and the variability factor between 0,28-
1,73% (Table).
Conclusion: Ours results show compatibility of the two drugs that
allow their mixed combination in intra thoracic hyperthermic
chemotherapy. Attention must be done concerning the pH solution.
Table. Evolution of pH values of cisplatine
and gemcitabine mixed solutions.
T0 T1 T2 T3 T4 T5 Mean/ CV%
Std Deviation
High Gemcitabine 2.76 2.83 2.82 2.81 2.84 2.84 2.82/ 1.06
+ High Cisplatin 0.03011
Low Gemcitabine 3.13 3.14 3.15 3.15 3.14 3.13 3.14/ 0.28
+ Low Cisplatin 0.00894
Low Gemcitabine 3.08 3.08 3.06 3.08 3.09 3.09 3.08/ 0.36
+ High Cisplatin 0.01095
High Gemcitabine 2.8 2.9 2.92 2.86 2.93 2.92 2.89/ 1.73
+ Low Cisplatin 0.04996
4.04.09
Preliminary Toxicity Data from a Phase II study of Docetaxel/
Oxaliplatin for Patients with Advanced Non-Small Cell Lung
Cancer (NSCLC)
Milton, Daniel T.; Bitran, Jacob D.; Galvez, Angel G.; Tolzein, Kathy;
Nabhan, Chadi, Oncology Specialists, S.C., Park Ridge, IL, USA
Background: Oxaliplatin is an active anti-cancer agent that has a
favorable toxicity profile and encouraging activity in NSCLC. We
undertook this phase II study to characterize the objective radi-
ographic response rate, tolerability, and time to progression of oxali-
platin in combination with docetaxel in patients with advanced
NSCLC. Preliminary toxicity data are presented herein. 
Methods: Chemotherapy-naïve patients with confirmed NSCLC,
adequate organ function, Karnofsky Performance Status (KPS)
≥70%, and measurable disease were eligible. Patients received doc-
etaxel 30 mg/m2 on days 1 and 8 and oxaliplatin 85 mg/m2 on days
1 and 15 of a 28-day cycle, to a maximum of 6 cycles. Toxicity
Fourth International Symposium on Malignancies of the Chest and Head & Neck 911
Journal of Thoracic Oncology • Volume 1, Number 8, October 2006
assessments were performed with each subsequent cycle and were
graded according to the NCI CTCAE, version 3. 
Results: Ten patients have been enrolled to date with the following
characteristics: female: 4; KPS median: 90%; age median 72. Three
patients remain inevaluable: two recently started and have not com-
pleted cycle 1; the third withdrew prior to completing cycle 1 due to
a medi-port infection. Treatment-related toxicity (≥grade 2) for the 7
patients who completed ≥1 cycle: grade 3 fatigue (n=2), grade 2
fatigue (n=3), grade 3 anorexia (n=2), grade 2 anorexia (n=3), grade
3 nausea (n=1), grade 2 dysguesia (n=4), and grade 2 stomatitis
(n=1). One patient required treatment interruption and another
required dose reduction of both agents due to toxicity. Among the 5
response-evaluable patients, 2 experienced confirmed partial
responses by RECIST, each being associated with >70% reductions
in measurable disease.
Conclusions: These preliminary data suggest that oxaliplatin/ doc-
etaxel is tolerable in this community-based population, with fatigue
and anorexia being prominent side effects. This regimen appears to
have promising clinical activity that is worthy of continued study. 
4.04.10
EGFR and BCL-2 Expression is Prognostic for Survival in Non-
Small Cell Lung Cancer
Renouf, Daniel J.;1 Wood-Baker, Richard;2 Ionescu, Diana;3 Leung,
Samuel;3 Massoudi, H.;3 Gilks, Blake;3,4 Laskin, Janessa1,4
1 University of British Columbia, Vancouver, BC, Canada; 
2 University of Tasmania, Hobart, TAS, Australia; 3 Vancouver
General Hospital, Vancouver, BC, Canada; 4 British Columbia
Cancer Agency,Vancouver, BC, Canada
Objective: The purpose of this study is to use a large patient popu-
lation to identify immunohistochemical (IHC) biomarkers to enable
improved prognostication in patients with non-small cell lung carci-
noma (NSCLC).
Methods: A tissue microarray was constructed from 609 patients
with early stage NSCLC. IHC was used to detect 11 biomarkers
including EGFR, HER2, HER3, p53, p63, Bcl-1, Bcl-2, TTF-1,
CEA, Ch, and SNP. Staining for other biomarkers including VEGF,
k-ras, and e-cadherin is currently underway. A clinical database was
generated prospectively at the time of tissue collection. Survival out-
comes were obtained from a Provincial Cancer Registry database.
Univariate and multivariate analysis were done to look for a relation-
ship between biomarker expression, smoking history, and survival. 
Results: Survival data for 535 cases was available. As of June 2005
429 patients (80%) had died. 95% of the patients had a history of
smoking. Univariate analysis revealed that EGFR-Bcl-2 co-expres-
sion is prognostic for overall survival (OS) (p = 0.009) in all
NSCLC. Multivariate analysis revealed that Bcl-2 expression is
prognostic for OS (p = 0.012) and disease specific survival (p =
0.029) in all NSCLC. Other multivariate analysis models were test-
ed but failed to show a statistical significance. In addition EGFR
expression was found to be associated with a greater number of
years of smoking (p=0.027) in all NSCLC. Further staining results
will be available at the time of presentation.
Conclusions: Expression of EGFR and/or Bcl-2 is prognostic for
survival in NSCLC. EGFR expression is increased with prolonged
smoking exposure. Testing for EGFR and Bcl-2 expression in a
prospective study will help to clarify their clinical role in prognostica-
tion, and potentially reveal a predictive role for these markers as well.
4.04.11
Epac and Rap1 are Negative Regulators of Angiogenesis
Doebele, Robert C.;1 Hong, Jia;1 Zeitlin, Benjamin;2 Nor, Jacques
E.;2 Quilliam, Lawrence A.;3 Tang, Wei-jen;1 Lingen, Mark W.;1
Rosner, Marsha R.1
1 University of Chicago, Chicago, IL, USA; 2 University of
Michigan, Ann Arbor, MI, USA; 3 Indiana University School of
Medicine, Indianapolis, IN, USA
Angiogenesis has classically been defined as the assembly of
endothelial cells into capillaries from a pre-existing vasculature.
Since abnormal angiogenesis is a hallmark of many cancers, includ-
ing lung cancer, it is critical to identify factors that control this
process. Endothelial cells are enriched in the anthrax receptor; we
therefore determined the effect of anthrax edema toxin (ET), an
adenylyl cyclase, on angiogenesis. cAMP generated by ET does not
block proliferation or survival but causes cytoskeletal changes and
inhibits chemotaxis by human primary vascular endothelial cells
(HMVECs). These effects are due to the action of a downstream
cAMP effector, Epac, a guanine nucleotide-exchange activating pro-
tein for Rap1 (RAP1-GEF). ET induces transcription of Epac-related
activators of Rap1, Epac2 (RapGEF4) and RapGEF5. Like ET, acti-
vated Epac or Rap1 induce cytoskeletal changes and block chemo-
taxis in human endothelial cells, and the mechanism likely involves
Rap1 inhibition of RhoA and its effector Rho Kinase. Epac also
potentiates VEGF activation of ERK, a kinase implicated in
HMVEC proliferation. Finally, injection of an Epac activator or
HMVECs expressing active Rap1 into mice inhibits microvessel
development. These results identify Epac and Rap1 as inhibitors of
chemotaxis and angiogenesis and highlight Rap1 as a key regulator
of signaling cascades leading to endothelial cell proliferation,
chemotaxis and angiogenesis. The availability of small molecule
activators of Epac/Rap1 could represent a novel approach for the
treatment of vascular tumors. 
4.04.12
Concurrent Chemoradiation vs. Radiation Therapy alone in the
treatment of Locally Advanced Nasopharyngeal Carcinoma
(NPC): An Institutional Review
Yao, Shaoyee;1 Wu, Jonn;2,3 Laskin, Janessa2,3
1 Dept of Medicine, University of British Columbia, Vancouver, BC,
Canada; 2 British Columbia Cancer Agency, Vancouver, BC,
Canada; 3 University of British Columbia, Vancouver, BC, Canada
Background: NPC is common in Southeast Asia; because of immi-
gration patterns, the city of Vancouver is in a unique position to
study this cancer in a North American setting. In 1998 a landmark
phase III study demonstrated the superiority of concurrent chemora-
diation (CR) compared to standard radiation (RT) alone; therefore
CR is considered standard of care for patients (pts) with locally
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advanced disease (LAD). This study is a retrospective analysis of an
institutional experience with this recommendation. 
Methods: A chart review was completed on 141 patients who
received treatment for NPC between 2000- 2005 at the BC Cancer
Agency (BCCA) in Vancouver. Concurrent CR is defined as 3 cycles
of cisplatin at 100mg/m2; all radiation doses were >5500 cGy. 
Results: There was no difference in age or gender distribution. 74%
of pts were of Asian origin. 29 pts received CR.112 pts received RT
alone, 86 pts (77%) did not receive CR because they were not
referred to a medical oncologist; other reasons included: pt choice
(7%), co-morbidities (3%), weight loss (1%), and other (12%). Of
these 86 pts: 73 (85%) had LAD (67% Stage 2, 14 % Stage 3, and
4% Stage 4). To date, there is no difference in the number of pts
without disease recurrence (59% in RT; 61% in CR). Local and dis-
tant recurrence occurred in 14% and 27% in the CR arm and 22%
and 13% in the RT arms, respectively. 
Conclusion: Despite evidence that concurrent CR improves out-
comes for locally advanced NPC it appears that many pts are not
routinely referred to a medical oncologist. This may explain the sim-
ilar outcomes observed in this analysis and highlights the difficulties
of integrating evidence into clinical practice. 
4.04.13
The Role of Pax Transcription Factors in Lung Carcinogenesis:
Relationship to c-Met Receptor Tyrosine Kinase
Kanteti, Rajani P.; Nallasura, Vidya; Wang, Cindy Y.; Salgia, Ravi;
University of Chicago, Chicago, IL, USA
Lung cancer still remains one of the leading causes of all cancer
related deaths. The two major types are non small cell (NSCLC) and
small cell (SCLC) lung cancers. Amongst the two, prognosis in
patients with NSCLC is better compared to those with SCLC, how-
ever the overall survival rate is still very low (17%). A variety of
molecular changes due to various genomic alterations are known to
contribute to the development and spread of lung cancers, for
instance mutations in p53, RB, Ras, several receptor and non-recep-
tor tyrosine kinases are known to contribute to the variety of pheno-
types seen in lung cancer. One of the long term goals of our lab is to
map and study the biological significance of loss and gain of func-
tion mutations in various signaling molecules in lung cancer; with
the idea of developing novel therapeutics. In this regard, we exam-
ined the role of Pax transcription factors in lung cancer. To date, the
Pax family consists of nine members that are all characterized by
the presence of a paired domain. They are indispensable for various
developmental processes and several of them are known to play a
significant role in the development of various cancers. In this initial
study, we used a panel of both NSCLC and SCLC cell lines to deter-
mine the relative levels of various Pax proteins. To our great sur-
prise, we detected significant expression of Pax8 in NSCLC and
Pax5 in SCLC cell lines. In addition we could detect BCL2 but not
BCL-XL, especially in the SCLC cell lysates. Since Pax3 is a
known direct transcriptional activator of c-MET, a receptor tyrosine
kinase that is known to play a significant role in cancer metastasis,
we therefore determined the protein expression levels of c-MET in
the above cell lines. In general, in most of the cell lines where Pax
expression was detected, we also detected comparable levels of c-
MET. Using siRNA approach we will present evidence linking
expression of Pax to c-MET and also its effect on cell survival.
4.04.15
Inhibition of Non Small Cell Lung Cancer Cell Lines by
Inhibition of the CXCR-4 Pathway 
Ding, Yu;1,3 Muzik, Huong;1,3 Morris, Don;1,3 Bebb, Gwyn2
1 Tom Baker Cancer Centre, Calgary, AB, Canada; 2 Alberta
Cancer Board, Calgary, AB, Canada; 3 University of Calgary,
Calgary, AB, Canada
Background: Cell migration is an important component of the
metastatic process, and is a critical step in early stage disease.
Recent studies indicate that the CXCR4 receptor and its ligand, stro-
mal cell derived factor -1(SDF-1), may play a critical role in leuko-
cyte trafficking and homing of hematopoietic stem cells. The role of
CXCR4 in the migration of NSCLC cells has not been explored in
detail. We set out to investigate the expression of CXCR4 by
NSCLC cell lines and what effect inhibition of this axis would have
on the migration of NSCLC cell line in vitro.
Methodology: Two human NSCLC cell lines (H460 and H1299)
transfected with green fluorescent protein (GFP) were assessed for
CXCR4 expression by western blotting and flow cytometry.
Migration patterns were investigated using a 48-well Boyden cham-
ber. Chemoattractants (increasing concentrations of calf serum
(FCS), SDF-1) and/or inhibitors (an anti CXCR4 antibody) were
added to the lower wells, while cells in suspension were added to
the upper wells separated from the lower wells by a polycarbonate
filter. After incubation, non-migrating cells on the top side of the fil-
ter were wiped off. Migrating adherent cells on the underside were
stained with hematoxylin and counted microscopically at 20x mag-
nification. GFP transfected cells are readily visualized by immune-
fluorescence microscopy.
Results: Both cell lines express CXCR4 on their surface. Pore size
influences migration of NSCLC cells through the polycarbonate fil-
ter. Both cell lines migrated across the membrane in response to
increasing concentrations of FCS and SDF-1. Anti CXCR-4 antibod-
ies reduced the proportion of cells migrating across the Boyden
Chamber membrane by more than 60%.
Conclusions: Inhibition of the CXCR4/SDF-1 axis appears to inhib-
it the migration of these cells in vitro despite the presence of 20%
calf serum or SDF-1. The CXCR4 axis may play a role in influenc-
ing the migrational behavior of NSCLC cells. Additional experi-
ments to assess the role of small molecular inhibitors of CXCR4 are
currently underway. Use of CXCR4 inhibition strategies may be a
useful therapeutic tool to reduce systemic spread of early stage lung
cancer. In vivo experiments to explore this are currently being
designed.
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4.05.01
Is the Extent of Paratracheal Nodal Irradiation in Laryngeal
Cancer with Subglottic Extension Related to Outcome?
Ampil, Federico L.;1 Caldito, Gloria;2 Nathan, Cherie Ann O.;2
Lian, Timothy S.2
1 Division of Therapeutic Radiology, Louisiana State University,
Shreveport, LA, USA; 2 Louisiana State University Health Sciences
Center, Shreveport, LA, USA
Background: A management conundrum may exist for patients who
have laryngeal cancer with subglottic extension (LCSE) because the
extent to which the paratracheal lymph nodes (PLNs) require treat-
ment has not yet been ascertained.
Objective: To investigate postoperative radiotherapeutic manage-
ment and outcome in patients with LCSE.
Methods: Between 1983 and 2002, 26 individuals received radio-
therapy after total laryngectomy because of LCSE. The PLNs supe-
rior (and inferior in two cases) to the suprasternal notch were irradi-
ated in addition to the primary tumor bed. External beam irradiation
administered an overall total dose to the tumor bed/upper neck of
59Gy ± 4.9Gy (range 50-65Gy) and to the lower neck 50Gy ±
2.6Gy (range 50-60Gy). The follow-up period ranged from 5 to 185
months.
Results: Among the 24 evaluable patients, there were no instances
of tumor relapse in the upper mediastinum. The rates of recurrent
tumor in the neck and distant metastases were both 8% ± 12%. The
rate of failure in the neck was 7% ± 14% when the extent of sub-
glottic involvement by laryngeal cancer was between 15 and 19 mm
and 10% ± 20% when it was 20 mm or more (p>0.8). The Kaplan-
Meier survival rate at 6 years was 67% ± 18%.
The site of recurrent tumor in the neck was peristomal or in the pos-
terior cervical node area (level 5); distant disease was in the elbow
or lung. Three patients received radiotherapy for palliation of recur-
rent or progressive tumors. Survival after the appearance of disease
relapse or progression did not exceed 10 months.
Conclusion: The observed results lead us to the conclusion that
even with the non-irradiation of the PLNs in the superior medi-
astinum of the chest, postoperative radiotherapy can achieve reason-
able long-term disease-free survival in patients with LCSE.
4.05.02
Socioeconomic Status (SES) is an Independent Prognostic
Factor For Overall Survival (OS) in Nasopharyngeal Carcinoma
(NPC) and Affects Individual Ethnicity Differently
Ou, Sai-hong I.;1 Zell, Jason A.;1 Ziogas, Argyrios;2 Anton-Culver,
Hoda2
1 Chao Family Comprehensive Cancer Center, Orange, CA, USA; 
2 Genetic Epidemiology Research Institute, Irvine, CA, USA
Background: We have reported that socioeconomic status (SES) is
an independent prognostic factor for overall survival (OS) in
nasopharyngeal carcinoma (NPC). We investigated how overall sur-
vival of individual ethnicity is affected by SES.
Patients and Method: 1657 newly diagnosed NPC patients from
1992 to 2002 were analyzed from the population-based California
Cancer Registry. Individual patients were assigned to a SES quintile
according to the Yost index. Five-year survival rate estimates and
Kaplan-Meier survival curves were calculated. Cox proportional
hazard ratios were used to identify independent prognostic factors
for survival.
Results: SES is an independent prognostic factor for OS for NPC
(SES5[highest] vs SES1[lowest]; HR = 0.69; P = .003) in the Cox
proportional hazard model. The trend of decreasing HR for overall
survival from SES1 to SES5 is also significant (HR = 0.92; P =
.003) with an average of 8% reduction in the risk of death with each
increase in SES quintile. Applying the same Cox proportional haz-
ard model to individual race, SES was a significant prognostic factor
for OS for African-American (HR = 0.75; P = .028), Hispanic (HR =
0.77; P = .016) and non-Chinese Asian (HR = 0.82; P = .004)
patients. However SES was not a significant prognostic factor for
OS for the 2 major constituents of non-Chinese Asian, Filipino and
Vietnamese. SES was significant prognostic factor for other remain-
ing non-Chinese Asian (HR = 0.70; P = .004).
Conclusions: SES is an independent prognostic factor for overall
survival in NPC. However, individual ethnicity is affected differently
by SES.
4.05.03
Concurrent Radiation Therapy and Weekly Docetaxel in Elderly
Patients with Oropharyngeal Carcinoma
Anghel, Rodica; Isacu, Irina; Bacinschi, Xenia; Tarlea, Alin; Minea,
Laurentia; Oprea, Laura; Savin, Viorel, Institute of Oncology
Bucharest, Bucharest, Romania
Background: To evaluate the compliance and efficacy of concurrent
weekly docetaxel and radiation therapy as definitive treatment for
elderly patients with oropharyngeal carcinoma.
Materials and Methods: 20 patients, over 65 years of age, with pri-
mary oropharyngeal cancer, who were treated with concurrent doc-
etaxel and radiation therapy, were reported between January 2003
and December 2005. The distribution depending on stage was: stage
II - 4 patients, stage III - 6 patients, stage IV - 10 patients (IV A - 7
patients and IV B - 3 patients). The total dose of radiotherapy was
70 Gy. Chemotherapy was delivered weekly and consisted in
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Docetaxel 10 mg/sqm. 4 more cycles of chemotherapy ( Docetaxel
and Cisplatin) were administrated after concurrent radiochemotherapy.
Results: Only 2 patients interrupted the radiochemotherapy due to
related toxicities, especially acute grade III - IV mucositis. Grade III
- IV hematological toxicities were observed in 5 patients, and grade
III - IV mucositis in 4 patients. At the time of analysis 18 patients
are alive and 11 of them are disease free.
Conclusion: Concurrent weekly docetaxel and radiation therapy did
not affect patients’ compliance to treatment; acute toxicities were in
acceptable limits. Concurrent radio - chemotherapy was well tolerat-
ed and results and acute toxicities were comparable with younger
patients. Elderly cancer patients should be offered optimal treatment
depending on their functional status not on chronological age.
4.05.04
Target Volume Delineation and Conformal Radiation Therapy
in the Management of Adenoid Cystic Carcinoma of the
Paranasal Sinuses
Nagda, Suneel N.; Emami, Bahman; Pederson, Aaron; King,
Stephanie; Millbrant, Linda; Clark, Joseph; Petruzzelli, Guy, Loyola
University, Maywood, IL, USA
Purpose/Objective: Accurate target volume (TV) delineation is
challenging but important in the radiotherapeutic management of
adenoid cystic carcinoma of the paranasal sinuses (ACC-PNS) due
to propensity for perineural invasion. We reviewed our experience
and propose TV delineation methods.
Methods and Materials: Between January 1997 and May 2004,
thirteen patients with ACC-PNS were treated with conformal radio-
therapy, nine of these with intensity modulated radiation therapy
(IMRT). Twelve underwent initial surgery and half of these, skull-
based. Nine had known perineural invasion. The clinical TV encom-
passed the tumor bed and uninvolved regions at risk: palate-P, ptery-
gopalatine fossa-PPF, infratemporal fossa-ITF, skull base including
foramens rotundum/ovale-SB, cavernous sinus-CS, medial and
infra-orbital region-MO/IO, ipsilateral nasal cavity-NC,
nasopharnyx-NP, and other sinuses-OS. Median RT dose was 60 Gy
(56-70). TVs were retrospectively reviewed.
Results: Twelve patients are alive with a median follow up of 36
months. One patient, who did not have surgery, experienced local
recurrence and subsequently died of disease. There were no margin-
al recurrences. The 3-year locoregional control rate is 92%. Twelve
patients had TVs available for review. All regions except ITF, MO,
NP, and CS were included in >90% of patients. ITF was only
included in those who underwent skull-based surgery.
Conclusions: The TV inclusion of particular regions at risk may
reduce local recurrences in ACC-PNS. Further studies to refine TV
delineation methods in PNS cancer patients are awaited. 
Nagda: Figure 1
4.05.05
Usefulness of Beam Number and Angle Optimization in IMRT
of Unilateral Head and Neck Cancer
Dombrowski, John J.; Siddiqui, Mohammed; Sethi, Anil; Emami,
Bahman, Loyola University Medical Center, Maywood, IL, USA
Purpose/Objective: Generic IMRT plans with equispaced beams do
not always produce optimal results for all head and neck patients.
Doses to organs at risk (OAR) may be suboptimal and the treatment
times may be too long. IMRT of unilateral target volumes can be
improved with modifications to beam number and angle that
increase sparing of OARs, such as, the contralateral salivary glands
and spinal cord.
Materials/Methods: Thirteen patients with unilateral parotid cancer
were retrospectively analyzed for this study. Dose prescription was
at least 60 Gy (range 60-68Gy). For each patient, three coplanar
IMRT plans to the original dose prescription were evaluated: 7 equi-
spaced beams, 3 ipsilateral beams with standard angles, and 3 ipsi-
lateral beams with customized angles. Doses were normalized to the
prescribed dose for each patient. Plans were evaluated for target
coverage, OAR doses and total monitor units (MU). 
Results: Dose coverage for both CTV and PTV was within 1% and
3% respectively in all three plans. Compared to the 7 beam plan,
Dmax, Dmean, and Dmin for the contralateral parotid in the 3 beam
plans were reduced by 16.1Gy, 11.5Gy, and 3.9Gy, respectively.
Similarly, Dmean and Dmin for mandible were also reduced by
6.6Gy and 3.1Gy using the 3 beam plans. The customized 3 beam
plan showed a trend to lower OAR doses. Total MU in the 3 beam
plans were on average 27% lower than the 7 beam plans. 
Conclusions: Optimal placement of fewer beams in IMRT planning
can reduce treatment time, normal tissue toxicity, while maintaining
adequate target dose coverage.
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4.05.06
Experience and Outcome Statistics with Combined Modality
and Multidisciplinary Management of Head and Neck (H & N)
Malignancies in a Community Cancer Center.
Sen, Kaushik; Bjoralt, Marilyn, Dakota Cancer Institute, Fargo,
ND, USA
Combined modality treatment with optimal use of surgery,
chemotherapy and radiation therapy has been shown to improve
both the survival as well as the cosmetic outcome of H & N cancer
management. The concurrent use of platinum-based chemotherapy
and radiation can improve organ preservation rate without compro-
mising survival but at the cost of increased treatment related acute
toxicities. This report of our multidisciplinary H & N clinic investi-
gates whether such intensive therapy can be delivered safely and
effectively in the setting of a small-town community cancer program.
A total of 158 patients were referred and treated between 2001 and
July 2005. Average age was 50-79 years and the most common his-
tology was squamous cell carcinoma. Forty four percent had stage II
or higher disease at presentation. Fourteen percent of stage I, 25%
of stage II, and 80% of stage III-IV patients received combined
modality treatment. Twenty nine percent of these patients (stage I-
IV) were treated non-surgically with organ preservation achieved in
98%. There was no treatment related deaths. Two year survival data
is given below that compares favorably with SEER statistics.
Toxicities were easily manageable in the community outpatient setting
with less than 10% of patients requiring TPN or hospital admission.
In the majority of cases 70-72 Gy of radiation was given utilizing
IMRT and concurrent Cisplatin at a dose of 100 mg/m2 on days 1, 22
and 43 of radiation therapy.
This review indicates that combined modality treatment can be 
utilized effectively in the community setting for H & N cancers. The
results are comparable with those reported from large referral insti-
tutions. 
4.05.07
Use of a Novel Premedication/Hydration Regimen Improves
Tolerability of Amifostine in Outpatient Setting
Samuels, Michael;1 Zak, Michelle;2 Oronos, Joy2
1 Vice Chairman, Dept. of Radiation Oncology, Mt. Sinai Medical
Center, Miami Beach, FL, USA; 2 Mt. Sinai Medical Center, Miami
Beach, FL, USA
Background: Amifostine, a radioprotector, has a moderate emeto-
genicity that can be exacerbated in patients receiving combined
modality therapy. A community-based evaluation of subcutaneous
(SC) amifostine (n = 443) that lacked adequate prehydration/ pre-
medication strategies, reported nausea/vomiting and skin rash
(grades 1-4) in 60% (30% probably/definitely related to amifostine)
and 19% of patients, respectively. Method: Retrospective chart
review of 21 patients from July 2005 to May 2006, administered SC
amifostine and novel premedication regimen (table). Weekly assess-
ments of nausea, vomiting and skin rash were analyzed.
Results: Fourteen patients (67%) completed the entire course of
amifostine and all patients complied with the premedication regi-
men. Two (9%) of 21 patients, experienced nausea (any grade) relat-
ed to amifostine and 1 patient (4.8%) discontinued due to this
adverse event; 4 (19%) discontinued due to development of general-
ized rash after 7-9 doses of amifostine. Rash resolved rapidly with
use of hydrocortisone 1% cream.
Conclusions: The 9% incidence of nausea is the lowest reported in
published literature. Incidence of generalized rash (19%) is compa-
rable to rates reported in the community-based study. Daily nursing
support and use of water bottle are needed to ensure compliance
with hydration component of the pretreatment regimen.
Dose Timing prior
to amifostine
Water (Oral Hydration) 32 oz 2-3 h 
Zofran (Ondansetron) 8 mg oral 90 mins 
Zyrtec (Cetrizine) 10 mg oral 90 mins 
Amifostine 500 mg SC two-site
(reconstituted in 2.9 cc NS)
4.05.08
The Results of Surgery and Postoperative Radiotherapy on
Local Control and Survival in Advanced Stage Carcinoma of the
Base of Tongue
Dombrowski, John J.;1 Emami, Bahman;1 Mohammed, Nasiruddin;1
Jabbari, Syed H.;2 Petruzzelli, Guy1
1 Loyola University Medical Center, Maywood, IL, USA; 2 Fayaz
Bakhsh Hospital, Tehran, Iran
Purpose/Objective: A retrospective review of patients treated for a
cancer of the base of tongue was undertaken to investigate the
results of surgery with adjuvant radiation ± chemotherapy, or pri-
mary chemoradiotherapy on local control, overall survival and
recurrence-free survival at Loyola University Medical Center. 
Materials/Methods: From 10/1984 To 6/2005, a total of 135 pts
were identified with a primary base of tongue carcinoma. Ninety-
two patients met eligibility criteria and were analyzed. The patient’s
stage was reviewed from pathologic and clinical information, and
reported according to the AJCC Sixth Edition Staging Handbook.
The median dose to the base of tongue was 64 Gy (range 0 to
79Gy). The majority of patients were stage IVA (65 pts). Follow up
was a median of 20.5 months.
Results: The two and five year overall survival is 73.6% and 52.2%,
respectively. The median survival is 2.3 yrs. The local control at two
and five years is 78.9% and 65% respectively. The two and five year
recurrence-free survival is 72.1% and 60.7%, respectively. The
median recurrence-free survival is 1.8 yrs. Extension to the floor of
mouth decreased overall survival and recurrence-free survival.
Overall survival was reduced by extension to soft palate.
Recurrence-free survival was also reduced by posterior tonsilar pil-
lar extension. There was a significantly higher survival in patients
treated at Loyola University Medical Center compared to outside
institutions. The detailed analysis of the side effects during radiother-
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apy and their severity will be presented and discussed with emphasis
on the extent of surgery, duration of radiotherapy, and survival.
Conclusions: The combination of surgery and postoperative radia-
tion ± chemotherapy for base of tongue carcinoma shows high local
control rates and overall survival amidst advanced stage disease.
4.05.09
Intensity Modulated Radiotherapy Can Spare the Mucosa to
Potentially Reduce Acute Mucositis in Head and Neck
Radiotherapy
Dombrowski, John J.; Siddiqui, Mohammed; Sethi, Anil; Emami,
Bahman, Loyola University Medical Center, Maywood, IL, USA
Purpose/Objective: IMRT has provided adequate coverage of the
target volumes while reducing dose to healthy organs like parotid
glands, thus lowering the rate of treatment toxicity. We hypothesized
that identification of mucosa as an organ at risk (OAR) in IMRT
plans could reduce OAR dose and therefore the severity of acute
mucositis in treatment of head and neck cancers. 
Materials/Methods: Four patients with head and neck cancer were
consecutively identified with treatment volumes in close proximity
to the pharyngeal mucosa. An equispaced 7 field coplanar IMRT
plan was created and optimized without specifying a dose constraint
to the mucosa. Subsequent IMRT plans added only the mucosa as an
OAR with a maximum dose constraint. Results were analyzed for
target coverage and sparing of mucosa and other critical organs. 
Results: Target dose coverage was similar in all IMRT plans. The
mean mucosal dose was directly correlated to the specified maxi-
mum OAR dose constraint. At 20Gy maximum dose constraint,
IMRT plans showed 13Gy reduction in the mean mucosal dose
(p=0.0088). In addition, the percent volumes covered by 20, 30 or
40Gy isodose were reduced by 33, 42 and 29% (average values),
respectively (p=0.0013 - 0.004). The contralateral parotid mean dose
was 6 Gy (range 0.8 - 16.8Gy) for all plans. Other critical structure
doses were maintained at acceptable levels.
Conclusions: Preliminary data demonstrates that IMRT provides the
capability to reduce the dose and possible toxicity to the mucosa
while maintaining an acceptable target volume dose with the identi-
fication of the mucosa as an organ at risk. A prospective protocol is
underway to further evaluate our hypothesis.
4.05.10
Intensity Modulation Radiation Treatment for Head and Neck
Cancer: The Northwestern University Experience.
Koneru, Nagendra; Logemann, J A.; Gopalkrishnan, M; Mehta, R;
Rademaker, R W.; Pelzer, H; Mittal, B B., Northwestern Memorial
Hospital, Chicago, IL, USA
Purpose: To review the Northwestern University experience with
intensity-modulated radiotherapy (IMRT) in the treatment of head
and neck cancer.
Materials and Methods: From October 2001 to September 2005,
64 patients with head and neck cancer were treated with IMRT for
curative intent. 26 patients were treated with parallel opposed beams
with tissue compensator followed by IMRT boost (group A), and the
remaining 38 patients were treated with IMRT alone (group B).
Three planning treatment volumes (PTV1, PTV2, and PTV3) were
used. Toxicities were categorized into acute toxicity CTC (<90 days
post treatment), chronic worst toxicity RTOG (>90 days), chronic
worst toxicity SOMA scale, and at last follow-up SOMA scale and
RTOG. 
Results: The median follow-up for the 64 total patients was 11.9
months (m). The median follow up for group A was 12.3m. The
median follow up for group B was 11.5m (p=.25 compared with A).
The local progression-free survival, and distant disease free survival
for the entire population was 91% and 75% respectively at 2 years.
There were 3 local recurrences and 8 distant recurrences. 18 of 64
patients (28%) had cervical/esophageal stricture formation, however
there was no significant difference in incidence between both groups
(p=0.58). However, group B was found to have significantly less
acute dysphagia when compared to group A (37% vs 73%, p=.01).
Also, fewer group B patients had the need for G-tube placement
compared with group A patients (42% vs 73%, p=.02). 
Conclusions: IMRT alone or as a boost is a reasonable treatment
option compared to conventional external beam radiation therapy for
the treatment of head and neck cancer. While there was no differ-
ence in local-regional control between the two groups in this analy-
sis, IMRT when given alone appears to have less toxicity. 
4.05.11
Week On/Week Off (WO/WO) Chemoradiation vs.
Conventional Chemoradiation (CRT): A Preliminary Analysis of
Toxicity and Efficacy 
Kao, Johnny; Packer, Stuart; Duffey, Dianne; Lavaf, Amir; Hoch,
Benjamin L.; Som, Peter; Woo, Peak; Genden, Eric M., Mount Sinai
School of Medicine, New York, NY, USA
Introduction: Concurrent chemoradiation has improved outcomes
for advanced head and neck cancer. However, the optimal chemora-
diation regimen remains controversial. We analyzed the relative
acute toxicity profile and preliminary efficacy data of two common-
ly utilized chemoradiation regimens.
Methods: Twenty five consecutive patients receiving chemoradia-
tion for stage II-IV head and neck cancer (80% stage IV or recur-
rent) treated by a multidisciplinary head and neck cancer team
between 7/05 and 6/06 were analyzed. Nine patients received
WO/WO (Haraf, Clin Cancer Res 9: 593, 2003) consisting of con-
current 5-FU, hydroxyurea, paclitaxel and twice daily radiation
(median dose 72 Gy). Sixteen patients received CRT consisting of
concurrent platinum-based chemotherapy and daily continuous
course radiation (median dose 68 Gy). Most patients were treated
with definitive chemoradiation (68%) and IMRT (92%). Induction
chemotherapy was more commonly utilized in the WO/WO group
(7/9) than in the CRT group (1/16). 
Results: Based on post-treatment PET/CT and/or pathological
assessment, all treated patients are free of locoregional disease at
last follow-up. One patient in each group had distant relapse.
Despite higher mean radiation doses and use of more intensive
chemotherapy, patients treated with WO/WO had similar rates of
grade ≥3 mucositis (56% vs. 63%, p=0.4), infection (22% vs. 19%,
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p=0.8) and mean duration of grade ≥3 pain (6 weeks vs. 6 weeks,
p=0.5) as CRT. Grade ≥2 dermatitis was more common with
WO/WO (44% vs. 6%, p=0.02). There was one fatal infection in the
CRT group. 
Conclusions: This analysis suggests that both WO/WO and CRT are
highly active regimens and have a similar acute toxicity profile.
Longer follow-up is needed for a meaningful comparison of disease
control, late toxicity and quality of life between these two regimens.
4.05.12
Retospective Analysis of Single Agent Docetaxel in Patients with
Platinum-refractory Metastatic and/or Recurrent Squamous
Cell Carcinoma of the Head and Neck (SCCHN)
Zenda, Sadamoto;1 Onozawa, Yusuke;2 Onitsuka, Tetsuro;2 Iida,
Yoshiyuki;2 Nishimura, Tetsuo2
1 National Cancer Center East Hospital, Shizuoka, Japan 2 Shizuoka
Cancer Center, Shizuoka, Japan
Purpose: The objective of this retrospective study was to investi-
gate the efficacy and tolerability of single-agent docetaxel 60 mg/m2
for platinum refractory SCCHN patients.
Patients and Methods: Platinum-refractory patients with SCCHN
except nasopharyngeal cancer were included in the study. The dis-
eases with documented tumor progression (PD) during a platinum-
based treatment or recurrence within 6 months of platinum-based
chemoradiotherapy, were defined as platinum refractory. Treatment
schedule consisted of docetaxel 60mg/m2 was infused over 1-
2hours. Treatment was repeated every 3-4weeks until disease pro-
gression or unacceptable toxicity ocurred.
Results: Twenty patients were treated from September 2002 through
December 2005. The number of prior chemotherapy was one in 17
patients, two in two patients, and three in one patient. The overall
response rate was 10% (2/20) and the tumor control rate (partial
response and stable disease) was 25% (5/20). The median progres-
sion free and the median overall survival time were 1.7 and 4.6
months, respectively. The most common hematological toxicities
were leucopenia (grade 4; 35%) and neutropenia (grade 4; 30%).
Grade 3 febrile neutropenia occurred in two patients (10%). The
median hospital stay-period during the treatment was 5.4 days
(range, zero to 50 days).
Conclusion: Single-agent docetaxel (60mg/m2) regimen seemed to
have an acceptable safety profile for platinum refractory SCCHN
patients. Further prospective study is necessary to assess the effect
on survival.
4.05.13
Non-Platinum Based Chemotherapy with Irinotecan Plus
Docetaxel for Advanced and/or Metastatic Olfactory
Neuroblastoma: A Retrospective Analysis
Kiyota, Naomi; Tahara, Makoto; Ohtsu, Atushi; Kawashima,
Mitsuhiko, National Cancer Center Hospital East, Kashiwa, Japan
Background: Olfactory Neuroblastoma (ONB) is a rare tumor aris-
ing from the olfactory epithelium in the upper nasal cavity. Although
most reported chemotherapy for ONB was platinum-based, the opti-
mal regimen for ONB remains to be defined. We conducted a retro-
spective analysis to evaluate the efficacy and toxicities of non-plat-
inum-based chemotherapy with irinotecan plus docetaxel (ID) for
advanced and/or metastatic ONB. 
Methods: Patients (pts) diagnosed with ONB and treated with ID
between 1995 and 2005 in our institution were analyzed.
Chemotherapy consisted of three weekly administrations of irinote-
can 50-60 mg/m2 on day 1 and docetaxel 30-35 mg/m2 on day 1,
repeated every 4 weeks. After several cycles of ID, pts with locally
advanced disease received proton-photon radiation (PRT): total 64.8
Gy in 1.8 Gy fractions. 
Results: 12 patients with the following characteristics were recruit-
ed: median age, 58.5 years; 4 males and 8 females; 2 pts Kadish
Stage B and 10 Kadish Stage C; 3 pts with local recurrences after
surgical resection, including two who received adjuvant radiothera-
py and 9 with locally-advanced disease including 1 with lung metas-
tasis; 10 pts chemo-naive and 2 pts with prior chemotherapy. A
median of 2.5 cycles of ID was administered. Most common toxici-
ties ≥grade 3 were leucopenia (33%), neutropenia (42%) and diar-
rhea (25%). All 12 pts were evaluable for response: 3 (25%) had
PR, 6 (50%) SD and 3 (25%) PD. Of 7 pts who received PRT fol-
lowing ID, two achieved CR, 3 had PR and 2 had SD. The median
over all survival for patients receiving ID has not been reached
(range, 5.7 to 57.6 months). All pts who received PRT following ID
are still alive at a median follow up time of 16.6 months (range, 9.3
to 57.6 months). 
Conclusions: This is the first analysis of a non-platinum-based regi-
men for ONB. ID for advanced and/or metastatic ONB was effective
and tolerable. ID followed by PRT may be promising for locally
advanced ONB and warrants further investigation.
4.05.14
Phase II study of Bevacizumab in Combination with Docetaxel
and Radiation in Locally Advanced Squamous Cell Cancer of
the Head and Neck (SCCHN). 
Savvides, P.; Greskovich, J.; Bokar, J.; Stepnick, D. W.; Fu, P.;
Bergant, S.; Painter, L.; Prasse, J.; Remick, S.; Lavertu, P., CASE
Comprehensive Cancer Center, Cleveland, OH, USA
Background: VEGF expression has been shown to be up regulated
in SCCHN, representing a promising therapeutic target.
Bevacizumab is an anti-VEGF monoclonal antibody that may poten-
tiate the efficacy of concurrent radiation and docetaxel. We seek to
establish the efficacy and toxicities of the addition of bevacizumab
to concurrent radiation with docetaxel in patients with locally
advanced SCCHN.
Methods: Patients with previously untreated stage III-IVB SCCHN
receive standard once-daily radiation (70.2Gy, 1.8Gy/day), weekly
docetaxel (20 mg/m2/week for the duration of radiation) and
biweekly bevacizumab (5 mg/kg/two weeks) during and for up to
one year following radiation.
Results: A total of 8 patients (7 males, 1 female), mean age 58 years
(range 49-66), all with stage IV disease have been enrolled. Primary
site: pharynx (n=5) and larynx (n=3). 7 patients have completed
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chemoradiation and the only patient who underwent planned neck
dissection had a pathologic complete response. 3 more patients are
currently scheduled to undergo planned neck dissection. 3 patients,
in complete response, are currently receiving adjuvant bevacizumab. 
No unexpected toxicities were encountered during chemoradiation.
No episodes of severe bleeding noted.
Conclusions: For patients with locally advanced SCCHN, prelimi-
nary data suggest that the addition of bevacizumab to concurrent
radiation with docetaxel is feasible, safe and active. 




Re-Irradiation With IMRT and Chemotherapy for Recurrent
Head and Neck Cancer
Roman, Eloy;1,2 Blaya, Marcelo;1 Han, Hyo Sook;1 Biagioli,
Mathew;1 Harvey, Mark;1 Markoe, Arnold;1 Raez, Luis E.1
1 University of Miami, Miami, FL, USA; 2 Sylvester Cancer Center,
Miami, FL, USA
Background: Head and Neck Squamous Cell Carcinoma (HNSCC),
when locally advanced, usually recur despite combination therapy.
Response rates of 30-40% have been obtained using several modes
of salvage therapy including surgery, chemotherapy and brachyther-
apy alone or in combination. Despite these approaches there are few
long-term survivors. Intensity Modulated Radiation Therapy (IMRT)
is currently considered the next modality to be evaluated in the re-
irradiation setting. This study evaluates our experience using every
other week IMRT with concurrent chemotherapy.
Design: Forty patients with locally recurrent HNSCC were treated;
37 evaluated. All patients received every other week re-irradiation
with IRMT with concurrent weekly carboplatin (median AUC= 2) or
cisplatin (60-100mg/m2) ± 5-FU (800-1000mg/m2) or paclitaxel
175mg/m2 every three weeks. Patients received 6000 cGy at 200
cGy per fraction. 
Results: The median follow-up time was 12 months. The overall
response rate was 75.7 % with a complete response (CR) and partial
response (PR) of 56.8 % and 18.9 %, respectively. Among complete
responders, 33% recurred locally in a median time of 5 months. The
Kaplan-Meier estimate of disease-free survival, progression-free sur-
vival, and overall survival at 48 months is 58 %, 45%, and 28%,
respectively. At the time of last follow-up, 51.4% of patients were
still alive and 27.8% of patients had no evidence of disease. Grade 3
or 4 acute toxicities occurred in 20% of patients of which 13.3%
were hematologic requiring either growth factors or delay in
chemotherapy. No deaths occurred during the course of treatment.
Long-term complications consisted of one patient with an
esophageal stricture requiring repeated dilations, 2 patients with
chronic dysphagia, and 2 patients developing a pharyngeal-cuta-
neous fistula, one of which died from a carotid blowout occurring 6
months after treatment. 
Conclusions: Every other week IMRT with concurrent platinum
based chemotherapy continues to appear as a safe and effective
mode of treatment for patients with recurrent HNSCC. Final results
of this study will be presented at the meeting.
4.05.16
Phase II Trial of Gefitinib in Patients with Incurable Salivary
Gland Cancer
Blumenschein, George R. Jr.; Glisson, B S.; Burke, B.; Erasmus, J.;
Zinner, R.; Kies, M., The University of Texas M.D. Anderson
Cancer Center, Houston, TX, USA
Background: Conventional chemotherapy agents offer little effica-
cy for patients with incurable salivary gland cancer. EGFR (her1)
overexpression has been identifed in > 90% of salivary gland can-
cers in recent series. Thus, EGFR-targeted therapy with gefitinib
offers promise in treatment of this disease. 
Methods: From 6/04 to 7/06 35 patients with incurable salivary
gland cancer were accrued to a phase II trial of gefitinib (250 mg po
daily). Eligibility: ECOG PS 0-2, measurable disease, no prior
EGFR inhiibitors. Patients were accrued in two cohorts: (1) adenoid
cystic and (2) other histologies. Primary endpoint was response rate
based on RECIST criteria and imaging every 2 months. Analysis of
EGFR and her2 expression (IHC) on archival tumor was a second-
ary endpoint. 
Results: Patient characteristics, number(%): PS 1 26(93), M 19(68),
prior chemotherapy 6(21), adenoid cystic 19(68), adenocarcinoma
3(11), salivary duct 3(11), mucoepidermoid 2(7), and undifferentiat-
ed 1(3). Twenty-six patients received 71 courses. Two are in their
first course. Toxicity (26 pts), number (%): grade 1 diarrhea 20(77),
grade 1/2 rash 14(54), grade 1/2 anorexia 8(31), grade 1/2 fatigue
14(54), grade 1 nausea 4(15), grade 1 mucositis 4(15), grade 1 nail
change 2(8). No grade 3-4 effects observed. Three patients discon-
tinued therapy due to grade1-2 effects that were felt treatment-relat-
ed in only 1/3. Response (21 pts), number(%): CR/PR 0(0), SD 14
(67), PD 7(33). 13/14 pts with SD have adenoid cystic cancer.
Median duration of SD: 13 wks (4-19). One pt is dead from disease,
two have died from other causes. Accrual to the adenoid cystic
cohort is complete. Accrual to the other cohort is ongoing.
Conclusions: Gefitinib was well-tolerated and led to a high rate of
SD in adenoid cystic cancer. Interpretation of the value of SD
requires further f/u. This will be updated and expression of EGFR
and her2 will be presented. 
4.05.17
Phase II Study Of Bi-Weekly Capecitabine And Oxaliplatin In
Recurrent Head And Neck Squamous Cell Cancer
Zhong, Wangjian;1 Laber, Damian;1 Bumpous, Jeffery;1 Silverman,
Craig;1 Lentsch, Eric;1 Lilly, Bechy;1 Sheffield, Jackie;2 Goldsmith,
Linda;1 Hendler, Fred;1 Bhupalam, Leela1
1 Brown Cancer Center, University of Louisville, Louisville, KY,
USA; 2 University of Louisville, Louisville, KY, USA
Background: Recurrent and metastatic head and neck squamous
cell cancer (HNSCC) is a significant problem. First line chemothera-
py with agents such as platinum analogues and 5-FU has demon-
strated a response rate of 30-50%, with significant toxicity.
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Responses in chemotherapy refractory or relapsed patients are very
limited.
Our goal is to develop a more tolerable chemotherapy without com-
promising efficacy.
Methods: Single center, single arm phase II study. Regimen: oxali-
platin 85 mg/m2 IV day 1 and capecitabine 1500 mg (fixed-dose)
oral BID days 1-7, repeated bi-weekly (CapOx-BW).
Results: Patient characteristics: Twelve patients with locally recur-
rent or metastatic HNSCC have been enrolled. Prior to CapOx-BW
treatment, all patients had objective documentation of progressive
disease after surgery and radiotherapy. Nine subjects (75%) have
progressed after prior chemotherapies with cisplatin/5FU (5), carbo-
platin/paclitaxel (3), paclitaxel/ifosfamide/cisplatin (2) and carbo-
platin (1). Median age was 56 (39-87) and ECOG PS was 1 (0-2).
Objective Response: Out of three chemotherapy naïve subjects one
had a partial response (PR 33%) and one stable disease (SD 33%).
Out of nine patients with prior chemotherapy one attained a com-
plete response (CR 11%).
Toxicity: CapOx was well tolerated, with grade 3 fatigue 8%, grade
2 peripheral neuropathy 17% and grade 2 anemia 17%.
Conclusions: CapOx-BW is a well-tolerated, easy to administer and
effective drug therapy for patients with locally recurrent or metastatic
HNSCC. Accrual to this study is ongoing.
4.05.18
Conformal vs. IMRT Concomitant Boosts for IMRT Based Head
and Neck Treatment
Allen, Aaron; Wolfsberger, Luciant; Tishler, Roy B.; Court,
Laurence, Department of Radiation Oncology, DFCI/BWH, Boston,
MA, USA
Purpose: To evaluate conformal 3D-CRT vs. IMRT techniques for
the boost portion of a concomitant boost treatment schedule for
IMRT based head and neck radiation. 
Method and Materials: Nine-field IMRT plans were generated
using Eclipse TPS for 4 stage IV oropharynx patients and 4 stage IV
non-oropharynx patients, treating all target volumes initially to
57Gy. Two alternative plans were then generated to deliver a 15Gy
boost to gross disease: a 3D conformal plan, using 3-5 fields, and 5-
field IMRT plan. Boost volumes ranged from 25-60cc for group A
and 70-126cc for group B. The IMRT and 3D-CRT boost plans were
evaluated as individual graphic plans and as a cumulative with the
first course treatment for a total dose of 72Gy (IMRT/IMRT and
IMRT/3D-CRT combinations). The comparison assessed target cov-
erage, dose to critical structures (parotids, cord and oral cavity), hot
spots and number of monitor units (MU).
Results: Evaluated as a cumulative plan the IMRT/IMRT technique
gave clinically acceptable plans in terms of both target coverage and
dose to normal tissues and the hot spots were between 104-108%.
The IMRT/3D conformal technique also met the constraints for the
critical structures with hot spots between 102-111%. Both cumula-
tive plans achieved 97-100% coverage of boost volumes regardless
of boost volume size and location. Evaluated as individual plans
both the IMRT and 3D conformal boost plans achieved the desired
coverage while keeping the dose to critical structures clinically
acceptable; hot spots were located within the confines of the boost
volume. The number of MU’s ranged from 192-327 for the 3D-CRT
plan in comparison to 330-628 for the IMRT. Average planning time
was 1.0 and 2.5 hours for the IMRT and 3D-CRT boost, respectively.
Conclusion: Both boost techniques are dosimetrically equivalent.
Treatment technique can therefore be chosen based on the available
clinical recourses.
Translational Research – Head
and Neck Cancer
4.06.01
BIOMAb EGFRTM (Nimotuzumab) in Combination With the
Standard of Care in Squamous Cell Carcinoma of the Head and
Neck (SCCHN)
Kanaka Setty, Govind Babu; Kidwai Memorial Institute of
Oncology,Bangalore, Bangalore, India
Background: BIOMAb EGFR(TM), a humanized recombinant anti-
EGFR monoclonal antibody acts as a specific and active inhibitor of
the EGFR tyrosine kinase phosphorylation. EGFR is over expressed
in malignant tumors of epithelial origin, such as head and neck,
lung, colorectal, stomach, kidney, esophageal, renal, breast, ovarian,
prostate cancers, glioma and other malignant tumors. Almost 700
patients have been exposed to this mAb and several clinical trials. 
An open label, randomized study was conducted across three centers
in India using BIOMAb EGFRTM in combination with
Radiotherapy (RT) and Chemotherapy (CT) and Standard
Radiotherapy alone, in the treatment of advanced SCCHN.
Methods: Subjects with advanced stage III and stage IVA SCCHN
were randomly assigned to either nimotuzumab + RT or RT alone
and nimotuzumab + CT +RT or CT + RT. Nimotuzumab was given
at a dose of 200 mg weekly once for 6 weeks along with the stan-
dard of care. The primary endpoints were Response rates and
Safety; secondary endpoints were Disease-free Survival (DFS),
Progression-free Survival (PFS) and Overall Survival.
RECIST was used for Tumor evaluation. Adverse events were clas-
sified according to toxicity grades [For CT, CTC AE (version 3) and
for RT, (RTOG)].The study was conducted as per ICH-GCP and
local Regulatory guidelines.
Results: A total of 76 subjects were evaluable at the end of 24
weeks after treatment; the division being 17 in nimotuzumab+RT
arm,19 in RT arm,20 in nimotuzumab+CT+RT and 20 in CT+RT
arm.
An objective response rate of 76 % was achieved in the nimotuzum-
ab +RT arm as compared to 40 % in the RT arm (P=0.023); whereas
in the nimotuzumab +CT+RT arm the objective response rate was
100 % as compared to 70 % in the CT +RT arm (P=0.020).
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Of the nimotuzumab related adverse events only rash and chills
were rated by the investigator as certainly related to nimotuzumab.
The survival data is currently being collected for all the subjects.
Conclusions: Nimotuzumab could be safely added to standard of
care in SCCHN and it can help to achieve better tumor responses
without potentiating toxicity 
4.06.02
The Receptor Tyrosine Kinase c-MET as a novel therapeutic
target in Head and Neck Cancer
Seiwert, Tanguy Y.;1 Janamanchi, Varalakshmi;1 Klein-Szanto,
Andres;2 Jagadeeswaran, Ramasamy;1 Martin, Leslie;1 Lingen,
Mark W.;1 Cohen, Ezra E.;1 Ridge, John A.;2 Vokes, Everett E.;1
Salgia, Ravi1
1 University of Chicago, Chicago, IL, USA; 2 Fox Chase Cancer
Center, Philadelphia, USA
Objective: To determine expression, mutations, and effects on
motility of the receptor tyrosine kinase c-MET in head and neck
squamous cell carcinoma (HNSCC) and evaluate c-MET inhibition
with SU11274/siRNA.
Design: A total of 128 HNSCC, dysplastic, and normal tissues
(using immuno-histochemistry) and 10 HNSCC cell lines (using
immunoblot) were evaluated for c-MET, phospho-c-MET, and
Hepatocyte Growth Factor (HGF). In 5 cell lines, c-MET was inhib-
ited using SU11274/small interfering RNA (siRNA). Effects on sig-
naling (Immunoblotting), viability (MTT/Cyquant), and motility
(time lapse video) were determined. Mutational analysis of HNSCC
tumor tissue samples (n=54) and cell lines (n=12) was done.
Results: Eighty-four (66%) HNSCC tumor samples overexpressed
c-MET/phospho-c-MET pY1003 (dysplasia, n = 30 [64%]). Normal
tissue had the lowest rate of overexpression (n = 21 [23%]).
pY1230/1234/1235 overexpression was less prominent. Cytoplasmic
HGF expression was seen. All cell lines showed c-MET expression.
Five HNSCC cell lines were treated with SU11274. phospho-
Tyrosine immunoblots showed SU11274 dose-dependant effects.
Specifically, SU11274 lead to inhibition of c-MET signaling, with
decreased levels of phospho-c-MET (pY1003 and
pY1230/1234/1235), phospho-Akt (pT308), phospho-Erk1/2
(pTpY185/187), phospho-p70S6K (pT389), and phospho-SHP2
(pY542) at 2mM and complete abrogation at 5mM. Viability assays
with SU11274 and siRNA decreased cell growth in 3 HNSCC cell
lines (30%-75%). HGF stimulation had no effect consistent with
autocrine HGF production. c-MET inhibition lead a to marked
decrease in cell motility. Mutational analysis of 54 tumor tissues/ 12
cell lines revealed 6/1 not previously described mutations, in the
SEMA and JM domains.
Conclusions: (1) c-MET is overexpressed in HNSCC. (2) Novel c-
MET mutations in ~11% of HNSCC were identified. (3) Inhibition
of c-MET leads to a marked decrease in cell growth. c-MET is a
promising target in HNSCC.
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